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Introduction 
Allogeneic stem cell transplantation (allo-SCT) is a potent treatment option for patients 
suffering from high-risk haematological malignancies.1,2 This therapy is potentially 
curative, in which the allo-reactive natural killer (NK) and T cells from the stem cell donor 
can selectively recognise and kill residual malignant cells of the patient, known as the graft-
versus-tumour (GVT)-effect.1,3 Unfortunately, allo-reactive donor T cells not only target 
tumour cells, but can also recognise and attack healthy tissues of the patient, potentially 
causing the detrimental graft-versus-host disease (GVHD).4,5 This major drawback can 
lead to severe side effects and even transplantation related mortality (TRM), which limits 
the therapeutic feasibility of allo-SCT. In addition, recurrence of the malignant disease 
remains a major problem. Improved clinical results could arise from therapeutic strategies 
that aim for the prevention of GVHD, or control the progression of the malignancy. 
Additive therapies to fight residual tumour cells, which should not increase the risk for 
GVHD, could focus on the different donor immune effector cells that contribute to the 
GVT-effect, like tumour-reactive T and NK cells. In Part I of this thesis, we investigated the 
role of the relatively new IL17-producing T cell subtype in the pathophysiology of GVHD. 
Moreover, in Part II and Part III, we examined adoptive transfer of NK cells and donor T 
cells, as potential additive therapy for patients with haematological malignancies. 
Haematological malignancies
Haematological malignancies consist of various neoplasms that originate from either 
the lymphoid or myeloid lineages, including acute and chronic leukaemia’s, malignant 
lymphomas and plasma cell disorders. These combined account for approximately 8% 
of all newly diagnosed cancers in Europe, resulting in about 250,000 newly diagnosed 
patients every year.6,7 These cancers of the haematopoietic system occur, like solid 
malignancies, by DNA damage causing a loss of control of cell division. The consequence 
is accumulation of malignant cells in the bone marrow and other lymphoid organs, which 
occupy the space for normal haematopoiesis. This results in clinical symptoms like fatigue, 
bleedings and infections. Although haematological malignancies occur in all age groups, 
there is a preference for certain disorders at younger and older age. For instance, acute 
lymphoblastic leukaemia (ALL) is most common in paediatric patients.6,7 On the other 
hand, acute myeloid leukaemia (AML) and multiple myeloma (MM) occur predominantly 
in older adults, of which more than half of the patients is older than 65 years. The 5-year 
overall survival of these patients varies between 20-90%, in which the prognosis is 
influenced by the type of haematological malignancy, the subtype of the malignancy 
(e.g. the FAB-classification in AML), genetic abnormalities of the tumour, and patient’s 
characteristics like age and health status.6 The disease progression, as well as the patients 
health status, determines the choice of therapy. Standard treatments for haematological 
malignancies include chemotherapy and radiotherapy. These target the fast dividing 
malignant cells, which reduces tumour burden and can induce long-term remission. 
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Next to chemotherapy and radiotherapy, several new, more molecular targeted-drugs 
have been developed in the last decade. These drugs target tumour cells via specific 
molecular characteristics of the tumour. For instance, the first-line drug in chronic myeloid 
leukaemia (CML) nowadays is Imatinib, a tyrosine kinase blocker that inhibits the BCR-
ABL fusion protein.8 Furthermore, Lenolidomide has become an important agent in the 
treatment of MM, inducing tumour cell apoptosis as well as inhibiting angiogenesis and 
stromal cell support.9 Other promising drugs are the DNA methyltransferase inhibitors 
Azacitidine and Decitabine, which are currently tested as additive therapy in AML and 
myelodysplastic syndrome (MDS) patients who achieved remission after chemotherapy 
induction therapy.10 Next to these targeted drugs, the immune system can be exploited 
to fight cancer. By activating and directing the immune system towards tumour cells, one 
could potently induce a specific anti-tumour response and generate long-term immune-
surveillance against the tumour, preventing recurrence of the disease. One of the most 
effective cell-based immune therapies includes haematopoietic stem cell transplantation 
(SCT), which is a potent therapy for patients with a good general health, below the age of 
70 (although this age limit is increasing in time). 
Allogeneic haematopoietic stem cell transplantation 
Bone marrow transplantation was developed about 50 years ago to rescue cancer patients 
who suffered from lethal bone marrow ablation due to high dose chemotherapy.11 In time, 
this therapy has been adapted to the currently known SCT.2 For patients with high-risk 
haematological malignancies stem cell rescue is essential, as intensive myeoablative 
chemotherapy treatment will not only target the malignant haematological cells, but will 
also destroy healthy haematopoiesis. Therefore, SCT is crucial following multiple rounds 
of high-dose chemotherapy.
To reduce tumour burden and prevent graft rejection, patients are conditioned prior 
to SCT with high dose chemotherapy and/or radiotherapy. Following transplantation, 
stem cells in the graft find their way to niches in the bone marrow, where they will provide 
a new and healthy haematopoiesis. This will restore blood formation and reconstitute 
the various immune cells in the patient, which originates either from the patient itself 
(autologous SCT), or from a human leukocyte antigen (HLA)-matched donor (allogeneic, 
allo-SCT).12 Autologous SCT uses the patient’s own stem cells, which are collected prior 
to conditioning. Though this is relatively non-harmful compared to allo-SCT, recurrence 
of the disease is often observed in this setting. Allo-SCT on the other hand, is associated 
with more transplantation related toxicity, though the donor-derived GVT-effect of this 
therapy can completely eliminate residual tumour cells, resulting in long-term remission 
and possible cure of the disease.
Allo-SCT can be performed with stem cells from a relative, like a brother or sister, or 
from an unrelated voluntary HLA-matched donor obtained from the donor stem cell 
registry.13,14 The transplanted cells used to be collected via bone marrow aspiration, 
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however nowadays, stem cells are most often mobilized to the peripheral blood (PB) using 
granulocyte colony-stimulating factor (G-CSF), after which a less intensive aphaeresis can 
be used to collect the stem cells.15-18 Stem cells can also be transplanted from umbilical 
cord blood (UCB) units, stored post-partum.19 However, due to the low number of stem 
cells available in these UCBs, this is mainly performed for allo-SCT in children. To select 
a donor for allo-SCT, HLA-matching is essential to prevent graft rejection and induction 
of severe GVHD.20 There are two classes of HLA-molecules. Class I (HLA-I, e.g. HLA-A, -B, 
-C) present antigens to CD8+ T cells, while HLA Class II (HLA-II, e.g. HLA-DR, -DQ, -DP) is 
involved in antigen presentation to CD4+ T cells.21 By genetic inheritance, each person has 
their own combination of HLA molecules. HLA mismatching in allo-SCT results in strong 
activation of allogeneic T cells targeting healthy patient tissues that present patient-
specific HLA molecules. This results in the detrimental complication GVHD. Therefore, 
allo-SCT is performed in an at least 8-out-of-10 matched setting of the before named HLA-
molecules, not considering HLA-DP.20,22
As donor T cell subsets play a major role in GVHD, it can be decided to, either 
completely or partially, deplete T cells from the stem cell graft.3,23 However, as total T 
cell depletion would increase the risk of infections and lower the GVT-effect, this is not 
preferable. Therefore, in our centre, partially T cell depleted grafts still containing low T cell 
numbers (± 0.5 x 106/kg bodyweight of the patient), can be given. Alternatively, in vivo T 
cell depletion can be performed using anti-thymocyte globulin (ATG) or Alemtuzumab.24-26 
Although T cell depletion has the advantage of a lower risk on the development of GVHD, 
it also increases the risk for relapse as allo-reactive T cells play a key role in eliminating 
residual tumour cells that survived prior therapeutic interventions. 
The new donor immune cells in the patient have their own way to find, recognize, and 
kill the remaining malignant cells, of which the potential of NK cells, T cells, and dendritic 
cells (DCs) are further investigated and discussed in this thesis.1-3 To boost the reconstitution 
of the immune system, and enhance the GVT response, donor lymphocyte infusion (DLI) 
can be given to the patient post allo-SCT.27 This infusion of total non-selected donor 
lymphocytes can be applied as prophylactic therapy. This is often given after recovery of 
the allo-SCT (+/- 6 months post allo-SCT) when the conditioning-related inflammation has 
resolved, and only in the absence of GVHD, to prevent aggravation of severe GVHD by the 
donor T cells.28 DLI can also be given therapeutically as additive therapy in patients with 
persistence or reoccurrence of the disease.27 Although DLI has been shown to mediate 
clinical and molecular remissions, the different haematological malignancies vary in their 
sensitivity to this treatment. In particular chronic phase CML is highly sensitive to DLI, 
but patients with acute leukaemia, MM, and lymphoma responded less well, indicating 
that there are intrinsic differences between these cancers.28 Therefore, to prevent relapse 
of the disease and improve tumour-free survival after allo-SCT, development and clinical 
exploration of additive immune therapies is essential. Here, the holy grail in allo-SCT is to 
generate a GVT response in the absence of GVHD by choosing the optimal conditioning 
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regimen, T cell depletion strategy, post-transplant immunosuppressive treatment and 
additive anti-tumour immunotherapeutic interventions. 
Graft-versus-host disease
As mentioned above, GVHD is still a major cause of morbidity and mortality after allo-
SCT.4,5 This detrimental complication occurs in 20-40% of transplanted patients.29,30 It 
occurs in an acute or chronic form, which is mainly determined by the time of occurrence, 
with day 100 post allo-SCT as transition time point.4,5 Current treatment options for GVHD 
are the use of general immunosuppressive drugs, which is not favourable as this will also 
dampen the desired GVT-effect.31 More importantly, GVHD is not always halted by these 
drugs, and damage to the affected organs, like the skin, lung, gastrointestinal tract, and 
liver, can be fatal for the patient. GVHD is the major cause of TRM post allo-SCT, which 
occurs in around 15% of transplanted patients.29,32 Moreover, the morbidity induced by 
GVHD results in a reduced quality of life of severely affected patients.33,34
The pathophysiology of GVHD is a multistep process involving tissue damage and 
pro-inflammatory cytokine cascades induced by the pre-transplant conditioning regimen 
(Figure 1).4,5 The essential chemo- and radiotherapy prior to the allo-SCT mediate damage 
to various organs, which causes an excessive inflammatory environment. Here, donor-
derived T cells become potently activated, and subsequently traffic towards inflamed 
GVHD-prone organs. Trafficking of leukocytes occurs under the influence of chemokines, 
which are chemotactic molecules secreted by cells. These can be recognized by their 
corresponding receptor on the leukocytes, which signals them to home to the place of 
secretion. Upon homing, further tissue destruction occurs in the case of presentation of 
ubiquitous or epithelial expressed allo-antigens to infiltrating allo-reactive cytotoxic T 
cells. Moreover, macrophages, and other effector T cells subsets are recruited, resulting 
in further enhancement of GVHD. The adaptive immune system consists of two major 
subsets of T cells, CD4+ and CD8+ T cells. CD4+ T cells mainly produce cytokines to support 
other cells, and are therefore called ‘helper’ T (Th) cells. Conversely, CD8+ T cells are the 
more specialized killer cells, and named after their cytotoxic T (Tc) cell function.3,21 In 
addition, within CD4+ and CD8+ T cells, different subtypes have been identified, mainly 
based on their cytokine production profile (e.g. Th1, Th2, Th17, and Tc1, Tc17). In GVHD 
pathophysiology, the pro-inflammatory cells Th1-type CD4+ T cells and Tc1-type CD8+ 
T cells are involved, however, other T cell subtypes might play a pivotal role as well.35-38 
In particular, T cells producing IL17 were recently suggested to play a role in GVHD. The 
so-called CD4+ Th17 cells were discovered in 2006, and since then extensively studied 
and described in different inflammatory settings and diseases.39,40 These cells have been 
described to be involved in the pathology of several autoimmune diseases, including 
inflammatory bowel disease and rheumatoid arthritis, which have striking similarities with 
GVHD.41,42 Their counterparts, CD8+ Tc17 cells, are included in several of the more recent 
studies, and seem to show similar pro-inflammatory mechanisms.43-45 The role of these
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Figure 1. Graft-versus-host disease. The pathophysiology of GVHD is a multistep process involving tissue 
damage and pro-inflammatory cytokine cascades induced by the pre-transplant conditioning regimen. This 
results in activation of T cells by dendritic cells which induces T cell trafficking towards inflamed GVHD-prone 
organs. Further tissue destruction in these organs occurs in the case of presentation of ubiquitous or epithelial 
expressed allo-antigens to infiltrating allo-reactive cytotoxic T cells. TBI, total body irradiation; DAMPs, 
Damage-associated molecular pattern molecules; PAMPs, pathogen-associated molecular pattern molecules; 
GVHD, graft-versus-host disease.
IL17-producing T cells in GVHD is described in more detail in Chapter 2, and investigated 
in Chapter 3 and 4 of this thesis.
Immune biology of GVT responses
The GVT-effect of allo-SCT is based on several immune cells. Two of the most important 
donor-derived effector cells in the GVT-effect are cytotoxic CD56+ NK and CD8+ T cells. 
These cells have their own specific mechanism to recognise and kill the malignant cells 
(Figure 2).
Natural Killer cell versus tumour cell
NK cells are part of the innate immune system, and contribute about 5-15% of the 
lymphocyte population. These cells are important effector cells that can kill target cells 
without prior sensitisation i.e. ‘Natural’ Killing.46-49 The balance in signalling through their 
activating and inhibitory receptors determines the activation level of the NK cell.50 The 
most characterised receptor family are the inhibitory killer-cell immunoglobulin receptors 
(KIRs) and NKG2A.51 The KIRs recognize autologous HLA-I, thereby discriminating self from 
non-self, and NKG2A can bind to HLA-E. Signalling through these inhibitory receptors 
prevents NK cell activation. However, in the absence of self HLA-I, for instance on tumour 
cells which down-regulate HLA-I, thereby escaping from T cell immunity, no inhibitory 
signal is given.52 In addition, virus infected cells as well as tumour cells express several 
(stress induced) activating ligands, which bind to activating receptors on the NK cells. 
These include Fc-binding receptor CD16, activating KIRs, NKG2C, NKG2D, DNAX Accessory 
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Figure 2. Anti-tumour responses by T and NK cells. NK cells are activated by malignant cells via enhanced 
signalling through activating receptors like CD16, DNAM1 and NCRs, and the lack of inhibitory signals through 
KIRs and NKG2A due to HLA-Class I down-regulation or KIR-ligand mismatch. T cells are activated by dendritic 
cells via presentation of a TCR-matched antigen and a positive balance in inhibitory and stimulatory signals. 
Activated CD8+ T cells will recognise and target the malignant cell upon recognition of the presented antigen 
and stimulatory signals. Both NK and CD8+ T cells can produce cytokines and effector molecules to enhance 
inflammation and kill the malignant cell.
Molecule-1 (DNAM1), and natural cytotoxicity receptors (NCRs).51,53 When the balance of
these combined signals is shifted towards the stimulatory signals, NK cells will be activated 
and can kill their target cells. This can occur via several killing mechanisms, including 
CD16-mediated antibody dependent cellular cytotoxicity (ADCC), release of cytotoxic 
granules containing perforin and granzymes, tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL)-dependent cytotoxicity and Fas-mediated apoptosis.49,54,55 
Importantly, NK cells are one of the first lymphocytes which reconstitute after allo-
SCT.56 Their reconstitution has been associated with reduced relapse rates, indicating their 
contribution to the GVT-effect.57-60 Especially in the setting of KIR-ligand mismatch, donor 
NK cells contribute to improved survival.57,59,61 This KIR-ligand mismatch can occur in the 
absence of a full HLA-match between patient and donor. If the patient expresses HLA-C or 
HLA-Bw44 of a different class than the donor, donor NK cells miss a ligand on the malignant 
patient cells for ligation with their inhibitory KIR. Thereby, NK cell are less inhibited which 
can result in activation of the donor NK cells and killing of the residual patient cells. Ruggeri 
et al, observed improved relapse-free survival of high-risk AML patients in the presence 
of a KIR-ligand mismatch, compared to a matched setting after HLA-haploidentical allo-
SCT.57 Also allo-SCT with UCB-derived stem cells showed improved relapse-free and 
overall survival when a KIR-ligand mismatch was present.61 In addition, increased NK cell 
numbers were correlated with improved anti-tumour responses, but not with GVHD.58 
Though the GVT-effect of donor NK cells post allo-SCT might be limited due to full HLA-
matching and therefore no KIR-ligand mismatch between patient and donor, NK cells are 
a promising immunotherapy in the treatment of haematological malignancies.
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Cytotoxic T cell versus tumour cell
Donor-derived T cells, part of the adaptive immune system, play a major role in both GVHD 
as well as GVT responses post allo-SCT.29,62 T cells are generated in the bone marrow after 
which they are educated in the thymus.21 Upon release into the periphery, these T cells are 
selected based on their expression of a T cell receptor (TCR), which specifically recognises 
a non-self antigen in the context of self-HLA molecules. These naive T (Tn) cells have never 
seen the antigen before, and are therefore non-experienced. Due to a wide variability in 
rearrangements of TCR-gene segments, the specificity of the Tn cell repertoire is extremely 
diverse. Upon encounter with their TCR-specific antigen and appropriate co-stimulation 
by an antigen presenting cell (APC), like DCs, T cells become activated and respond.
DCs are the most potent APCs of the human body. They are the guides of our immune 
system, where they sample antigens and define T cell responses against non-self and 
malignant peptides.63 There are various DC subsets present in the human immune 
system.64,65 First, DCs are divided in myeloid and plasmacytoid DCs (mDC and pDCs, 
respectively). Although the name dendritic cell comes from the dendrite-shaped mDCs, 
the later discovered pDCs are round and contain a non-dendritic shape.66,67 This latter, 
relatively small, DC subset, is responsible for the generation of Type I interferons (IFN; e.g. 
IFNα) and are mainly involved in anti-viral responses. mDCs on the other hand can be 
subdivided in BDCA1+ and BDCA3+ DCs and respond to various toll-like receptor patterns, 
including dead cells.64,68,69
The activation of T cells is, next to recognition of their TCR-specific antigen, dependent 
on the balance between co-stimulatory and co-inhibitory signals. For instance, if a DC 
expresses high levels of the co-stimulatory ligand CD80, this can bind to the co-stimulatory 
molecule (CSM) CD28 on T cells. On the other hand, co-inhibitory receptors like cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4), B- and T-lymphocyte attenuator (BTLA), and 
Programmed Death-1 (PD-1) on T cells can bind to their corresponding ligands, inhibiting 
T cell activation.21,70,71 In the healthy situation, this inhibitory pathway prevents sustained 
T cell activation and thereby protects against induction of auto-immune diseases. One 
of the most studied co-inhibitory molecules (CIM) is PD-1, which can bind to its ligands 
PD-Ligand (PD-L)1 or PD-L2.70,72 The balance in signalling through these various CIMs 
and CSMs will determine the activation state of the T cell. Upon activation, T cells will 
start to proliferate and produce cytokines, for instance IL2 and IFNγ, which further boosts 
the immune response, and will result in a pro-inflammatory tumour micro-environment. 
Moreover, activated antigen-specific CD8+ T cells can recognize and kill tumour cells 
expressing the antigen of interest. Targeting an antigen which is expressed specifically by 
tumour cells can therefore boost the specific GVT-effect.
Important antigens in anti-tumour T cell immunity post-transplantion are tumour-
associated antigens (TAA) and allo-antigens. TAA are highly expressed by tumour cells, 
but generally also at low levels by normal cells. The immunogenicity of TAA varies, 
and immunotolerance could occur as these antigens are derived from self proteins. In 
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contrast, highly potent T cell-based immunity can be elicited against recipient-specific 
allo-antigens. Though allo-SCT is generally performed in a HLA-matched setting, there 
are many genetic differences between the patient and the donor due to single nucleotide 
polymorphisms (SNPs). These SNP variations can lead to amino acid differences between 
patient and donor peptide sequences, resulting in the formation of non-self epitopes 
for the donor T cell system. HLA-bound peptides derived from these polymorphic genes 
are called minor histocompatibility antigens (MiHAs).62 Over the last decades, extensive 
research has been performed on these MiHAs, as they are interesting targets for boosting 
specific post-transplant anti-tumour immunity. Namely, if the patient expresses the MiHA, 
but the donor does not (the so called MiHA-mismatch), a strong T cell response can occur 
against this MiHA. This is similar as observed for anti-viral responses, as in both cases the 
antigen is recognised as non-self.29,73 Our centre recently showed that the presence of a 
MiHA-mismatch is favourable for the clinical outcome of the transplantation.29 Especially 
in patients where MiHA-specific CD8+ T cells could be determined, an improved relapse-
free survival was observed. Interestingly, in various malignancies, the emergence of 
MiHA-specific CD8+ T cell responses was shown to precede clinical remission in patients 
treated with allo-SCT and DLI. These observations demonstrate the attractiveness of 
MiHAs as potent target antigens in post-transplantation immunotherapy to prevent or 
treat tumour recurrences.
By selection of MiHAs that are exclusively expressed by cells of the haematopoietic 
system, donor T cells will only attack these haematopoietic patients cells. This will result 
in a specific clearance of residual malignant cells after allo-SCT. In contrast, MiHAs with 
a broad expression pattern are the major players in inducing GVHD in a HLA-matched 
setting, as donor T cells will target this antigen also on healthy tissues.74,75 The best studied 
GVHD-related MiHAs are the HY-antigens.76 In the setting of a male patient who receives 
stem cells from a female donor, a donor T cell response can occur against the HY-antigen. 
This HY-antigen, expressed by all male cells, can be the cause of severe GVHD which is 
detrimental to the patient.29,77 Therefore, though transplantation of male patients with a 
female donor could result in anti-tumour reactivity via the HY-antigen, this might not be 
favourable due to the high-risk on the induction of severe GVHD.29 Importantly, several 
MiHAs have been discovered with a haematopoietic-restricted expression pattern. 
Interesting therapeutic MiHA-candidates in this respect are HA1,78 LRH1,79 UTA2-180 and 
ARHGDIB,81 which are presented in HLA-A2 or HLA-B7 and could mediate a selective GVT-
effect without the induction of GVHD.
Adoptive immunotherapy to boost anti-tumour immunity
Though effective GVT responses can be induced post allo-SCT, relapses remain a major 
problem. Therefore additive therapies are essential to improve clinical effects. In the 
development of these therapies, special attention should be paid to the balance between 
GVT and GVHD responses, in order to prevent the induction of severe and potentially 
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lethal GVHD. This can be achieved via various approaches. In this thesis we investigated 
adoptive transfer of UCB-NK cells, as well as generation and boosting MiHA-specific CD8+ 
T cells. 
Adoptive NK cell therapy
Adoptive NK therapy as cancer therapy started with infusions of autologous NK cells, though 
this appeared to be clinically ineffective.82,83 Therefore, a shift was made towards infusions 
of allogeneic NK cells, from a relative or unrelated donor. A number of trials have been 
performed with infusion of allogeneic NK cell in patients suffering from various malignant 
diseases.84 The group of Miller treated patients with renal cell carcinoma, recurrent ovarian 
cancer, breast cancer, and AML with T cell-depleted lymphocytes containing 20-45% NK 
cells, combined with three weeks of IL-2 infusions.85,86 In these studies the safety of NK cell 
therapy was shown, but remission was only observed in AML patients. As the sensibility 
of NK cell therapy towards haematological cancers was observed in multiple trials, current 
NK cell therapy focuses in the haematological setting.
The challenge in NK cell therapy is to obtain sufficient numbers of a relatively pure 
cell product. As NK cells are only 5-15% of the lymphocyte population, collecting NK cells 
from peripheral blood for adoptive therapy results in low NK cell numbers which could 
explain the limited clinical effects.87,88 More importantly, the peripheral blood NK-cell 
enriched product contains also contaminating allo-reactive T cells, which can result in 
detrimental GVHD. Alternatively, NK cells could be generated ex vivo from haematopoietic 
stem/progenitor cells (HSPC). This could result in a more pure NK cell product, with high 
cell numbers for multiple infusions which can contribute to a better anti-tumour effect 
and survival of patients suffering from a haematological malignancy. For that reason, a 
method was developed by our laboratory which generates high numbers of NK cells from 
UCB-derived CD34+ HSPCs.89-91 During a 6 week culture period, a unique infusion product 
is created which is rich (>70% pure) in NK cells with high cytolytic functions, and free of 
allogeneic T and B cells. These NK cells are currently tested in a Phase I clinical trial in the 
Radboudumc in Nijmegen (NL31699.000.10). The preclinical testing and optimisation of 
this NK cell therapy in vitro and in mouse models showed promising results, which are 
described in Chapter 5 and 6 of this thesis.
Boosting MiHA-specific CD8+ T cells
MiHAs are attractive targets for hosting a triggering GVT-effect. Enhancement of an anti-
tumour response could be achieved via the boosting of MiHA-specific CD8+ T cells. For 
this purpose, a MiHA should be selected of which the expression pattern is restricted to 
the haematopoietic system, thereby boosting a GVT response without the induction of 
GVHD.74,75,92 Research in the last decades defined many MiHAs which are restricted to the 
haematopoietic system.28,73,75,76,85 These could be used for additional therapeutic strategies. 
For instance, during donor selection a preference could be given to a haematopoietic-
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restricted MiHA-mismatch between the donor and the patient, if multiple donor 
candidates are available. In addition, T cell therapy could be applied by the adoptive 
transfer of ex vivo-generated MiHA-specific CD8+ T cells.93,94 Moreover, one could boost 
the expansion of MiHA-specific CD8+ T cells in vivo using DC vaccination, in which the DCs 
present only the MiHA of interest.95-97 
As DCs direct T cell responses against non-self and malignant peptides, they can be 
used as additive therapy to initiate, direct, or boost anti-tumour responses in vivo. In the 
last decades monocyte-derived DCs were used as therapeutic cells in various cancer 
fields.98-100 These studies showed that DC vaccination is a safe and promising strategy 
for the treatment of solid or haematological cancers in in vitro and mouse models. 
However, clinical trials show only limited efficacy.101,102 Therefore, DC vaccines need to be 
optimised, in order to impove the initiation and boosting of tumour-reactive T cells. As 
the activation of T cells is dependent on the balance of co-stimulatory and co-inhibitory 
signals, manipulation of the expression pattern of CIMs and CSM on DCs could generate 
more stimulatory DC for therapeutic purposes. This is of specific interest as it has been 
shown that upon chronic antigen stimulation, as is the case with persistent malignant 
cells, T cells have high expression of the inhibitory receptor PD-1.103,104 We have shown 
previously, that by interfering with this pathway, using blocking antibodies against PD-1 
or PD-L1, impaired T cells can be reinvigorated in their proliferation. Currently, several 
clinical trial are performed which demonstrate the potency of these blocking antibodies 
in the treatment of cancer.105,106 This shows that selective interference with CIMs and their 
ligands can result in an enhanced activation of T cells. The superior immunotherapeutic 
effect of interference with CIMs on DC was shown by our group, in which silencing of 
the co-inhibitory ligands PD-L1 and L2 resulted in more stimulatory DCs.96,97 This resulted 
in better outgrowth of MiHA-specific CD8+ memory T cells, compared to control DCs in 
vitro. The potential of these PD-L silenced DCs in priming of naive antigen-specific T cell 
responses, and boosting the expansion of MiHA-specific CD8+ memory T cells in a mouse 
model is investigated in Chapter 7 of this thesis.
Adoptive T cell therapy
Adoptive T cell transfer in the treatment of cancer has been applied in various approaches. 
One of these is the transfer of bulk T lymphocytes, obtained from PB and expanded ex 
vivo prior to infusion.107 Isolation of tumour-infiltrating lymphocytes (TILs) is an alternative 
strategy.108 These tumour-specific T cells are (after possible ex vivo expansion) transferred 
back to the patient. Currently, clinical trials are ongoing using engineered antigen-specific 
T cells.109-111 These studies combined demonstrate that the use of tumour-reactive T cells 
for additive anti-tumour therapy can be a strong strategy, however the choice of T cell 
is of critical importance. As mentioned previously, the antigen-specificity of the T cells 
is essential to gain a strong GVT-effect without the detrimental GVHD. In addition, the 
differentiation state of the T cells can determine the effectiveness of the therapy.
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Following antigenic stimulation of Tn precursor cells, proliferation and differentiation 
is initiated. Currently, two leading T cell differentiation models have been reported in 
literature, postulating either a linear or divergent differentiation model.112-114 Although 
there is controversy whether the generation of the effector/memory subsets occurs in 
hierarchy or side by side, both models result in the formation of functionally distinct T 
cell subsets. These contain the early memory subsets, stem cell memory T (Tscm) cells and 
central memory T (Tcm) cells, and the later arising subsets, effector memory T (Tem) cells and 
effector T (Teff) cells (Figure 3).
113,115 These subsets have been extensively characterized, 
each showing their own phenotypical and functional characteristics. Tn cells express the 
molecules CD45RA and CCR7.21,113 CCR7 is used by the Tn cells to gain access to the lymphoid 
organs like the lymph node, where they can meet DCs for activation. Upon differentiation, 
they lose expression of these markers and gain expression of CD45RO.113 Tscm cells reside 
within the Tn-like pool and can be discriminated from Tn cells using CD95.
116,117 Compared 
to Tn cells in response to an initial activation, the general hallmark of memory T cells is 
their ability to mount a faster and stronger proliferative response to antigen re-encounter. 
Conversely, although terminally differentiated Teff cells show potent anti-tumour killing 
capacity, most of them die after a single act of duty. While the early memory Tscm and Tcm 
cells possess not only higher proliferative capability, they are also capable of differentiating 
into the later effector T cell subsets.113,118 Most importantly, they can replicate themselves, 
known as self-renewal capacity. As this self-renewal capacity is less profound in other 
T cell subsets, Tscm-like cells would be most favourable for therapeutic approaches. This 
was demonstrated by Klebanoff et al, who showed the development of adoptive T cell 
therapy in time.119 Using the same mouse model, comparable anti-tumour effects were 
achieved with 500 times less Tscm cells than the ‘old fashioned’ IL2-activated Teff cell. This 
demonstrates the potential of Tscm cells in therapeutic strategies to fight malignant cells. 
Currently, protocols for the ex vivo generation of tumour-specific CD8+ T cells mainly 
result in Tem and Teff cells. As these are not the most optimal cells for adoptive T cell therapy, 
Figure 3. Linear T cell differentiation model. Upon activation of naive T cells, T cells will differentiate into 
various memory and effector cells. Proliferation and self-renewal capacity decreases upon differentiation. Tn, 
naive T cell; Tscm, stem cell memory T cell; Tcm, central memory T cell; Tem, effector memory T cell; Teff, effector T 
cell.
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early memory tumour-reactive T cells is favourable.113,120 There are various ways to interfere 
manipulation of the culture protocol to inhibit T cell differentiation and thereby generate 
with T cell activation and differentiation. First of all, cytokines can be used. As IL2 activates 
T cells, replacement by IL7, IL12, IL15, and/or IL21 has resulted in generation of T cells 
with various differentiation patterns.121-123 However, via these approaches anti-tumour 
immunity was not highly increased. Using a pharmaceutical inhibitor mimicking Wnt-
signalling on the other hand was more successful.124,125 This arrested T cell differentiation, 
resulting in Tscm cells, which after TCR-transfer provided a potent anti-tumour effect. 
However, due to a coincided block in proliferation,121 this strategy is not applicable in the 
absence of TCR-transfer. Targeting different pathways involved in T cell differentiation, 
which do not fully block T cell proliferation, would provide an alternative approach. The 
Akt-pathway is closely connected to the Wnt-signalling pathway and is involved in T cell 
differentiation.126 Manipulation of the Akt-pathway to ex vivo generate MiHA-specific CD8+ 
T cells with an early memory phenotype, is explored in Chapter 8 of this thesis.
Outline of this thesis
Allo-SCT can be a curative treatment for patients with a haematological malignancy. 
However, 30-40% of patients suffer from relapse of the malignant disease. Though certain 
T cells are of great importance in the GVT-effect targeting the malignant cells, others play 
a role in the detrimental GVHD causes high TRM, which is still around 15%. This occurrence 
of GVHD limits the therapeutic feasibility of allo-SCT. Therefore it is essential to understand 
the pathophysiology of this complication. In addition, additive therapies which boost the 
GVT-effect should be developed to lower relapse rates. These therapies should be tumour-
specific and should not increase the risk on GVHD. Combined, this will decrease relapse 
rates, which eventually will improve survival of allo-SCT patients.
To prevent GVHD or identify new therapeutic targets, it is important to understand the 
pathophysiology of this complication, with all players involved. Therefore, in the first part 
of this thesis, we investigated the role of a relatively new T cell subset in the development 
of GVHD, namely IL17-producing T cells. In Chapter 2, we reviewed IL17-producing T cells 
and various adjacent aspects, regarding their involvement in GVHD. We discuss the role 
of the pre-transplant conditioning, as well as different DC subsets which can trigger IL17-
producing T cells in the initiation of the inflammation. In addition, we discuss multiple 
pathways which could target the IL17 pathway to prevent the occurrence of GVHD.
To study whether IL17-producing T cells play a role in the initiation or enhancement 
of GVHD, we investigated whether SNPs in genes important for these T cells were 
associated with GVHD occurrence. In Chapter 3, the role of SNPs in the IL23 receptor and 
the chemokine receptor CCR6 in GVHD incidence are investigated. The receptor of IL23 is 
expressed on IL17-producing T cells, though in contrast to previous findings, we did not 
observe a correlation with the occurrence of GVHD. The chemokine receptor CCR6, which 
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is also expressed on IL17-producing T cells, is involved in trafficking of T cells towards 
inflamed tissues as well as trafficking to GVHD-prone organs like the liver, gut, and skin. 
We found that two SNPs in and close to CCR6 were correlated with the occurrence of 
chronic GVHD. This suggests that either of these SNPs may influence the function of CCR6, 
and thereby play a role in the migration of CCR6+ cells to GVHD-affected tissues.
Next, we further investigated the migration of IL17-producing T cells towards 
GVHD tissues in Chapter 4, using the marker CD161. It has been shown that CD161 is a 
distinguishing surface marker for CD4+ and CD8+ T cells producing IL17. We determined 
levels of circulating CD161+ T cells in patients post allo-SCT and correlated this with the 
occurrence of GVHD. We found that three months after allo-SCT, levels of CD161+ T cells 
were lower in patients who developed GVHD. These cells, which co-express CCR6, could 
home towards CCL20, which is expressed in GVHD-affected skin and gut. Finally, we 
showed that CCR6+ T cells were present in GVHD-affected skin and gut, further suggesting 
their involvement in the initiation and/or the development of the disease.
In Part II two of this thesis we investigated the potential of adoptive NK cells transfer as 
treatment for haematological malignancies. NK cells were generated from UCB-derived 
CD34+ HSPC, as described by our group,90,91 and tested for their in vivo anti-leukemic 
potential in mouse models. In Chapter 5 of this thesis we describe the migration potential 
of UCB-NK cells in vitro using various chemokine receptors and their ligands. In addition, we 
show the biodistribution of 111In labelled NK cells upon infusion in immune deficient mice. 
This demonstrated the migration of NK cells to the bone marrow, which is essential for 
targeting haematological malignancies. Moreover, we show that infused NK cells further 
mature in vivo, where they acquire expression of CD16 and KIRs. Finally, we tested the 
anti-tumour response of UCB-NK cells in our intrafemural (IF) AML tumour model. In this 
IF model the leukaemia is injected in its natural habitat, the bone marrow, to demonstrate 
the therapeutic potential NK cells upon migration. We show a strong reduction in tumour 
growth and 25% long-term survival of mice following adoptive NK cell therapy.
To further improve the potency of UCB-NK cells, the culture protocol was manipulated 
in which IL2 (NK15/2 cells) was replaced by IL12 (NK15/12 cells), as IL12 was described 
to possibly enhance functional properties. In Chapter 6, we describe that IL12 addition 
resulted in a NK cell product expressing higher levels of KIRs. These cells demonstrate 
greater anti-tumour responses in vitro and in our IF AML mouse model. We demonstrate 
that this is mediated by upregulation of ICAM-1, due to IFNγ which was dominantly 
secreted by KIR+ NK15/12 cells. Most importantly, NK15/12 maturated faster in vivo 
compared to NK15/2 cells, which could contribute to the improved anti-tumour effect.
Part III of this thesis describes the potential of ex vivo-generation of MiHA-specific CD8+ T 
cells for adoptive transfer, in combination with DC vaccination. In Chapter 7, we investigate 
the potency of PD-L silenced DCs. These DCs with more stimulatory potential showed 
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augmented priming of MiHA-specific CD8+ T cells in vitro. In addition, in immune deficient 
mice, antigen-specific CD8+ T cells could be efficiently expanded using DC vaccination. 
Most importantly, the expansion of adoptively transferred ex vivo-generated MiHA-
specific CD8+ T cells was superior after vaccination with PD-L silenced DCs compared to 
control DCs.
In Chapter 8, we focus on T cell differentiation during the ex vivo generation of MiHA-
specific CD8+ T cells. As early memory cells are postulated to have superior anti-tumour 
immunity, we studied the potency of inhibiting T cell differentiation via inhibition of the 
Akt-pathway. First, we show the lack of early memory MiHA-specific CD8+ T cells early 
post allo-SCT, indicating the need for additive MiHA-related therapies. Moreover, we 
demonstrate that by inhibition of Akt-signalling, T cell differentiation of primed MiHA-
specific CD8+ T cells could be inhibited, resulting in early memory T cells. These Akt-
inhibited MiHA-specific CD8+ T cells displayed improved expansion capacity in vitro and 
in vivo upon DC vaccination, which contributed to enhanced anti-tumour effect in our IF 
multiple myeloma bearing mice.
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Abstract
GVHD is still a major complication of allogeneic stem cell transplantation (allo-SCT). The 
pathophysiology of GVHD is a multistep process initiated by tissue damage and pro-
inflammatory cytokine cascades induced by the pre-transplant conditioning therapy. This 
eventually results in Th1-driven tissue damage. However, increasing evidence indicates 
the involvement of IL17-producing T cells in GVHD pathogenesis. Both CD4+ and CD8+ 
IL17-producing T cells are suspected to initiate the Th1 response and aggravate tissue 
inflammation, resulting in full blown GVHD. In this review, we discuss the involvement of 
IL17-producing T cells in GVHD and the factors involved in their expansion, differentiation 
and activation. Different dendritic cell (DC) subsets, like plasmacytoid DCs and DC NK 
lectin group receptor 1+ myeloid DCs have the capability to stimulate Th/Tc17 responses 
through the release of cytokines. Pivotal cytokines include IL1β, IL6, IL23, and TGFβ, 
which are known to drive differentiation and expansion of IL17-producing T cells, and 
these cytokines are highly elevated in patients after allo-SCT. Potent activators of these 
DC subsets are motifs that are released upon tissue damage and microbial exposure 
during allo-SCT. These motifs aggravate the Th/Tc17 response via the activation of 
various pathogen recognition receptors, thereby initiating and perpetuating GVHD. More 
comprehensive understanding of the factors and DC subsets driving the IL17 pathway will 
result in the development and testing of novel therapeutic approaches for the prevention 
of GVHD.
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Introduction
GVHD is still a major complication and limitation of allogeneic stem cell transplantation 
(allo-SCT).1,2 The pathophysiology of GVHD is a multistep process involving tissue damage 
and pro-inflammatory cytokine cascades induced by the pre-transplant conditioning 
therapy.2,3 Furthermore, innate immune activation caused by perturbed host-microbe 
interactions at epithelial barriers increases inflammation and antigen presentation.4 This 
results in an excessive inflammatory environment in which donor-derived CD4+  and 
CD8+ T cells become activated by antigen presenting cells. In addition, T cell trafficking 
towards inflamed GVHD-prone organs like skin, lung, gastrointestinal tract, and liver is 
strongly augmented. Further tissue destruction in these organs occurs in the case of 
presentation of ubiquitous or epithelial expressed allo-antigens to infiltrating alloreactive 
T cells. Moreover, dendritic cells (DC), macrophages, and other T cell subsets are recruited, 
resulting in further enhancement of GVHD. In particular, T-helper (Th)1-type CD4+ T cells 
and T-cytotoxic (Tc)-1 type CD8+ T cells play an important role in the effector phase of 
GVHD pathophysiology.1,2,5 However, recent studies indicate that also other T cell subsets, 
like Th/Tc17 cells, are involved in the initiation and aggravation of GVHD.6-9 In this review 
we will discuss the role of these IL17-producing T cells in GVHD development and potential 
therapeutic strategies targeting the IL17 pathway to diminish or prevent this detrimental 
complication. 
Requirements for differentiation of IL17-producing cells
Generally, IL17-producing T cells differentiate from naive T (Tn) cells, though plasticity 
of other T cell subsets into IL17-secreting T cells has been shown.10 The differentiation 
towards IL17-producing CD4+ (Th17) and CD8+ (Tc17) T cells is dependent on various 
cytokines (Figure 1). Several studies have shown the importance of IL1β and IL6 in Th/
Tc17 differentiation.11,12 This was shown both in mouse models as well as in vitro cultures 
of human T cells. The additional role of TGFβ in this process is still unclear, mainly due 
to differences in mouse and human studies. Most mouse studies showed that TGFβ 
is essential in Th/Tc17 differentiation. However, human Th/Tc17 cells can be generated 
in vitro without the presence of TGFβ.11 Generally, in the presence of IL1β and IL6 (and 
possibly TGFβ), while IFNγ and IL4 are absent to induce Th1 or Th2 skewing, differentiation 
to IL17-producing T cells is initiated. In addition, IL23 plays a pivotal role in the commitment 
and maintenance of Th17 cells.12 Furthermore, IL23 showed to play a major role in the 
generation of pathogenic Tc17 cells, as IL23 treated Tc17 cells were potent inducers of 
autoimmune diabetes, while Tc17 cells treated with TGF-β and IL6 were not.13 Moreover, 
the cytokine IL21 is also involved in self-maintenance, as this cytokine is produced by the 
Th/Tc17 cells themselves.14
The cytokines required for Th/Tc17 differentiation are released from diverse immune 
(e.g. myeloid DC (mDC) and plasmacytoid DC (pDC)) and non-immune antigen presenting 
cells on activation of pathogen recognition receptors (PRRs) by motifs released upon 
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tissue damage and/or microbial exposure, including various danger-associated molecular 
patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), respectively. 
Since the human body epithelial barriers are inhabited by multiple microbes, both 
Th17 and Tc17 cells are of particular importance in the protection against extracellular 
microbes and defence mechanisms in the epithelial barriers of skin, gut, and lung. 
Release of IL17 has indeed been shown to enhance barrier defence for instance by the 
production of antimicrobial peptides. Consistently, Th/Tc17 cells have been described 
to play a major role in the initiation of autoimmune disorders and other inflammatory 
conditions that originate at epithelial barriers such as Crohn’s disease and Psoriasis.15 As 
GVHD predominantly affects the gut, skin, and liver, Th/Tc17 cells are also suspected to be 
major players in the onset of GVHD.
Figure 1. Th/Tc17 cell differentiation. Cytokines produced by e.g. dendritic cells differentiate naive T cells 
(Tn) towards Th/Tc17 cells. DC, dendritic cell; Tn, naive T cell; Th/Tc, helper T cell/cytotoxic T cell.
Th/Tc17 cells and their role in GVHD
Indicative data from animal models
Several mouse studies demonstrated the involvement of Th/Tc17 cells in the onset 
and persistence of GVHD.7,16,17 Carlson et al. showed development of lethal GVHD upon 
injection of in vitro-generated Th17 cells in a bone marrow transplantation mouse model.7 
In addition, adoptive transfer of IL17-/- T cells delayed the occurrence of GVHD compared to 
wild type (WT) T cells.17 However, the precise role of Th/Tc17 cells in GVHD is still debated 
as Yi et al. reported initiation of Th1-driven GVHD in the absence of IL17.18 On the contrary, 
Yi et al. also observed IL17-driven GVHD when the Th/Tc1 cytokine IFNγ was absent.19 
Interestingly, Yu et al observed a lower GVHD incidence while sparing the GVT effect, only 
when both the Th/Tc17 driving transcriptions factor retinoic acid-related orphan receptor 
(ROR)γt as well as Th/Tc1 inducing transcription factor t-bet were targeted simultaneously.20 
Targeting only RORγt elevated IFNγ levels, while IL17 was highly increased when t-bet was 
abolished. But, targeting both resulted in the lack of both cytokines and the absence of 
GVHD. Interestingly, Fulton et al attenuated GVHD by only targeting RORγt, though in this 
mouse model no increase in IFNγ was observed as a consequence of lacking IL17.21 In 
addition, targeting RORγt in this mouse model only effected serum IL17, while Yu et al 
showed disturbed levels in several GVHD target organs.20,21
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Next to IL17, Th/Tc17 cells could also play a role in GVHD via production of IL22.22 
IL22, which is related to the IL10-family, has a paradoxical role in inflammation with both 
protective and inflammatory effects. Though it was shown that IL22 produced by innate 
lymphoid cells protected intestinal stem cells from immune-mediated damage during 
GVHD,23 IL22 is also involved in the pathogenesis of several inflammatory diseases like 
rheumatoid arthritis and psoriasis.24,25 Interestingly, a recent study revealed a possible role 
of IL22 in GVHD as adoptive transfer of IL22-/- instead of WT T cells reduced acute GVHD 
severity.26 In conclusion, collective findings in experimental mouse models suggests 
that Th/Tc17 contribute to the pathophysiology of GVHD through both IL17 and IL22 
production.
Studies in allo-SCT patients
Next to mice, a key role of Th/Tc17 cells in human GVHD pathogenesis has been 
reported.6,8 Interestingly, increased levels of circulating Th17 cells have been described 
in GVHD patients.8,27 For instance Liu et al showed increased circulating IL17-producing 
CD4+ T cells in patients at the onset of GVHD, compared to time matched controls.27 
Furthermore, a single nucleotide polymorphism (SNP) in the IL23 receptor, important in 
Th/Tc17 differentiation, has shown a protective role in the development of acute GVHD 
in two independent studies.28,29 However, as the functional consequence of the SNP is yet 
unknown, it cannot be stated whether IL17 differentiation would be inhibited or enhanced. 
Although the potential involvement of Th17 cells in GVHD has been proposed by multiple 
studies, Broady et al. found an expansion of Th1 rather than Th17 cells in GVHD-affected 
skin.30 However, Th17 cells have been shown to co-produce IFNγ or revert completely 
into Th1 cells.10 Regarding this proposed plasticity of Th17 responses, other (surface) 
markers would be more reliable to study the involvement IL17-producing T cells in GVHD. 
Using CD161, the distinguishing surface marker for both CD4+ and CD8+ T cells capable 
of producing IL17,31 we recently showed decreased levels of circulating Th/Tc17 cells in 
GVHD patients, while they infiltrated in GVHD-affected skin.9 This was in concordance with 
data published by Bossard et al. who reported significantly higher absolute numbers of 
Th/Tc17 cells in GVHD-affected intestinal mucosa, using the markers CD161, RORγt, and 
CC chemokine receptor (CCR)6.6 This suggests that Th/Tc17 cells could be involved in the 
onset of GVHD via their migration potential toward GVHD target organs, thereby exerting 
a pro-inflammatory effect as well as increasing the recruitment of alloreactive Th/Tc1 
cells and other immune cells. However, many factors like the conditioning regimen and 
different post-transplant immune suppressive therapy will have a prominent impact on 
expansion kinetics and involvement of Th/Tc17 and Th/Tc1 responses in GVHD in patients.
Th/Tc17 trafficking to GVHD target organs
Migration towards GVHD target organs could take place via multiple chemokine axes 
as Th/Tc17 cells display high levels of the chemokine receptors CCR6 and CXCR3.22 
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Interestingly, we showed that a single nucleotide polymorphism in CCR6 present in the 
donor, resulted in lower GVHD incidence.32 Its ligand, CCL20, is constitutively expressed 
in the GVHD target organs such as the liver, colon, small intestine, lung, and skin.33 
Additionally, damage of the epidermal permeability barrier, as well as stimulation with 
IL1ß – both known to be elevated after conditioning of allo-SCT patients – results in up-
regulation of CCL20 expression.9,34,35 We indeed showed that GVHD-affected skin and gut 
display high expression of CCL20 both by keratinocytes and infiltrating immune cells.9 
Furthermore, increased expression of the CXCR3-ligands, CXCL9 and CXCL10, has also 
been described in serum of GVHD-patients and their affected tissues.36 These chemokines, 
which are strongly upregulated upon inflammation, can attract migrating Th17 cells, 
resulting in their recruitment into GVHD-affected tissues, and therefore decreased levels 
of circulating CXCR3+ T cells as described in GVHD patients.36,37 This endorses the various 
migration routes of Th/Tc17 cells towards GVHD-target tissues.
Crosstalk of Th/Tc17 with Th/Tc1 cells 
Upon recruitment of Th/Tc17 cells into GVHD tissues, other T cell subsets are attracted. 
Crosstalk between Th/Tc1 and Th/Tc17 cells in GVHD development is very likely as has 
also been suggested in other immune related diseases.38,39 In this regard we suggest that 
shortly after allo-SCT Th/Tc17 cells could play an important role in initiating the GVHD 
response, which is thereafter overshadowed by a tremendous Th/Tc1 response causing 
the main damage in the tissues. This hypothesis has been underscored by histological 
data showing that in early-stage mild gut GVHD higher numbers of Th17 cells were found 
than in patients with severe GVHD after allo-SCT.40 Possibly, Th/Tc17 and Th/Tc1 responses 
act either sequential or simultaneously together in GVHD. This was also observed in 
inflammatory bowel disease, another IL17-driven disease, in which a synergy of Th1 and 
Th17 cytokines was observed.38 The dependence of these subsets upon each other has 
been clearly demonstrated in different studies. In the absence of IFNγ (with or without 
IL4) differentiation towards IL17-producing T cells was increased, resulting in augmented 
GVHD.19 However, visa versa, lack of IL17 increased IFNγ production, resulting in Th1-
driven GVHD.18 Taken together, crosstalk between Th/Tc17 and Th/Tc1 cells is apparent 
in the setting of GVHD, in which upon initiation of Th/T17 cells, Th/Tc1 cells will be 
potently activated and aggravate the disease. However, no hard evidence yet exist for this 
sequential T cell response and further research is warranted to understand dynamics and 
crosstalk of these two cooperating T cell subsets in GVHD.
Factors promoting Th/Tc17 activation and expansion after allo-SCT
Role of DC subsets
The role of DCs in GVHD development has been established more than a decade ago by 
Shlomchik et al.41 Although it has been demonstrated that both DCs from host as well 
as the donor can contribute, less is known about the role of the different DC subsets in 
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GVHD. The most common known DCs, the mDCs, have been shown to play a role in GVHD 
in several mouse models.41,42 Especially, depletion of host mDCs in recipient mice has been 
shown to prevent GVHD. In addition, low levels of circulating mDCs in allo-SCT patients 
have been described to correlate with the development of severe acute GVHD, suggesting 
migration of these cells to GVHD sites.43 
Another DC subset which has recently been associated with GVHD are pDCs. Notably, 
increased levels of pDCs were detected in affected gut tissue of acute GVHD patients.6 
Also a decrease in circulating pDCs was correlated with acute GVHD, suggesting active 
migration from the periphery into inflamed tissue.43 Furthermore, pDCs are capable of 
producing high levels of IL1β, a key cytokine in the development of GVHD and the IL17 
differentiation pathyway.44,45 Interestingly, it was shown that presence of IL1β resulted 
in increased IL17 production by CD161-expressing CD8+ Tc17 cells.46 Moreover, pDC 
leukaemia is often associated with isolated cutaneous lesions due to skin accumulation of 
leukemic pDCs,47 suggesting their involvement in inflammatory diseases of the skin, like 
GVHD.
Moreover, pDCs could be potentially activated via TLR9 by self-DNA, released upon 
the pre-transplant conditioning. While viral DNA can gain access to the intracellular TRL9 
receptor, self-DNA does not gain direct entry to endosomes and TLR9 under normal 
conditions. However, in the presence of the endogenous cationic antimicrobial peptide 
LL37, pDCs can be also activated by self-DNA.48 The main function of LL37 peptide is 
to prevent microbial invasion of damaged epithelial surfaces by directly killing a broad 
spectrum of pathogens including bacteria, protozoa, fungi, and viruses. Besides this, it 
has the ability to bind self-DNA, released by for instance dying cells after the conditioning 
regimen, to form aggregates and condensed particles that are transported into pDCs, 
allowing TLR9 signalling.48,49 LL37 is normally not expressed in healthy skin, but is transiently 
produced by keratinocytes and released by infiltrating neutrophils in response to skin 
wounding or infections.50 In psoriatic skin, LL37 has been identified as a key mediator in 
pDC activation.48 As the conditioning regimen, containing chemotherapy and total body 
irradiation, probably results in increased LL37 and self-DNA exposure, and thereby robust 
pDC activation, a Th/Tc17 response will be triggered, starting the inflammatory response 
of GVHD.
Another relevant DC subset possibly involved in the initiation of GVHD could be DC NK 
lectin group receptor 1 (DNGR1)+ CD141+ mDCs. This DC subset, capable of producing IL6, 
IL12, TNF, and IFNβ, has the capacity to induce Th17 responses.51,52 Recently, it was shown 
that these DNGR1+ DCs are activated upon interaction with filament actin (F-actin), which 
has been shown to be strongly exposed upon cell damage.53 Since the pre-transplantation 
conditioning regimen of allo-SCT patients results in host tissue damage and thereby 
possible exposure of F-actin, DNGR1+ DCs could be activated and thereby promoting 
Il17 responses. Therefore, both pDCs as well as DNGR1+ DCs could play a key role in the 
activation of IL17-producing T cells and thereby in the onset of GVHD.
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Role of microbe- and damage association patterns
The role of innate immune activation by host microbe interactions at epithelial barriers in 
the pathogenesis of GVHD is increasingly recognized.4,54,55 Already in 1971 it was shown 
by studies in chimeric mouse models that germ-free or gut-decontaminated mice showed 
reduced GVHD-related mortality.56,57 Recently, the composition of the gut microbiota 
and changes that occurred therein following allo-SCT were shown to be pivotal in the 
pathogenesis of GVHD in both mice and humans, supporting previous observations.58 
Bacteria and fungi, but also viruses, have been associated with the occurrence of GVHD.59-
61 In addition, the use of antibiotics resulted in reduced anaerobic bacteria and a lower 
incidence of acute GVHD.62 The fungus Candida albicans has also been shown to result 
in increased incidence of acute GVHD.63 This was in line with the study of Marr et al. who 
showed that prophylactic fluconazole prevented Candida infections, and resulted in a 
lower GVHD incidence.64 
These microbes, and their PAMPs, that potentially contribute to GVHD are mainly 
present early after allo-SCT, which is during the initiation phase of GVHD.61 Intriguingly, 
most of these commensal microbes and pathogens can elicit strong Th17 responses. As 
several microbes elicit plastic immune responses during the progress from mucosal to 
systemic infection, with Th17 responses preceding Th1, it can be imagined that Th/Tc17 
might be an early event in GVHD that precedes massive Th/Tc1 driven tissue damage. 
Microbes could influence Th17-mediated GVHD indirectly by activating innate immune 
cells via PRRs and more directly and specific by eliciting CD4+ and CD8+ T cell responses 
through the several DCs subsets. The role of the latter in GVHD is unknown but suggested 
by a role for microbe-specific CD4+ Th17 and Th1 responses in colitis and syngeneic GVHD 
of the gastrointestinal tract.65,66 In addition, Jankovic et al. showed that activation of the 
PRR NLRP3 by PAMPs and DAMPs, i.e. uric acid, contributed significantly to the occurrence 
of intestinal GVHD, which was mediated by IL1β-mediated skewing of the Th response 
towards a Th17 type.67 Furthermore, it has been observed that Th17 cells can respond 
to microbial antigens.68,69 More specifically, CD161-expressing T cells can be activated 
by Escherichia coli resulting in an inflammatory cytokine response.68 In addition, IL17-
secretion by CD4+ T cells was observed upon stimulation with Candida albicans.69 Plausibly, 
pDCs could play a role in the activation of Th17 cells by microbes via TLR 7 and 9.70 In 
this regard, Yu et al. found increased IL17 production by T cells upon co-culture with TLR7 
stimulated pDCs.45 In addition, similar data was observed when pDCs were activated with 
Influenza A or HIV-infected cells. As also viral infections by herpes simplex virus (HSV) and 
cytomegalovirus (CMV) have been associated with the occurrence of GVHD, activation of 
pDCs by these viruses could contribute to the initiation of the disease.59,60 Furthermore, 
pDCs are activated by extracellular and intracellular bacterial DNA and RNA, supposedly 
via TLR7 and TLR9 after CD32-mediated uptake.71,72 In an animal model for the Th17-driven 
disease Multiple Sclerosis, initiated by exposure to Mycobacterium tuberculosis and 
pertussis toxin, depletion of pDCs resulted in less severe clinical symptoms as well as less 
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Th17 cells.44 All together, this supports that pDCs could also initiate a Th/Tc17-response via 
activation by microbial antigens.
Role of cytokines
Pre-transplant conditioning regimen results in tissue damage with a subsequent rise of 
various (pro-inflammatory) cytokines.73,74 Already within the first weeks after allo-SCT, 
levels of IL1β, IL6, IL8, IL10, IL21, IL23, and TNFα are increased, which can remain high up 
to 12 weeks after allo-SCT.27,73 Increased levels of IL6 have been reported in several studies 
and has been correlated to the occurrence of infections and GVHD.75,76 Importantly, TGFβ 
appears also elevated during the first weeks after allo-SCT in acute GVHD patients.74 As 
described in previous paragraphs, these cytokines are mainly produced by DCs upon 
activation due to tissue damage and microbe exposure. Several of these cytokines are 
involved in the differentiation and expansion of Th/Tc17 cells, which could result in 
increased levels of Th/Tc17 cells after allo-SCT, as previously described by us and others.8,9
Additionally, a trend towards higher IL17 serum levels has been observed in acute 
GVHD patients.77 This was in alliance with data published by Espinoza et al. who found 
that patients receiving a transplant from donors with a SNP in the promoter region of the 
IL17 gene, were more prone to the development of GVHD.78 Interestingly, T cells with this 
allele produced more IL17 than those without. Furthermore, Lui et al. showed increased 
IL17 in the serum of GVHD patients, however IL22, also produced by Th/Tc17 cells, was 
decreased in these patients.27
Next to IL17 and IL22, Th/Tc17 cells also produce IL21 to support self-renewal.14 The 
lack of the IL21R on T cells prevented GVHD while sparing the GVT effect.79 However, only 
low IL17 levels were detected in this mouse model, and the lack of IL21R on T cells resulted 
mainly in an increase of Tregs which could play a role in the prevention of GVHD. In this 
regards, antibody blockade of IL21 also protected mice from the development of GVHD.80 
Also in this study no effect on IL17 levels were detected, though IFNγ was decreased and 
again an increase of Tregs was described.
Taken together, the increased levels of cytokines induced by the conditioning regimen 
results in expansion and activation of Th/Tc17 cells after allo-SCT. This could be an 
important, initial driver of the development of GVHD, though the cytokines produced by 
the Th/Tc17 cells might not all contribute to GVHD development.
Targeting Th/Tc17 responses to prevent GVHD
Currently, GVHD treatment options rely largely on the suppression of the whole immune 
system, using immunosuppressive drugs such as cyclosporine A and mycophenolate 
mofetil. Though this treatment can reduce GVHD intensity in a proportion of the patients, 
treatment success remains modest, especially in patients with severe GVHD.81 In addition, 
suppression of the whole immune system predisposes patients to an increased risk of 
infections and tumour relapse. Therefore, selective prevention of GVHD would be a far 
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more favourable strategy. With more comprehensive understanding which factors and T 
cells subsets are involved in GVHD development, improved targeting strategies could be 
exploited to prevent GVHD. Selective GVHD prevention will likely reduce the non-relapse 
related mortality, and importantly increase quality of life. 
Manipulation of T cells in graft and DLI
Complete or partial depletion of T cells from the graft has the ability to reduce the 
occurrence of GVHD.82 However, crude T cell depletion strategies will also reduce the 
therapeutic graft-versus-tumour (GVT)-effect. By more specific T cell depletion strategies, 
like depletion of  only CD161+/Th/Tc17 cells, the GVT effect could be sustained by the non-
GVHD initiating T cells. In addition, depletion of the different DC subsets, such as pDCs 
and DNGR1+ DCs, could also be a target as specific depletion of DCs from the graft could 
inhibit the initiation of GVHD. Though, to spare the GVT-effect, depletion of specific DC 
subsets might be more favourable.
In vivo manipulation of Th/Tc17 cell differentiation
In addition to manipulation of the graft and donor lymphocyte infusion, in vivo targeting 
of Th/Tc17 cell populations could additionally lower the generation of these cells in time. 
Upregulation of the gene RORyt is crucial in the generation of Th/Tc17, as in the absent 
of this transcription factor, Th/Tc17 differentiation is lost. Different mouse models showed 
less GVHD upon adoptive transfer of RORγt-/- compared to WT T cells.20,21 In patients, small 
molecule inhibitors for RORγt, as described by Huh et al,83 could prevent the differentiation 
of Th/Tc17 cells, and thereby prevent the occurrence of GVHD.
PRR inhibitors
Prevention of GVHD could also be achieved by prevention of the activation of DCs by 
PAMPs and DAMPs. As these molecules have been implicated in GVHD pathobiology 
extensively, especially during the initiation phase, they could be promising cascade targets 
in the prevention of GVHD.33 By inhibiting the PRRs, activation of pDCs and DNGR1+ mDCs 
could be prevented, thereby suppressing the Th/Tc17 activation. 
Cytokine inhibition
An alternative approach to inhibit Th/Tc17 responses would be to influence cytokine 
cascades involved in the IL17 pathway. Blocking of IL1β, which is a major player in GVHD, 
with Canakinumab (IL1β antibody) or its receptor with Anakinra (IL1R antagonist), could 
interfere with the activation of Th17 cells.84 However, blockade of IL1β has shown some 
contradictory results in GVHD treatment.85 Promising results have been obtained by anti-
IL17 (Ixekizumab) and anti-IL17 receptor (Brodalumab) in the treatment of the IL17-driven 
skin disease Psoriasis.86,87 Although, blocking IL17 using Secukinumab (IL17 blocking 
antibody) was associated with increased infections in Crohn’s disease patients, only local 
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and no systemic fungal complications were observed showing the feasibility to safely 
interfere with Th17 responses.88 Promising results have also been found by depletion of 
the p40 subunit of IL12 and IL23 with Ustekinemab (IL12/IL23 blocking antibody), which 
is approved for the treatment of Psoriasis. A recent case report showed the potency of 
Ustekinemab in GVHD treatment, as a complete remission was observed after treatment 
of steroid-resistant GVHD with this blocking antibody.89 Depletion of IL12 (p70) and 
IL23 could also be achieved by using a small molecule inhibitor, which also for Psoriasis, 
resulted in lower IL17 levels.90 Combined, blockades of signalling pathways could be used 
for the prevention and or treatment of GVHD, blocking the Th/Tc17 initiation.
Conclusion and future perspectives
Recent years, new and exciting insights have been gained in the pathogenesis of 
GVHD, and increasingly, a role for IL17-producing cells and the Th/Tc17 pathway has 
been acknowledged. In the future, it might be proven that the specific context of allo-
SCT determines whether IL17-producing T cells play an important role or not. As IL17-
producing cells are mainly involved in epithelial barrier defences of gut, lung, and skin, 
organs where GVHD occurs, it can be anticipated that the role of the Th/Tc17 pathway in 
GVHD is greatest in the presence of tissue damage (e.g. resulting from myeloablative and 
reduced-intensity conditioning), microbial exposure (e.g. infection or gut translocation), 
and release of pro-inflammatory cytokines including IL1ß, IL6 and IL23. Consequently, 
IL17-producing cells emerge and activate early on, that is during or directly after the 
conditioning-induced tissue damage and innate immune activation. Thereafter, they set 
the stage for full-blown GVHD by inducing aggravated tissue inflammation, immune cell 
recruitment, and priming alloreactive Th1/Tc1 responses. Being an early event in GVHD, 
the Th/Tc17 pathway seems a both logical and suitable target for preventive interventions, 
and this is most appealing as treatment of manifested acute GVHD remains difficult with 
50% being steroid refractory and resulting in a high mortality.
Many factors are involved in the differentiation, expansion and activation of IL17-
producing T cells in allo-SCT recipients. Different DC subsets, like pDCs and DNGR1+ mDCs, 
have the capability to activate Th/Tc17 cells through the release of cytokines. Pivotal 
cytokines include IL1β, IL6, IL23, and TGFβ, which are known to drive the differentiation 
and expansion of IL17-producing T cells and these cytokines have been shown elevated in 
patients after allo-SCT. Potent activators of these DC subtypes are motifs that are released 
on tissue damage (and microbial exposure) during allo-SCT. These motifs aggravate the 
Th/Tc17 response via activation of various PRRs, thereby initiating and perpetuating 
GVHD. At all these different levels interventions are possible (which are summarized in 
Figure 2). Attractive approaches are preventing the occurrence of tissue damage by using 
less toxic conditioning, and inhibiting Th/Tc17 generation by scavenging PAMPs and 
DAMPs that activate DCs, modulating the PRR pathways, and/or inhibiting key cytokines 
with monoclonal antibodies e.g. IL1ß with Anakinra and Canakinumab, and IL23 with 
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Ustekinumab. In addition, Th/Tc17 can be targeted more specifically by depleting them 
from the graft, inhibiting their tissue homing properties, or inhibiting their effector 
cytokines and related receptors, especially IL17, for instance with Ixekizumab and 
Brodalumab.
Although much new preventive strategies seem promising, further investigations are 
warranted. Still many question remain to be answered on the role of different subsets of 
lymphocytes, including Th/Tc17, in acute GVHD. Nevertheless, the insights we now gain 
rapidly on the IL17-producing T cells open up new ways that can, and should be explored 
for the prevention and treatment of GVHD. This way we could enhance allo-SCT outcome 
and improve the quality-of-life of haematology patients.
Figure 2. Th/Tc17 pathway involved in GVHD and it potential targets. TBI, total body irradiation, F-actin, 
filament actin; DNGR1, DC NK lectin group receptor; DC, dendritic cell; DAMP, danger-associated molecular 
patterns; PAMP, pathogen-associated molecular patterns, Th/Tc, helper T cell/cytotoxic T cell.
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Abstract
Graft-versus-host disease (GVHD) and fungal infections are frequent complications 
after allogeneic haematopoietic stem cell transplantation (allo-SCT). Single nucleotide 
polymorphisms (SNPs) in genes of the immune system can influence the inflammatory 
cascade and T cell-driven alloimmune reactions after allo-SCT, and thus increasing the 
incidence of GVHD and infectious complications. Here, we investigated the effect of SNPs 
in IL23R and CCR6 on post-transplantation outcome in 161 recipients of partially T cell-
depleted allo-SCT. Remarkably, IL23R SNPs were not associated with clinical outcome, 
but we found that disparities in the CCR6 tagSNP rs2301436 and SNP rs3093023 are 
independently associated with the occurrence of chronic GVHD (cCVHD) and invasive 
fungal disease. In multivariate analysis, patients receiving a transplant from a homozygous 
rs2301436 G allele donor showed less cGVHD (odds ratio (OR) 0.16; p=0.002), as was the 
case for a homozygous donor rs3093023 G allele (OR: 0.24 p=0.005). In parallel, this GG 
genotype at rs2301436 in donors was associated with a higher incidence of invasive 
fungal disease at day 100 after allo-SCT (OR 3.59; p=0.008). This study shows that CCR6 
SNPs can be used to predict clinical outcome, and that polymorphisms in the CCR6 gene 
may influence T cell-mediated immune reactions after allo-SCT.
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Introduction
Graft-versus-host disease (GVHD) and fungal infections remain major causes of morbidity 
and mortality in allogeneic haematopoietic stem cell transplantation (allo-SCT).1 The 
pathophysiology of acute GVHD (aGVHD) is a multistep process involving tissue damage 
and cytokine release induced by pre-transplant conditioning followed by alloreactive 
T cell expansion, trafficking and destruction of target tissues by effector T cells.2 The 
pathogenesis of cGVHD is even more complex and has not yet been fully defined.3;4 
Recent insights have challenged the paradigm of GVHD being almost exclusively a Th1 
mediated immune disorder as studies have shown a role for Th17 responses in acute as 
well as cGVHD. Similarly new insights have emerged in the field of antifungal immunity 
showing a pronounced role of Th17 responses, including the release of cytokines IL17 and 
IL22, in fungal defences complementing Th1 responses.
The IL23/Th17 pathway is a new player at the crossroads of innate and adaptive 
immunity.5 Th17 cells are induced by the release of IL1β, IL6, and TGFβ from APC, and 
further expansion is enhanced by IL23, although controversy still exists because of 
the considerable differences seen in animal and human studies.6 Th17 CD4+ T cells are 
characterized by expression of retinoid-related orphan receptor-γt (RORγt) and the 
chemokine receptors CCR4 and CCR6.7 CCR6 expression has recently been shown pivotal 
for Th17 migration to the gut in inflammatory bowel disease and the joints in rheumatoid 
arthritis.8 Th17 responses seem predominantly involved in host  barrier defences of the 
skin and mucosa,9 enhancing the innate immunity against extracellular microorganisms, 
including fungi, through increased phagocyte recruitment and production of antimicrobial 
peptides.10 However, this pathway is also reportedly involved in the occurrence of 
different autoinflammatory and autoimmune diseases.5;11 Therefore, the IL23/Th17 axis is 
now studied with regards to transplantation complications, with an emphasis on GVHD 
and infections, although the existence of alloreactive Th17 cells also suggests a possible 
role in graft-versus-tumour (GVT) immunity.12-14 However, most studies on the IL23/Th17 
axis in GVHD have been performed in animal models and the role in human GVHD is still 
controversial.15;16
Currently, the strongest evidence for a role of the IL23/Th17 pathway in human 
allo-SCT comes from the association between a non-synonymous IL23 receptor (IL23R) 
single nucleotide polymorphism (SNP), rs11209026 (Arg381Gln) in transplant donors 
and the incidence of aGVHD.17-19 This SNP is one of the now many so-called non-HLA 
polymorphisms that have been associated with allo-SCT outcome.20 Previously, we have 
shown that performing partial T cell depletion of donor transplants did not reduce the 
impact of nucleotide-binding oligomerization domain 2 (NOD2) SNPs on GVHD and 
treatment-related mortality (TRM) in the setting of HLA-matched sibling allo-SCT.21 In order 
to investigate whether SNPs in genes that are more directly involved in T cell-mediated 
immunity, including those involved in the IL23/Th17 pathway, are more influenced by the 
T cell depletion strategy, we undertook a retrospective analysis on the impact of IL23R 
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polymorphisms (rs11209026 and rs11805303) in a homogenous cohort of Dutch patients 
(n=161) receiving a partially T cell-depleted allo-SCT. In addition, we studied the impact 
of a tagSNP for CCR6 (rs2301436) and SNP rs3093023, as these SNPs have been associated 
with the occurrence of Crohn’s disease and rheumatoid arthritis.22;23 
Here, we found that the IL23R SNPs did not associate with the occurrence of GVHD, but 
we show that CCR6 tagSNP rs2301436 and SNP rs3093023 were significantly associated 
with less cGVHD. In addition, CCR6 tagSNP rs2301436 was also associated with a higher 
incidence of invasive fungal disease (IFD) following partially T cell-depleted allo-SCT. 
Patients and Methods 
Patients and donors
One hundred and sixty-one (n=161) Dutch patients and their donors were included in 
the study. All had been admitted to our transplant unit between 1996 and 2009 for an 
HLA-matched sibling, partially T cell-depleted allogeneic allo-SCT. In order to obtain the 
most homogenous cohort possible, we selected only patients receiving myeloablative 
conditioning. One hundred and twenty-four (n=124) patients had been given idarubicin 
in their conditioning regimen. The characteristics of patients, donors and SCT procedures 
are depicted in Table 1. Patients and donors had given their informed consent to the 
prospective collection of data and DNA samples for investigational use, which was 
approved by the Radboud university medical center Institutional Review Board.
Treatment protocol
All patients had been treated according to the same protocol that has been described 
previously.21 Briefly, the conditioning regimen consisted of cyclophosphamide (60 mg/
kg for 2 days) in combination with either total body irradiation (TBI 4.5 Gy for 2 days) 
or busulfan (4 mg/kg for 4 days). Idarubicin (42 mg/m2 in 48 hours) was often added in 
these conditioning regimens to reduce the risk of relapse in the setting of partially T cell-
depleted allo-SCT.24 On day 0, all patients were given a stem cell graft containing a median 
of 3.4 x 106 CD34+ cells/kg (range 0.8-11.6; bone marrow or peripheral blood stem cells) 
and a median of 0.5 x 106 CD3+ T cells/kg (range 0.3-0.8) achieved by dosed T cell ad back. 
GVHD prophylaxis consisted of cyclosporine A (CsA) only. Anti-microbial prophylaxis 
consisted of 500 mg ciprofloxacin given twice daily and 500 mg valaciclovir given three 
times daily. Fluconazole was only given at a dose 200 mg/d orally to patients who were 
considered colonized by Candida albicans. No mold-active prophylaxis was given. 
Definition of outcome variables
aGVHD was graded according to the criteria by Przepiorka et al and cGVHD were classified 
according to the revised Seattle criteria of Lee et al.4,26 IFD were scored according to the 
EORTC/MSG consensus guidelines, but only probable and proven cases were included in 
the analysis.25 Blood cultures were considered positive if a microorganism was recovered 
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from one or more bottles, with the exception of coagulase-negative staphylococci, for 
which two separate positive blood cultures with the same strain were required.27 Early 
gram-positive bacteraemia was defined as bacteraemia with streptococci or staphylococci 
occurring between the start of conditioning until engraftment. TRM, disease-free survival 
(DFS), and overall survival (OS) were defined according to standard criteria. 
Characteristic Study group (n=161)
Median age at transplantation, years (range) 48 (19-64)
Sex, no. male (%) 104 (65%) 
Sex of patient/donor pair, no. (%)
- Male/female
- Other
42 (26%)
119 (74%)
Underlying disease, no. (%)
- AML/MDS
- ALL
- CML/MPS
- NHL/CLL
88 (55%)
18 (11%)
29 (18%)
26 (16%)
Advanced disease stage, no. (%) 46 (29%)
Conditioning regimen, no. (%)
- Cy-Bus
- Cy-TBI
- Ida-Cy-Bus
- Ida-Cy-TBI
8 (5%)
29 (18%)
16 (10%)
108 (67%)
Stem cell source, no. (%)
- Bone marrow
- Peripheral blood
62 (39%)
99 (61%)
T cell depletion method, no. (%)
- Elutriation
- CD34 selection
- CD3/CD19 depletion
44 (27%)
85 (53%)
32 (20%)
Acute GVHD, no. (%)
- Grade 2-4
- Grade 3-4
57 (35%)
21 (13%)
Chronic GVHD, no. (%)
- Limited
- Extensive
n = 142
16 (10%)
25 (16%)
Invasive fungal disease day 100, no (%)
- Candidaemia
- Invasive mould disease*
- Probable/proven
16 (10%)
12 (7.5%)
8 (5%)
Table 1. Patient, donor and transplant characteristics. *EORTC/MSG consensus.25 Abbreviations: 
AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; ALL, acute lymphatic leukaemia; 
CML, chronic myeloid leukaemia; MPS, myeloproliferative syndrome; NHL, non-Hodgkin lymphoma; 
CLL, chronic lymphatic leukaemia; Cy, Cyclophosphamide; Bus, busulfan; Ida, idarubicin; TBI, total body 
irradiation; GVHD, graft-versus-host disease.
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SNP genotyping using the KASPar system
Genotyping was performed for SNPs rs11209026 (Arg381Gln) and rs11805303, which 
are polymorphisms in the IL23R gene and in linkage disequilibrium with each other.28 In 
addition, a tagSNP for CCR6, rs2301436, was genotyped. This SNP is located in the FGFR1OP 
gene, adjacent to CCR6, and has been associated with Crohn’s disease.23 SNP rs3093023 
is located within the CCR6 gene and has been associated with rheumatoid arthritis.22 The 
HLA-matched allo-SCT donor-recipient pairs were genotyped by specific KASPar assays 
(KBioscience, Hoddesdon, United Kingdom), which are fluorescence-based competitive 
allele-specific PCR using non-labelled primers. Details of the method used can be found 
at http://www.kbioscience.co.uk. Primer sequences are listed in Table 2.
SNP Gene Allele Forward primer (5‘ to 3‘) Reverse primer (5‘ to 3‘)
rs11209026 IL23R
a
gaaggtgaccaagttcatgctttga 
ttgggatatttaacagatcattcc
gtctaaatcagaaaacagaaattctgcaaa
g
gaaggtcggagtcaacggattggg 
atatttaacagatcattccg
rs11805303 IL23R
c
gaaggtgaccaagttcatgcttgca 
aacagagaactgtttcctc
gtcggagctttgtctatttagcaactaat
t
gaaggtcggagtcaacggattgct 
tgcaaacagagaactgtttcctt
rs2301436
tagSNP 
CCR6
t
gaaggtgaccaagttcatgctctgg 
gtaatggaaaagggcttct
tctgtttgatataaactaaattgacctctt
c
gaaggtcggagtcaacggattctgg 
gtaatggaaaagggcttcc
rs3093023 CCR6
a tattgaaacttcctcaaatttaaaatcacat
tttatgcacctcacagtgtctatgcaaat
g attgaaacttcctcaaatttaaaatcacac
Table 2. Primer sequences for KASPar genotyping assays.
Statistical analysis
Association between polymorphisms in recipient and donor at the one hand and 
occurrence of aGVHD, cGVHD, relapse, and IFD before day 100 after allo-SCT at the 
other hand were tested using the chi-square test and Fisher exact test if appropriate and 
univariate logistic regression analysis. To control for possible confounders as, for example, 
aGVHD and gender combination we used multivariate logistic regression analyses. 
Treatment related mortality, overall survival and time occurrence of IFD were analysed 
using Kaplan Meier curves and the logrank test. All statistical analyses were performed 
using the cmprsk package of open source language R version 2.6.2 (www.r-project.org, 
R Foundation, Vienna, Austria). A p value <0.05 was considered to indicate statistical 
significance.
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Results
SNP genotype frequencies 
The genotype frequency for both patient and donor of the polymorphisms rs11209026, 
rs11805303, rs2301436 and SNP rs3093023 are presented in Table 3. For the IL23R SNP 
rs11209026 (i.e. Arg381Gln) there was virtually no difference observed between the GA or 
GG genotype frequency between donors and patients. A homogenous AA gene variant 
for rs11209026 was not observed for any of the donors or patients. Genotype frequencies 
for the IL23R SNP rs11805303 as well as for the CCR6 tagSNP rs2301436 showed equal 
distribution among donors and patients. 
Variable
Number evaluable n (%)
Patient Donor Patient Donor
rs11209026 (IL23R)
- GG
- GA
160 158 140 (87.5%)
20 (12.5%)
140 (88.5%)
18 (11.5%)
rs11805303 (IL23R)
- CC
- CT
- TT
160 159
79 (49.5%)
59 (37%)
22 (13.5%)
79 (50%)
63 (39.5%)
17 (10.5%)
rs2301436 (tagSNP CCR6) 
- AA
- AG
- GG
159 156
32 (20%)
79 (50%)
48 (30%)
29 (18.5%)
81 (52%)
46 (29.5%)
rs3093023 (CCR6) 
- AA
- AG
- GG
153 153
24 (16%)
72 (47%)
57 (37%)
30 (20%)
68 (44%)
55 (36%)
Table 3. SNP genotype frequencies in patients and donor.
SNPs in IL23R and CCR6 are not associated with the incidence of aGVHD 
The cumulative incidence of aGVHD grade 2-4 was 35% (57/161), with grade 3-4 occurring 
in 13% (21/161) (Table 1). Both polymorphisms in the IL23R gene, rs11209026 and 
rs11805303, as well as the CCR6 SNPs rs2301436 and rs3093023, were not associated with 
the incidence of aGVHD (data not shown). Importantly, in contrast to previous studies,17 
patients who received a transplant from a donor with a GA genotype at the IL23R SNP 
rs11209026 (Arg381Gln) did not experience less aGVHD. 
Association between the CCR6 polymorphisms and cGVHD
Of the 142 patients at risk for cGVHD, 10% developed limited and 26% extensive cGVHD 
(Table 1). In univariate analysis, the donor genotype of the CCR6 tagSNP rs2301436 and 
SNP rs3093023 were significantly associated with the occurrence of cGVHD (Table 4). The 
other significant variable included previous aGVHD. For tagSNP rs2301436 the cumulative 
incidence of cGVHD was 10% for the GG genotype versus 38% and 33% for the AG and 
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Outcome 
parameter
Variable
Univariable Multivariable
OR p-value OR p-value
Chronic 
GVHD
Donor rs2301436 GG vs. AA/AG 0.19 (0.06-0.58) 0.004 0.16 (0.05-0.51) 0.002
Recipient rs2301436 AG vs. AA/GG 2.86 (1.32-6.16) 0.007 2.23 (0.97-5.42) 0.06
Donor rs3093023 GG vs. AA/AG 0.31 (2.12-0.76) 0.02 0.24 (0.09-0.65) 0.005
Recipient rs3093023 AG vs. AA/GG 2.92 (1.37-6.49) 0.02 3.02 (0.09-0.65) 0.01
Acute GVHD 4.5 (2.07-9.77) 0.0001 4.69 (2.00-10.95) 0.0004
Gender combination 1.58 (0.70-3.52) 0.27 1.54 (0.60-3.93) 0.37
Relapse
Recipient rs2301436 AA vs. AG/GG 2.21 (1.00-4.88) 0.05 1.88 (0.74-4.76) 0.18
Chronic GVHD 0.38 (0.16-0.87) 0.02 0.26 (0.10-0.68) 0.006
Prophylactic DLI 0.64 (0.30-1.35) 0.24 0.34 (0.14-0.86) 0.02
Diagnosis (CML vs. other) 4.97 (2.5-12.07) 0.0004 4.86 (1.73-13.62) 0.003
Conditioning Ida vs. Non-Ida 0.49 (0.24-1.04) 0.06 0.49 (0.20-1.23) 0.13
IFD day 100
Donor rs2301436 GG vs. AA/AG 2.60 (1.10-6.13) 0.03 3.59 (1.41-11.25) 0.008
Donor rs3093023 GG vs. AA/AG 2.18 (0.88-5.40) 0.09 2.15 (0.89-5.36) 0.01
Acute GVHD 2.08 (0.86-5.01) 0.10 2.41 (0.89-6.53 0.08
Conditioning Ida vs. Non-Ida 3.17 (0.90-11.24) 0.07 3.32 (0.86-12.78) 0.08
Dectin-1 Y238X recipient vs. wt 0.76 (0.16-3.70) 0.73 0.46 (0.08-2.64) 0.38
Table 4. Influence of clinical factors on cGVHD, relapse, IFD at day 100: univariate and multivariate 
analysis. Abbreviations: CML, chronic myeloid leukaemia; DLI, donor lymphocyte infusion; GVHD, graft-
versus-host disease; Ida, idarubicin; IFD, invasive fungal disease.
Figure 1. Influence of genotype of rs2301436 on the incidence of cGVHD. (A) Recipients receiving a stem cell 
graft from a homozygous donor for rs2301436 (i.e. genotyped as GG), showed a significant lower incidence of 
cGVHD (p=0.004, univariate analysis; p=0.002, multivariate analysis). (B) Recipients genotyped as AG showed a 
higher incidence of cGVHD (p=0.007, univariate analysis; p=0.06, multivariate analysis). (C) Recipients receiving 
a stem cell graft from a homozygous donor for rs3093023 (i.e. genotyped as GG), showed a significant lower 
incidence of cGVHD (p=0.01, univariate analysis; p=0.005, multivariate analysis). (D) Recipients genotyped as 
AG showed a higher incidence of cGVHD (p=0.006, univariate analysis; p=0.01, multivariate analysis).
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AA genotype, respectively (p=0.004) (Figure 1A and Table 4). In addition, the recipient 
genotype at tagSNP rs2301436 was also associated with cGVHD in univariate analysis, 
with an incidence of 39% for the heterozygous AG genotype versus 17% and 20% for the 
homozygous AA and GG genotypes, respectively (p=0.007) (Figure 1A and Table 4). For SNP 
rs3093023 the cumulative incidence of cGVHD was 15% for the GG genotype versus 39% 
and 32% for the AG and AA genotype, respectively (p=0.02) (Table 4). Also the recipient 
genotype at SNP rs3093023 was associated with cGVHD in univariate analysis, with an 
incidence of 41% for the heterozygous AG genotype versus 19% for both the homozygous 
AA and GG genotypes, respectively (p=0.02) (Figure 1B and Table 4). Although we have 
found in both SNPs an association between the heterozygous genotype AG in recipients 
and cGVHD, these association did not seem very plausible given that comparison of the 
A allele versus G allele frequencies revealed no risk allele. No significant associations were 
found between the IL23R SNPs rs11209026 and rs11805303 with the incidence of cGVHD 
(data not shown). 
In multivariate analysis, besides aGVHD, the donor genotype at rs2301436 and 
rs3093023 remained significantly associated with the incidence of cGVHD. Interestingly, 
the GG genotype versus AA and AG genotypes in donors showed a protective effect 
with an OR of 0.16 (95% CI: 0.05-0.51, p=0.002) for rs2301436 as was also observed for 
rs3093023 (OR of 0.24; 95% Cl: 0.09-0.65, p= 0.005) (Table 4). In contrast, the influence of 
female to male SCT proved not to be significant in multivariate analysis (p=0.37). These 
data indicate that the GG donor genotype at tagSNP rs2301436 and SNP rs3093023 in the 
CCR6 region is protective for cGVHD.
TRM, relapse and OS were not significantly influenced by the polymorphisms studied
The median follow-up was 68 months (range 8-157 months) for surviving patients and 8 
months (range 0-90 months) for the patients who died. Relapse includes molecular, genetic, 
and haematological relapse, occurring in 54 out of 154 evaluable patients (35%). Known 
risk factors for relapse were significant in our multivariate analysis, with the diagnosis of 
CML, absence of cGVHD, and not having received prophylactic DLI increasing the risk of 
relapse (Table 4). Recipient genotype at CCR6 tagSNP rs2301436 was associated with the 
incidence of relapse; AA 50%, AG 27%, and GG 38% (p=0.05 for AA versus AG/GG) (Table 4). 
However, in multivariate analysis this proved no longer significant. No effect effects were 
observed for any of the other tested SNPs. Relapse free survival and overall survival at 5 
years were 37.5% and 55%, respectively, and 1-year treatment related mortality was 21%. 
None of the investigated SNP showed any association with these outcome parameters. 
Donor GG genotype at rs2301436 influences the occurrence of IFD
The incidence of candidemia and invasive mold infections at 100 days was 10% and 7.5%, 
respectively (Table 1). The GG genotype at rs2301436 in donors was associated with a 
higher incidence of IFD (32%) opposed to AA (12%) and AG (16%) (p=0.03 GG vs. AA/ 
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AG, Table 4 and Figure 2). In multivariate analysis donor rs2301436 genotype was the 
only significant risk factor, although the presence of aGVHD and conditioning regimen
containing idarubicin both showed a trend towards more IFD (Table 4). Donor rs3093024
GG genotype was accompanied by an increased, but not significant, incidence of IFD 
(24% vs. 15% (AA) and 12% (AG), p=0.22). In a previous study, we determined the gene 
status of the Dectin-1 polymorphism Y238X, for which it is known that it influences 
candida colonisation and possibly invasive aspergillosis in SCT recipients.29-31 However, 
no association was found between the Dectin-1 genotype and IFD at day 100. These data 
suggest that the GG genotype at CCR6 tagSNP rs2301436 influences post-transplant 
immunity against fungal infections.
Also the influence on the impact of Gram-positive bacteraemia was examined for 
all 4 tested SNPs, but no associations were found. Data on CMV and EBV reactivation 
were incomplete and insufficient to perform proper statistical analysis, although EBV 
reactivation seemed not influenced by any of the SNPs.
Figure 2. Cumulative incidence of IFD at day 100. Donor GG genotype at CCR6 tagSNP rs2301436 was 
associated with a higher incidence of IFD (dashed line) opposed to AA and AG (black line) (p=0.03, log-rank 
test).  
Discussion
The role of polymorphisms in non-HLA genes in the outcome of allogeneic SCT is a subject 
that has received much attention in the last few years. In particular focus here lies on SNP 
located in genes involved in the immune system. However, with few exceptions, a general 
problem with genetic association studies has been that documented associations are very 
much context dependent and as a result often difficult to confirm and reproduce. This 
also seems to apply to the rs11209026 IL23R polymorphism, as a large study failed to 
confirm an impact on GVHD in the particular setting of SCT from unrelated donors.32 Also 
in our current study, we were not able to reproduce the repeatedly described protection 
against aGVHD of the donor GA genotype at the SNP rs11209026.17-19 This GA genotype, 
resulting in Arg381Gln, is believed to perturb the IL23 receptor function reducing allo-
reactive T cell responses that mediate aGVHD. We believe that the reason we could not 
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confirm this genetic association is mainly due to the practice of ex vivo T cell depletion 
in all of our transplants, this opposed to Elmaagacli et al. who did not perform any T cell 
depletion.17 The allele frequency was however comparable between the two cohorts (A 
allele frequency ≈ 6%), but the incidence of GVHD was lower in our study, which is directly 
related to the use of T cell depleted stem cell grafts. T cell depletion most likely results in 
a delayed T cell recovery which might influence the pathogenesis of aGVHD. By altering 
the kinetics and reducing the impact of T cell function, the influence of genetic variations 
such as those in the IL23/Th17 pathway may be changed as well. Context dependency is 
a recurring theme in studies on genetic associations and discrepancies are often found, 
emphasizing that one should be cautious generalizing results from previous association 
studies. 
Studying a second gene prominent in the IL23/Th17 pathway, the chemokine receptor 
CCR6, we found significant associations between donor genotype at rs2301436 and 
rs3093023 and the occurrence of cGVHD. In case of rs2301436, the incidence of IFD was 
significantly increased, as for rs3093024 only a trend towards a higher incidence was seen. 
The GG genotype of rs2301436 was protective for cGVHD, but conferred a high risk for 
developing IFD. SNP rs2301436 is regarded as a tagSNP for the CCR6 gene, but the SNP 
itself lies within the FGFR10P gene.22 Functional consequences of the SNP itself, nor that of 
the CRR6 phenotype corresponding with the tagSNP, are yet completely known. However, 
recently the A allele of rs2301436 has been shown to associate with a modestly higher risk 
for both Crohn’s disease and rheumatoid arthritis, with a protective effect attributed to 
the G allele.23 Kochi et al. show that two different polymorphisms, both located within the 
CCR6 gene and in linkage disequilibrium with tagSNP rs2301436, regulate the expression 
of CCR6.22 We have tested the impact of one of these polymorphisms, SNP rs3093023, on 
the clinical outcome post allogeneic SCT and also observed a protective effect of the G 
allele. Although for these specific CCR6 associated polymorphisms no direct functional 
consequences are known, of other polymorphisms in strong linkage disequilibrium with 
rs3093023, functional studies have been performed. These studies show that a tri-allelic 
dinucleotide polymorphism correlated with CCR6 expression levels as well as with the 
presence of IL17 in rheumatoid arthritis patients.22 In the absence of data on any functional 
consequences due to the genotype of tagSNP rs2301436 or SNP rs3093023 regarding 
CCR6, we propose two general hypotheses which are not mutually exclusive. 
One hypothesis could be that the genotype GG at CCR6 SNPs rs2301436 and 
rs3093023 might represent the normal CCR6 variant opposed to what might be the 
dysfunctional A allele. Kochi et al describe that, in activated cells, the expression levels 
of CCR6 increase with the number of alleles (T).22  Normal levels of  CCR6 result in normal 
functioning APC and therewith contribute to intact mucosal immune homeostasis.33 Since 
distorted immune homeostasis predisposes to GVHD,34 the GG genotype could diminish 
the risk to excessive inflammation. In addition, normal CCR6-mediated Th17 homing 
might result in impaired Th1 responses, with decreased allo-reactivity and tissue damage 
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protecting subjects from GVHD,8 and decreased Th1-mediated antifungal defences with 
subsequently more infections.35;36 This hypothesis relies on the other hand strongly on 
the assumption that Th1 cells are more important for the onset of cGVHD than Th17 cells 
would be. An alternative hypothesis could be that genotype GG at the CCR6 SNPs might 
correspond to low levels of the CCR6 protein, impairing homing of APC and Th17 cells 
to GVHD target tissues and infection sites, as well as to T cell priming sites.37 Reduced 
APC function results in reduced allo-reactive T cell responses and GVHD, but on the other 
hand an increased risk of fungal infections due to less effective phagocyte recruitment.38 
Alternatively, reduced Th17 homing might reduce GVHD as also in humans a role for 
Th17 has been suggested.39 Additionally, impaired Th17 responses might perturb host 
antifungal defences, increasing the risk for IFD.40 This hypothesis relies however strongly 
on the assumption of an important, but not yet confirmed, role for Th17 in human SCT 
and cGVHD and IFD. 
Our study is the first to show an association with the donor-genotype of the CCR6 
tagSNP rs2301436 and the occurrence of cGVHD and IFD as well as an association with 
the donor-genotype of the CCR6 SNP rs3093023 and we think that these findings provide 
new clues for further research. We conclude that patients undergoing allogeneic SCT 
might benefit from typing for this particular SNPs when looking for a suitable stem cell 
donor, though further research on CCR6 gene variation is necessary.
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Abstract
The C-type lectin-like receptor CD161 is a well-established marker for human IL17-
producing T cells, which have been implicated to contribute to the development of graft-
versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT). In this 
study, we analysed CD161+ T cell recovery, their functional properties and association 
with GVHD occurrence in allo-SCT recipients. While CD161+CD4+ T cells steadily recovered, 
CD161hiCD8+ T cell numbers declined during tapering of Cyclosporine A (CsA), which 
can be explained by their initial growth advantage over CD161neg/lowCD8+ T cells due 
to ABCB1-mediated CsA efflux. Interestingly, occurrence of acute and chronic GVHD 
was significantly correlated with decreased levels of circulating CD161+CD4+ as well as 
CD161hiCD8+ T cells. In addition, these subsets from transplanted patients secreted high 
levels of IFNγ and IL17. Moreover, we found that CCR6 co-expression by CD161+ T cells 
mediated specific migration towards CCL20, which was expressed in GVHD biopsies. 
Finally, we demonstrated that CCR6+ T cells indeed were present in these CCL20+ GVHD-
affected tissues. In conclusion, we showed that functional CD161+CCR6+ co-expressing 
T cells disappear from the circulation and home to GVHD-affected tissue sites. These 
findings support the hypothesis that CCR6+CD161-expressing T cells may be involved 
in the immune pathology of GVHD following their CCL20-dependent recruitment into 
affected tissues.
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Introduction
Graft-versus-host disease (GVHD) is still one of the major causes of morbidity and mortality 
after allogeneic stem cell transplantation (allo-SCT).1 The pathophysiology of GVHD is 
a multistep process involving tissue damage and pro-inflammatory cytokine cascades 
induced by the pre-transplant conditioning regimen.1,2 This results in an excessive 
inflammatory environment in which donor-derived CD4+ and CD8+ T cells become 
potently activated. In addition, T cell trafficking towards inflamed GVHD-prone organs 
including skin, lung, gastrointestinal tract, and liver is increased. Further tissue destruction 
in these organs occurs in the case of presentation of ubiquitous or epithelial expressed 
allo-antigens to infiltrating allo-reactive cytotoxic T cells. Moreover, macrophages, and 
other effector T cells subsets are recruited, resulting in further enhancement of GVHD.1,3-5 
In particular, Th1-type CD4+ T cells and Tc1-type CD8+ T cells play an important role in 
GVHD pathophysiology.6,7 but other T cell subsets with specific phenotype and functional 
characteristics might play a pivotal role as well.
The contribution of pro-inflammatory Th17 cells in various autoimmune disorders has 
raised the question of the role of IL17-producing T cells in GVHD. Although some mouse 
studies showed that these T cells are involved in the onset and persistence of GVHD.8-11 
others claim a protective role of Th17 cells.12 Furthermore, human studies performed on 
Th17 cells also show conflicting results.13-16 An increase in circulating Th17 cells, as well as 
an imbalance between Th17 and regulatory T cells, has been correlated with occurrence 
of GVHD.13-15 However, Broady et al. found an expansion of Th1 rather than Th17 cells in 
GVHD-affected skin.13 Though, Bossard et al. recently showed that the absolute number 
of Th17 cells using the markers CD161, RORγt, and CC chemokine receptor (CCR)6 were 
significantly higher in intestinal mucosa of patient with acute GVHD.16 Regarding the 
proposed plasticity of Th17 responses.17 CD161 and CCR6 may be more reliable surface 
markers to study the involvement of Th17 and Tc17 cells in GVHD.
Interestingly, it has been shown that CD161 is a distinguishing surface marker for both 
CD4+ and CD8+ T cell subsets producing IL17 and/or IFNγ.18,19 CD161, also known as killer 
cell lectin-like receptor superfamily B member 1 (KLRB1) or natural killer receptor protein 
1a (NKRP1a), is a type II membrane glycoprotein with characteristics of the C-type lectin 
superfamily20 The function of CD161 on T cells has not been clearly defined yet, but a role 
in T cell co-stimulation has been indicated.21,22 Furthermore, CD161 has been implicated 
to play a role in trans-endothelial migration.23,24 CD161 is moderately expressed on CD4+ 
T cells, but within the CD8+ T cells population a distinct subset clearly expresses high 
levels of CD161.25-32 The comparable phenotype between Th17 cells and CD161hiCD8+ T 
cells, including explicit IL17-production and their expression of RORγt.25,27,30 suggests that 
these cells are the equivalent of Th17 cells within the CD8+ T cell population, namely Tc17 
cells. Distinctively, CD161-expressing T cells display high levels of the chemokine receptor 
CCR6, for which we recently showed that a single nucleotide polymorphism in this gene 
correlates with occurrence of chronic GVHD.33 CCR6 has only one ligand, CCL20, which 
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is constitutively expressed in organs such as the liver, colon, small intestine, lung, and 
skin.34 Furthermore, damage of the epidermal permeability barrier, as well as stimulation 
with IL1ß, results in up-regulation of CCL20 expression.35,36 This suggests that CD161-
expressing T cells have the capability to migrate to the target organs involved in GVHD. 
In this study, we investigated the repopulation kinetics, functional properties, and 
associations with GVHD of CD161-expressing CD4+ and CD8+ T cells in patients who 
received allo-SCT for a haematological malignancy. We observed that decreased levels of 
circulating CD161-expressing T cells, with the specific migratory capacity towards CCL20 
expressed in GVHD tissues, and the potential to secrete IL17 and IFNγ, correlate with the 
occurrence of GVHD.
 
Material and Methods
Patients and healthy controls
Patients treated between 1993 and 2008 with allo-SCT for a haematological malignancy 
in the Radboud University Nijmegen Medical Centre were included in this study (Table 
1). All patients received a HLA-matched sibling allo-SCT which, irrespective of donor 
source or conditioning regimen were partially depleted of T cells. Until November 2001 
counterflow centrifugation elutriation was used,37 and from that moment onwards T
Characteristics n=76
Age at transplantation, years (median, range) 47 (19-63)
Sex, no. males (%) 42 (55%)
Underlying disease, no. (%)
- ALL/AML/MDS
- CML
- NHL/CLL
53 (70%)
11 (14%)
12 (16%)
Conditioning regimen, no. (%)
- Cy-Bus
- Cy-TBI
- Ida-Cy-Bus
- Ida-Cy-TBI
4 (5,5%)
10 (13%)
7 (9%)
55 (72,5%)
Graft source
- Bone marrow
- Peripheral Blood
 
32 (42%)
44 (58%)
Acute GVHD, no. (%)
- Grade 1-4
- Grade 3-4
40 (53%)
9 (12%)
Chronic GVHD, no. (%)
- Limited
- Extensive
17 (22%)
14 (18%)
Table 1. Patient characteristics. Abbreviations: ALL, acute lymphatic leukaemia; AML, acute myeloid 
leukaemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukaemia; NHL, non-Hodgkin lymphoma; 
CLL, chronic lymphatic leukaemia; Cy, cyclophosphamide; Bus, busulphan; TBI, total body irradiation; Ida, 
idarubicin; GVHD, graft-versus-host disease.
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cell depletion was performed with immunomagnetic CD34-enrichment or CD3/CD19 
depletion (Miltenyi Biotec).38 CD3+ T cells were added back in the graft with a median ± 
SD of 0.43 ± 0.51 x 106 cells/kg bodyweight. GVHD prophylaxis consisted of Cyclosporine 
A (CsA) in almost all patients, and was dosed 1.5 mg/kg bidaily intravenously for the first 
two weeks, and thereafter 1 mg/kg bidaily intravenously or 2.5-3 mg/kg bidaily orally. 
Tapering of CsA was started in the absence of GVHD after two months and stopped at 
three months. The occurrence of acute GVHD was graded according to the criteria by 
Przepiorka et al.39 Chronic GVHD was classified according to the revised Seattle criteria of 
Lee et al.40 PBMCs were isolated using Ficoll-Hypaque gradient from PB samples that were 
collected at several time points after allo-SCT. Absolute cell levels were calculated using 
the lymphocyte count from the PB sample and the percentages of the different T cells 
populations measured in the PBMCs. PBMCs of healthy controls were isolated from buffy 
coats supplied by the Sanquin Blood Supply Foundation. Patients and healthy donors had 
given their informed consent which was approved by the RUNMC Institutional Review 
Board.
Flow cytometry 
Flow cytometry was performed using the following directly conjugated antibodies: CD3 
(UCHT1, Beckman Coulter, Biolegend), CD4 (13B8.2, Beckman Coulter; OKT4, Biolegend), 
CD8 (3B5, Invitrogen), CD45RA (H100, Biolegend), CD161 (191B8, Miltenyi Biotech), CCR6 
(53103, R&D Systems), CCR7 (150503, R&D Systems; G043H7, Biolegend). Expression of 
CD161 and additional markers was determined by staining for 30 minutes at 4°C. Cells 
were washed with phosphate-buffered saline (PBS)/0.5% BSA (Sigma). To determine the 
Rhodamine 123 (Rh123, Sigma) efflux, cells were labelled with 10 µg/ml Rh123 in IMDM 
containing 1% BSA for 30 minutes at 4°C. Then, cells were incubated for 30 minutes in the 
cell incubator at 37°C, followed by a standard staining procedure. Cells were measured on 
the Cyan-ADP 9 color analyser (Beckman Coulter). Analysis was performed using Summit 
software.
Quantative RT-PCR
Quantitative RT-PCR for expression of the ABCB1 transporter was performed on T cell 
subsets. From both CD4+ and CD8+ T cells, CD161-subsets were sorted on a FACS ALTRA 
(Beckman Coulter). Total RNA was extracted using the Quick-RNA miniPrep isolation kit 
(Zymo Research) in accordance with the manufacturer’s instructions. Subsequently, cDNA 
was generated using standard methods.41 ABCB1 expression was determined using the 
following primers and probe: ABCB1-forward, 5’- ACTGAGCCTGGAGGTGAAGAAG-3’; 
ABCB1-reverse, 5’-TTTGCCATCAAGCAGCACTT-3’; ABCB1-probe, 5’-FAM-TCCTGGAGCGGT 
TCTACGACCCCTT-3’. Reactions were run on an ABI 7900-HT Real-time PCR System and 
analysed with Sequence Detection Systems 2.3 software (Applied Biosystems). Expression 
is shown in ΔΔCt values and was quantified relative to CD161-CD4+ T cells, which was set 
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at 1 ΔΔCt value. ΔΔCt was calculated as follows: 2^(-ΔCtsample − ΔCtCD161-CD4+ T cells), in which 
ΔCt was normalized for the porphobilinogen deaminase (PBGD) housekeeping gene by 
calculating ΔCt = CtABCB1 − CtPBGD per sample. 
T cell proliferation assay
To compare the effect of immunosuppressive drugs on proliferation of CD161hi 
versus CD161neg/lowCD8+ T cells, PBMCs from healthy controls were labelled with 5 µM 
carboxyfluorescein diacetate succinimidyl (CFSE, Molecular Probes Europe) for 15 minutes 
at 37°C in IMDM. Cells were stimulated in a mixed lymphocyte reaction (MLR) using 
irradiated allo-PBMCs in IMDM (Invitrogen) /10% human serum (HS, PAA Laboratories), 
200 U/ml IL2 (Chiron), 5 ng/ml IL7 (Immunotools), and 5 ng/ml IL15 (Immunotools). CsA 
(BioVision) was added at the start of the MLR culture. CFSE levels of CD161hi and CD161neg/
lowCD8+ T cells were measured by flow cytometry after seven days.
Intracellular cytokine staining
To determine the cytokine production by the different T cell subsets, intracellular cytokine 
staining was performed. PBMCs were stimulated with PMA and ionomycin for 4 hours 
with Brefeldin A (all BD) present for the last 3 hours. Cells were stained for CD3, CD4, CD8, 
and CD161 as described. Then cells were fixated, permeabilized (eBioscience) and stained 
for IL17 (eBioscience) and IFNγ (BD). Non-stimulated cells and IgG1 (Dako) stainings were 
used as controls. 
Immunohistochemistry
Enzymatic immunohistochemical staining for CCL20 was performed as described 
previously42 on 4 µM formalin fixed paraffin embedded tissue sections prepared from 
skin and gut biopsies obtained from patients diagnosed with either acute or chronic 
GVHD. Briefly, after baking for 1 hour at 66°C, slides were subsequently deparaffinised in 
xylol and rehydrated in a series of ethanol. Endogenous peroxidase was blocked using 
methanol/0.3% H202 for 20 minutes. The sections were then subjected to heat mediated 
antigen retrieval in a microwave using 10 mM citrate buffer (pH 6.0). Anti-CCL20 (R&D 
Systems) was diluted in PBS/1% BSA and the sections were incubated overnight at RT 
in a humidity chamber. Anti-CCL20 detected enzymatically using Powervision (Dako) 
followed by colour development with 3.3-diaminobenzidine. After counterstaining with 
haematoxylin, the sections were mounted in Pertex. 
Triple immunofluoresent staining was performed in parallel on tissue sections that 
were subjected to deparaffinization and antigen retrieval as described above. Note that 
endogenous peroxidise blocking was not performed. Primary antibodies specific for CD3 
(DAKO), CD4 (R&D Systems), and CCR6 (R&D Systems), were diluted in PBS/1% BSA and 
the sections were incubated overnight at RT in a humidity chamber. Bound antibodies 
were detected with appropriated diluted secondary antibodies (donkey anti-rabbit IgG 
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Alexa-546, donkey anti-mouse IgG Alexa-488 and donkey anti-goat Alexa-647, all from 
Invitrogen). After washing in PBS, the sections were mounted in moviol.
Migration assay
Migration towards CCL20 was measured in 96 or 24 well plates containing transwell inserts 
with 5 µm pores (Costar). IMDM/10% HS with CCL20 (Immunotools) was added to the 
lower compartment. CD3+, CD4+ or CD8+ T cells were selected using the standard MACS 
procedure (Miltenyi Biotech) and 0.75 or 2.5 x 106 cells were loaded into the inserts. After 2 
hours in a 37°C incubator, cells in the lower compartment were harvested and labelled for 
CD3, CD4 or CD8, and CD161. Migration was determined by flow cytometry by acquiring 
events for a fixed time period and presented as the relative migration compared to input.
Statistical analysis
Statistical analysis for experimental data was performed using GraphPad Prism 4. 
Statistical significance of difference was analysed using an one-tailed student t-test, 
parametric, non-parametric, one-way or two-way analysis of variance (ANOVA), followed 
by the appropriate post-hoc test, all as indicated in the figure legends. Correlation analysis 
was performed by calculating the Spearman correlation coefficient.
Associations of CD161+CD4+ and CD161hiCD8+ T cells with the occurrence of acute 
or chronic GVHD after allo-SCT were tested using univariate logistic regression analysis. 
To this end the percentages and absolute cell counts of CD161hiCD8+ levels, as well as 
the absolute levels of CD161+CD4+ T cells were logarithmically transformed because of 
their positive skewing. To correct for possible confounders, we used multivariate logistic 
regression analyses. Regression analyses were performed using SAS 8.2 software. For all 
analyses p<0.05 were considered to be significant.
Results
Determining the normal distribution of CD161-expressing T cells in healthy controls
In order to evaluate the repopulation kinetics of CD161+CD4+ and CD161hiCD8+ T cells 
in allo-SCT recipients, we first determined their frequency and absolute numbers in 
peripheral blood (PB) of healthy controls. Within the CD4+ T cell population, a clear CD161+ 
subset could be identified, with an average ± SD of 17.7 ± 5.8% and 174.1 ± 47.8 x 106 
CD161+CD4+ T cells/L (Supplementary Figure 1A-B, n=16). As expression levels of CD161 
were higher on CD8+ T cells, CD8+ T cells were divided in CD161neg/low and CD161hi cells 
(Supplementary Figure 1C). An average of 11.6 ± 7.2% (n=42) CD161hi cells within the 
CD8+ T cell population and 48.3 ± 45.9 x 106 (n=22) CD161hiCD8+ T cells/L was observed 
(Supplementary Figure 1D). Reference ranges were set as the mean ± SD to compare cell 
numbers found in allo-SCT recipients with those of healthy controls.
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Reconstitution of CD161-expressing T cells after HLA-matched allo-SCT
To investigate the repopulation kinetics of CD161-expressing T cells in patients after 
HLA-matched allo-SCT, PBMCs isolated from peripheral blood of 76 patients at 1, 3, 
6, and 12 months post-transplant were analysed by flow cytometric analysis. While 
the percentage of CD161+CD4+ T cells were found to be higher compared to healthy 
controls, the CD161hiCD8+ T cell population was lower (Figure 1A). Although in most 
patients CD161hiCD8+ T cells were present at low frequency, in some patients a relative 
high frequency of CD161hiCD8+ T cells could be detected at one month after allo-SCT. 
However, the frequency of both CD161+CD4+ as well as CD161hiCD8+ T cells diminished in 
time. However, CD161+CD4+ T cells mainly decreased from 3 months onwards, while the 
frequency of CD161hiCD8+ T cells already declined after one month where after it remained 
relatively stable (Figure 1A). On the other hand, the absolute number of CD161+CD4+ and 
CD161hiCD8+ T cells increased in the first months after allo-SCT, where after they stabilized 
but remained below the reference ranges (Figure 1B). Meanwhile, the total CD4+ and CD8+ 
T cell number expanded. From 3 months onwards, a relative overshoot of the percentage 
(data not shown) and absolute number of CD161neg/lowCD8+ T cells was observed in a 
substantial proportion of the patients (Figure 1C).
Remarkably, the frequency of CD161hiCD8+ T cells was found to be the highest 
in patients with a low percentage of CD3+ T cells (data not shown) or CD8+ T cells, as 
observed for both absolute levels (data not shown) as well as for percentages (Figure 1D). 
In contrast, this was not observed for CD161+CD4+ T cells. Altogether, these data show that 
both CD161+CD4+ T cells and CD161hiCD8+ T cells reconstitute shortly after HLA-matched 
allo-SCT. However, while CD161+CD4+ T cells are found at higher counts compared to those 
of healthy controls and reconstituted to normal levels, the percentage of CD161hiCD8+ T 
cells declines in time due to the expansion of the CD161neg/lowCD8+ T cells.
CD161hiCD8+ T cells are relative resistant to CsA treatment 
Since the highest frequency and a specific decrease in the percentage of CD161hiCD8+ T 
cells was observed shortly after allo-SCT, we speculated that these cells were not affected 
by the immunosuppressive drugs which is routinely supplied to our patients in the first 
months after allo-SCT in order to prevent severe GVHD. CsA can be transported out of 
the cell by the ABCB1 transporter, which has been shown to be present on CD161hi but
not on CD161neg/lowCD8+ T cells.32,43 To determine whether the ABCB1 transporter is also 
present on CD161-expressing CD4+ T cells qPCR analysis was performed on mRNA of 
sorted CD161-CD4+, CD161+CD4+, CD161neg/lowCD8+, and CD161hiCD8+ T cells. Next to the 
high ABCB1 mRNA expression in CD161hiCD8+ T cells (p<0.01), this transporter was also 
expressed by CD161+CD4+ T cells, though levels were lower (Figure 2A). This difference in 
ABCB1 mRNA expression levels correlated with the efflux of the fluorescent dye Rh123 by 
the various subsets (Figure 2B). Especially CD161hiCD8+ T cells displayed a more efficient 
Rh123-efflux compared to their CD161neg/low counterparts. In contrast, CD161+CD4+ T cells, 
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Figure 1. Reconstitution of CD161-expressing T cells in patients after allo-SCT. (A) Percentage of 
circulating CD161+ within CD4+ and CD161hi within CD8+ T cells in patients at 1 (n=11, 20), 3 (n=50, 71), 6 (n=19, 
24), and 12 (n=19, 22) months. (B) Absolute levels of circulating CD161+CD4+ and CD161hiCD8+ T cells in patients 
at 1 (n=8, 20), 3 (n=50, 71), 6 (n=19, 24), and 12 (n=19, 22) months. (C) Absolute number of circulating CD161-
CD4+ and CD161neg/lowCD8+ T cells in patients at 1 (n=8, 20), 3 (n=54, 69), 6 (n=19, 24), and 12 (n=19, 22) months. 
(D) Correlation between the percentage of circulating CD161+CD4+ and CD4+ T cells (n=58), and CD161hiCD8+ T 
cells and CD8+ T cells (n=70) at 3 months after allo-SCT. Lines represent median value, grey areas represent the 
reference range of healthy controls (mean ± SD). Statistical analysis was performed using a One-way ANOVA 
followed by a Bonferroni post-hoc test (CD4) or non-parametric One-way ANOVA followed by a Dunns post-
hoc test (CD8). Correlations were determined by calculating the Spearman correlation coefficient (R). *p<0.05, 
**p<0.01, ***p<0.001.
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expressing lower mRNA levels of ABCB1 were hardly able to efflux Rh123. 
To determine whether expression of the ABCB1 multi-drug transporter indeed mediates 
resistance of CD161-expressing T cells to CsA-induced functional impairment, CFSE-
labelled PBMCs were stimulated in an MLR using irradiated allo-PBMCs in the presence 
or absence of physiological levels of CsA.44 Indeed, CsA hardly affected CD161hiCD8+ T 
cell proliferation, whereas it exerted a strong dose-dependent inhibition on proliferation 
of CD161neg/lowCD8+ T cells (p<0.001; Figure 2C-D). For CD4+ T cells, no difference in CsA-
mediated inhibition was observed between CD161+ or CD161-CD4+ T cells (data not 
shown). Collectively, these data demonstrate that the presence of the ABCB1 transporter 
on CD161hiCD8+ T cells, but not on CD161+CD4+ T cells, confers relative resistance from 
CsA treatment.
Figure 2. CD161hiCD8+ T cells escape from functional inhibition by CsA. (A) Relative ABCB1 expression 
determined by qPCR on sort-purified CD161-CD4+, CD161neg/lowCD8+ (white bars) and CD161+CD4+, CD161hiCD8+ 
(black bars) T cells. Expression is normalized to that of CD161-CD4+ T cells. Data represent the mean ± SEM of 
2 independent healthy donors. (B) PBMCs were labelled with Rh123, cultured for 30 minutes, and measured 
by flow cytometry for CD3, CD4, CD8, and CD161. A representative sample is shown gated on CD3+CD4+ and 
CD3+CD8+ T cells. (C-D) CFSE-labelled PBMCs were stimulated in an MLR with irradiated allo-PBMCs in the 
presence or absence of CsA. CFSE levels were determined after 7 days of culture. (C) Flow cytometry data 
of one representative experiment is shown gated on CD3+CD8+ T cells. Numbers represent percentages of 
proliferation per subset. (D) Relative proliferation is depicted as the percentage proliferating CD161neg/lowT 
cells (white bars) and CD161hiCD8+ T cells (black bars) compared to the condition without CsA, as mean + SD 
(n=3). One representative experiment out of 3 independent healthy donors is shown. Statistical analysis was 
performed using One way  ANOVA followed by a Bonferroni post-hoc test. *p<0.05, **p<0.01, ***p<0.001.
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Decreased levels of circulating CD161-expressing T cells are associated with a higher GVHD 
incidence
To determine whether CD161-expressing T cells are associated with the development 
of GVHD, statistical analysis was performed between relative and absolute cell counts of 
CD161+CD4+ and CD161hiCD8+ T cells measured in the circulation of patients at 3 months 
after allo-SCT and their GVHD status. Both the percentage (39.7%, range 20.7-60.7 vs. 
32.5%, range 3.25-49.44, p=0.025 ) and absolute levels (87.5 x 106/L, range 19-218 vs. 55.3 
x 106/L, range 4-182, p=0.009) of CD161+CD4+ T cells in peripheral blood were found to 
be significantly reduced in patients with acute GVHD (Figure 3A). This decrease was also 
observed for the absolute numbers of CD161hiCD8+ T cells (1.17 x 106/L, range 0.08-5.64, 
vs. 0.46 x 106/L, range 0.01-4.21, p=0.013) (Figure 3B). In addition, the percentage (0.62%, 
range 0.06-14.80, vs. 0.41%, range 0.04-2.50, p=0.019) as well as the absolute cell count 
(1.05 x 106/L, range 0.07-5.64, vs. 0.47 x 106/L, range 0.01-4.21, p=0.033) of circulating 
CD161hiCD8+ T cells were also inversely correlated with the development of chronic GVHD 
(Figure 3B). Importantly, correction for known confounders like patients’ age, gender 
combination, and source of the graft had no or only minimal impact on the significant 
association between decreased CD161-expressing T cell counts and the occurrence of 
GVHD (Table 2). Additionally, also correction for the relative and absolute number of 
total CD4+ or CD8+ T cells did not affect the observed correlation. These data indicate 
that reduced levels of circulating CD161+CD4+ and CD161hiCD8+ T cells correlate with an 
increased occurrence of GVHD.
Figure 3. Circulating CD161+CD4+ and CD161hiCD8+ T cells are decreased in allo-SCT patients who 
develop GVHD. (A) Comparison of percentage and absolute levels of circulating CD161+CD4+ T cells in patients 
3 months after allo-SCT and the occurrence of acute GVHD (Percentage, No n=28, Yes n=22; Absolute, No n=28, 
Yes n=22) and chronic GVHD (Percentage, No n=35, Yes n=15; Absolute, No n=35, Yes n=15). (B) Comparison of 
percentage and absolute numbers of circulating CD161hiCD8+ T cells in patients 3 months after allo-SCT and the 
occurrence of acute GVHD (Percentage, No n=34, Yes n=34; Absolute, No n=34, Yes n=32) and chronic GVHD 
(Percentage, No n=46, Yes n=22; Absolute, No n=46, Yes n=20). Lines represent mean (CD4) or median (CD8) 
values. Statistical analysis was performed using univariate logistic regression analysis. *p<0.05.
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Phenotype of CD161-expressing T cells in allo-SCT patients
To define the memory phenotype of CD161-expressing T cells in allo-SCT patients versus 
healthy controls, T cell subsets were analysed for the expression of CCR7 and CD45RA. In 
allo-SCT patients, CD4+ and CD8+ T cells have an increased proportion of effector memory 
cells (Tem) compared to healthy donors (Figure 4A-B, p<0.001). Only minimal differences 
were found in the differentiation status within the CD161-expressing T cell subsets 
between allo-SCT patient and healthy donors. While CD161+CD4+ T cells displayed both 
a central memory (Tcm) as well as a Tem phenotype, CD161
hiCD8+ T cells consisted mainly 
of Tem cells. Overall, CD161-expressing T cells in allo-SCT patients, in both the CD4
+ and 
CD8+ T cell population, seemed to be a bit more differentiated in their memory phenotype 
compared to healthy controls.
Figure 4. Memory phenotype of CD161-expressing T cells. (A) Memory phenotype of total CD4+ T cells 
(left panel) and CD161+CD4+ T cells (right panel) in healthy controls (○, n=18) and patients 3 months after allo-
SCT (●, n=55). (B) Memory phenotype of total CD8+ T cells (left panel) and CD161hiCD8+ T cells (right panel) 
in healthy controls (○, n=18) and patients 3 months after allo-SCT (●, n=55 and n=52 respectively). Tn, naïve 
(CCR7+CD45RA+); Tcm, central memory (CCR7+CD45RA-); Tem, effector memory (CCR7-CD45RA-); TemRA, 
CD45RA+ effector memory (CCR7-CD45RA+). Statistical analysis was performed using One-way ANOVA followed 
by a Bonferroni post-hoc test. *p<0.05, ***p<0.001.
CD161-expressing T cells in allo-SCT patients contain high frequency of IL17- and IFNγ-producers
Next, functionality of CD161-expressing T cells was investigated by defining their 
cytokine production profile. Therefore, PBMCs from both healthy controls as well as allo-
SCT patients were stimulated with PMA and ionomycin and subsequently stained for 
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intracellular cytokines (Supplementary Figure 2). Both CD161+CD4+ as well as CD161hiCD8+ 
T cells showed to be dominant producers of IL17 within their T cell compartment (Figure 
5B, p<0.001). Interestingly, for CD8+ T cells the percentage of IL17-secreting cells within 
the CD161-expressing cells was higher in allo-SCT patients compared to healthy controls 
(p<0.05). In addition, as compared to CD161-CD4+ T cells, the frequency of IFNγ-producers 
was increased in CD161+CD4+ T cells of healthy controls, but not for allo-SCT patients 
(Figure 5B, p<0.001). Together, these data demonstrate that CD161-expressing T cells of 
allo-SCT patients contain a high frequency of IFNγ- and IL17-producers.
Figure 5. IL17 and IFNγ production of CD161-expressing T cells after allo-SCT. (A) Representative IL17 and 
IFNγ production by intracellular cytokine staining from a healthy control and allo-SCT patient. (B) Comparison 
of IL17 (left panels) and IFNγ (right panels) production, measured by intracellular cytokine staining, between 
CD161- and CD161+CD4+ T cells, and CD161neg/low  and CD161hiCD8+ T cells in healthy controls (○) and patients 
1-3 months after allo-SCT (●). Data is shown as the percentage of positive cells, lines represent mean value. 
Statistical analysis was performed using One-way ANOVA followed by a Bonferroni post-hoc test, or a one-
tailed paired student t-test. *p<0.05, ***p<0.001.
CCR6-mediated migration of CD161-expressing T cells to CCL20 present in GVHD tissues
To explore the tissue-homing capacity of CD161-expressing T cells in allo-SCT patients, 
we determined expression of the chemokine receptor CCR6, within the corresponding 
memory-phenotype. CCR6 expression was found to be elevated on both CD161+CD4+ 
as well as CD161hiCD8+ T cells compared to their CD161-negative counterparts (Figure 
6A and Supplementary Figure 3, p<0.05). Next, the migration potential of CCR6+CD161-
expressing T cells towards CCL20, the sole ligand for CCR6, was determined in an in vitro 
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migration assay using either purified CD4+ or CD8+ T cells isolated from healthy controls. 
Where CCL20 induced robust migration of both CD161+CD4+ as well as CD161hiCD8+ T 
cells, their CD161-negative counterparts were unresponsive to this chemokine (Figure 6B; 
p<0.001). In addition, migration assays were performed using purified CD3+ T cells from 
allo-SCT patients, since CD8+ T cells numbers were too low, analysis was focused on CD4+ 
T cells. For these, specific migration of CD161+CD4+ T cells towards CCL20 was observed 
compared to CD161-CD4+ T cells (Figure 6C; p<0.001). These results support the concept 
that CCR6 expression on CD161+CD4+ and CD161hiCD8+ T cells facilitates preferential 
migration to CCL20-expressing tissues.
Figure 6. Preferential migration of CD161-expressing T cells to CCL20. (A) Comparison of CCR6 expression 
between CD161- and CD161+CD4+ memory T cells, and CD161neg/low and CD161hiCD8+ Tem cells of healthy donors 
(о) and patients 3 months after allo-SCT (●). The frequency of CD161+CD4+ T cells in the measured samples 
was 34.6-55.7% in allo-SCT patients (n=10) and 36.6-46.4% in healthy controls (n=3), and the frequency of 
CD161hiCD8+ T cells was 0.05-23.8% in allo-SCT patients (n=8) and 11.5-42.4% in healthy controls (n=3). Data is 
shown as mean fluorescent intensity (MFI). Lines represent mean value. (B) Migration of CD4+ and CD8+ T cell 
subsets to CCL20. CD4+ or CD8+ T cells were applied to the upper chamber and migrated to the lower chamber 
containing medium with or without CCL20. Migrated cells were analysed by flow cytometry. Migration is 
shown relative to input (mean ± SD) for CD161-CD4+ and CD161neg/lowCD8+ T cells (dashed line), and CD161+CD4+ 
and CD161hiCD8+ T cells (solid line) (n=3). One representative experiment out of 2 (CD4) or 3  (CD8) independent 
healthy donors is shown. (C) Migration of CD4+ T cell subsets to CCL20. CD3+ T cells were applied to the upper 
chamber and migrated to the lower chamber containing medium with or without CCL20. Migrated cells were 
analysed by flow cytometry. Migration is shown relative to input (mean ± SD) for CD161-CD4+ (dashed line), and 
CD161+CD4+ (solid line) (n=3). Two independent patients 3 months after allo-ST are shown. Statistical analysis 
was performed using Two-way ANOVA followed by a Bonferroni post-hoc test. *p<0.05, **p<0.01, ***p<0.001.
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To further substantiate the relevance of the CCR6-CCL20 pathway in guiding migration 
of CD161-expressing T cells to GVHD-prone organs, we next determined CCL20 expression 
in situ in skin biopsies obtained from allo-SCT recipients who developed acute or chronic 
GVHD (Figure 7A, Supplementary Figure 4). CCL20 expression could be clearly visualized 
in the epidermis of the skin. Moreover, CCL20 was also expressed on single cells present in 
the dermis in close proximity to the epidermal-dermal junction that is typically targeted 
by infiltrating T cells. 
Finally, to confirm homing of CD161+CCR6+ co-expressing T cells to GVHD tissues, skin 
biopsies of GVHD patients were examined for the presence of CCR6+ T cells. Infiltrated 
T cells were clearly visible in the skin derived from both acute as well as chronic GVHD 
patients, of which several cells displayed expression of CCR6 (Figure 7B). Among these
Figure 7. CCL20 is expressed in GVHD 
tissues and selectively attracts 
CCR6+ T cells. (A) CCL20 staining in 
skin biopsies of patients diagnosed 
with acute GVHD at respectively 49 
(UPN 833) and 30 days (UPN 877), or 
chronic GVHD 127 days (UPN 722) and 
321 days (UPN 741) days after allo-SCT. 
Squares indicate examples of single 
cells in the dermis in close proximity to 
the epidermal-dermal junction (acute 
GVHD) or in the epidermis which are 
situated in close proximity to or at the 
epidermal-dermal junction (chronic 
GVHD). Images were captured at 400X. 
(B) CD3 (red), CD4 (blue), and CCR6 
(green) triple staining in skin biopsies of 
patients diagnosed with acute GVHD at 
respectively 49 (UPN 833) and 30 days 
(UPN 877), or chronic GVHD 127 days 
(UPN 722) and 321 days (UPN 741) days 
after allo-SCT. White arrows and squares 
indicate examples of CD3+CD4+CCR6+ 
cells, yellow arrows and squares 
indicate examples of CD3+CD4-CCR6+ 
cells. Single stainings of the cells in 
squares are depicted under the image. 
Images were captured at 400X.
Decreased levels of IL17-producing CD161+CCR6+ T cells are associated with GVHD
4
85
cells, both CD3+CD4+ as well as CD3+CD4- T cells were detected. Also in GVHD-affected 
gut tissue, expression of CCL20 and CCR6+CD3+ T cells could be detected (Supplementary 
Figure 5). These data strengthen our hypothesis that the observed decrease of CD161-
expressing T cells from the circulation in GVHD patients is the result of their homing to 
CCL20-expressing GVHD tissues. 
Discussion
Th17 cells have been linked to the pathophysiology of GVHD, however data remains 
limited and contradictory.8-15 Recently, correlations have been made between Th17 and 
Tc17 cells and their involvement in GVHD using the well-established CD161 lineage-
identifier for IL17 producing CD4+ and CD8+ T cells subsets.16,18,19,26 The involvement of 
CD161-expressing T cells is further supported by their responsiveness to IL1ß,26 a key 
cytokine involved in GVHD.1,45 In this study, we investigated the repopulation kinetics of 
both CD4+ and CD8+ CD161-expressing T cells in allo-SCT patients, and their potential 
role in the development of GVHD. Remarkably, the relative proportion of CD161+ cells 
within the CD4+ T cells compartment was higher in allo-SCT patients compared to healthy 
controls. Furthermore, while CD161+CD4+ T cells reconstituted allo-SCT patients in a 
relatively balanced way, we found that the CD161hiCD8+ T cell frequency decreases within 
the first 3 months after allo-SCT, where after it remained stable at a low level. Interestingly, 
this relative decrease occurred during tapering of CsA, which is normally started two 
months after allo-SCT when GVHD is absent. During these first months after allo-SCT, 
CD161hiCD8+ T cells, expressing the ABCB1 transporter, have a proliferative advantage 
over CD161neg/lowCD8+ T cells as evidenced by their clear in vitro resistance to the CsA-
mediated inhibition of T cell proliferation. During tapering of CsA, this advantage gradually 
disappeared, which could explain the rise of CD161neg/lowCD8+ T cells and a relative decline 
of CD161hiCD8+ T cells. Furthermore, it has been described that CD161hiCD8+ T cells have 
a lower proliferation capacity compared to CD161neg/lowCD8+ T cells,31 which might result 
in a more robust expansion of CD161neg/lowCD8+ T cells at later time points after allo-SCT. 
Additionally, cell death as well as the administration of various drugs, like steroids for the 
treatment of GVHD, will also influence the repopulation kinetics shortly after allo-SCT. 
However, it is likely that the ABCB1-dependent CsA-efflux favours early repopulation of 
CD161hiCD8+ T cells following allo-SCT. 
In this current study, we are the first to show a correlation between reduced levels 
of circulating CD161+CD4+ and CD161hiCD8+ T cells and the occurrence of GVHD. 
Interestingly, a significant decreased frequency was observed in PB samples 3 months 
after allo-SCT from patients who had acute GVHD or who developed chronic GVHD later 
on. This information is of considerable significance as GVHD, of which the pathogenesis 
is still not fully understood, is the most profound adverse complication after allo-SCT.1,46
Although the number of patients analysed in this study did not allow statistical analysis 
for multiple confounding parameters at once, we found that the association between 
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decreased CD161-expressing T cells and GVHD remained independent from the total 
CD4+ or CD8+ T cell number and known confounders such as age, gender combination 
and graft source. Due to insufficient data, we were unable to take CsA blood levels along 
as a confounder in this study. However, if CsA levels in the patients’ blood would have 
interfered with the correlation of CD161-expressing T cells and GVHD, it is expected that 
higher CsA levels in GVHD patients would result in higher levels of CD161-expressing 
T cells due to their CsA resistance. Therefore, the found correlation between decreased 
levels of CD161-expressing T cells and GVHD would even be an underestimation.
Based on the found association, we speculated that the decrease in circulating CD161-
expressing T cells results due to specific recruitment into GVHD-affected tissues. Prevalent 
expression of CCR6, as well as the migration potential of both CD161+CD4+ cells and 
CD161hiCD8+ T cells to inflamed tissues, and their involvement in several inflammatory 
disorders have been described previously.25,28,30,35 Furthermore, our observations are in 
agreement with the recent study of Bossard et al.,16 who observed increased numbers 
of CD161+, RORγt+ and CCR6+ cells in GVHD-affected intestinal mucosa. Therefore, our 
findings support the pathogenic role of CD161+CCR6+ co-expressing T cells, preferentially 
containing Th17 and Tc17 cells, in GVHD developing after allo-SCT. 
Whether CD161-expressing T cells are directly involved in the onset and/or aggravation 
of GVHD remains to be proven. However, IL1α as well as IL1ß, which are part of the 
cytokine storm created after conditioning of the patient,5,45 could result in elevated CCL20 
production in GVHD-prone tissues. This possibility was shown by culturing endometriotic 
stromal cells in the presence of IL1ß, which increased their CCL20 secretion considerably.35 
Also damage to the skin, as well as culture of keratinocytes with IL1α increases CCL20 
secretion.36 Additionally, in agreement with other studies we have found that CD161+CD4+ 
and CD161hiCD8+ T secrete IFNγ and IL17.18,22,26,27,30 Interestingly, the IL17 production of 
CD161-expressing T cells is further increased after culturing these cells with IL1ß alone 
or in conjunction with IL23.18,26 Migration of CCR6+CD161-expressing T cells to the GVHD-
prone tissues could thereby result in IL17 production, priming the GVHD response, further 
enhancing CCL20 production, and recruiting other effector cells. Our data indicate that 
the decrease in percentage of CD161hiCD8+ T cells, already at 3 months after allo-SCT, 
could be an early sign of the clinical onset of chronic GVHD later on. All together, these 
data suggest that CD161-expressing CD4+ and CD8+ T cells with IL17 and/or IFNγ secreting 
properties, are involved in the onset of GVHD. 
In conclusion, here we show that following allo-SCT, patients are readily reconstituted 
with CD161-expressing T cells. Interestingly, the resistance of CD161hiCD8+ T cells for CsA-
mediated inhibition of proliferation might explain their observed repopulation kinetics. 
Most importantly, we observed that a decrease of both circulating CD161+CD4+ as well 
as CD161hiCD8+ T cells coincided with the occurrence of both acute and chronic GVHD. 
In fact, we demonstrate that the reduced number of CD161-expressing T cells could be 
seen as an independent predictor of GVHD, and that CCR6+CD161-expressing T cells 
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may be involved in the immune pathology of GVHD following their CCL20-dependent 
recruitment into affected tissues. 
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Supplemental Figure 1. CD161+CD4+ and CD161hiCD8+ T cells in healthy adults. (A) Flow cytometry data of 
a representative healthy control gated on circulating CD3+ cells. CD161-CD4+ and CD161+CD4+ T cell populations 
are depicted in the gates. (B) Percentage and absolute numbers of circulating CD161+ within CD4+ T cells in 
healthy adults (n=16). (C) Flow cytometry data of a representative healthy control gated on CD3+ cells. CD161neg/
lowCD8+ and CD161hiCD8+ T cell populations are depicted in the gates. (D) Percentage and absolute levels of 
circulating CD161hi within CD8+ T cells in healthy adults (n=42, n=22). Lines represent the mean value.
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Supplementary Figure 2. IL17 and IFNγ production determined by intracellular staining. Gating strategy 
of intracellular cytokine staining for IL17 and IFNγ after 4h stimulation with PMA and ionomycin.
Supplementary Figure 3. CCR6 is higher expressed on CD161-expressing T cells. Representative flow data 
of CCR6 expression on CD161-expressing CD4+ or CD8+ T cells in a patient after allo-SCT. Numbers represent the 
mean fluorescent intensity of the subset.
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Supplementary Figure 4. CCL20 expression in GVHD affected skin tissue. (A) Negative (without CCL20-
specific antibody) and positive (B) control staining for CCL20 in foreskin. (C) CCL20 staining in skin biopsies 
of two additional patients, conditioned with Cyclo-ATG-Bus (cyclophosphamide-antithymocyte globulin-
busilvex) and Flu-Mel-Alem (fludarabine-melphalan-alemtuzumab), who were diagnosed with acute GVHD 
at respectively 41 (UPN 1001) and 18 (UPN 10019) days after allo-SCT. Squares indicate examples of single cells 
in the epidermis which are situated in close proximity to or at the epidermal-dermal junction. Images were 
captured at 400X. 
 
Supplementary Figure 5. CCL20 expression and CCR6+ T 
cells in GVHD affected gut tissue. (A) CCL20 (brown colour) 
and (B) CD3 (red colour), CD4 (blue colour), and CCR6 (green 
colour) triple staining in a gut biopsy of a patient after allo-
SCT diagnosed with acute GVHD at 34 day after allo-SCT 
(UPN 902). White arrows and squares indicate examples of 
CD3+CD4+CCR6+ cells, yellow arrows and squares indicate 
examples of CD3+CD4-CCR6+ cells. Single stainings of the 
cells in squares are depicted under the image. Images were 
captured at 400X.
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NK cell therapy in haematological malignancies
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Abstract
Natural killer (NK) cell-based adoptive immunotherapy is an attractive adjuvant 
treatment option for patients with acute myeloid leukaemia. Recently, we reported 
a clinical-grade, cytokine-based culture method for the generation of NK cells from 
umbilical cord blood (UCB) CD34+ haematopoietic progenitor cells with high yield, purity 
and in vitro functionality. The present study was designed to evaluate the in vivo anti-
leukemic potential of UCB-NK cells generated with our GMP-compliant culture system 
in terms of biodistribution, survival and cytolytic activity following adoptive transfer in 
immunodeficient NOD/SCID/IL2Rγnull mice. Using single photon emission computed 
tomography, we first demonstrated active migration of UCB-NK cells to bone marrow, 
spleen and liver within 24h after infusion. Analysis of the chemokine receptor expression 
profile of UCB-NK cells matched in vivo findings. Particularly, a firm proportion of UCB-
NK cells functionally expressed CXCR4, what could trigger BM homing in response to its 
ligand CXCL12. In addition, high expression of CXCR3 and CCR6 supported the capacity 
of UCB-NK cells to migrate to inflamed tissues via the CXCR3/CXCL10-11 and CCR6/CCL20 
axis. Thereafter, we showed that low dose IL15 mediates efficient survival, expansion 
and maturation of UCB-NK cells in vivo. Most importantly, we demonstrate that a single 
UCB-NK cell infusion combined with supportive IL15 administration efficiently inhibited 
growth of human leukaemia cells implanted in the femur of mice, resulting in significant 
prolongation of mice survival. These preclinical studies strongly support the therapeutic 
potential of ex vivo-generated UCB-NK cells in the treatment of myeloid leukaemia after 
immunosuppressive chemotherapy.
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Introduction
Acute myeloid leukaemia (AML) is a clonal disorder characterized by the accumulation 
of abnormal myeloid progenitor cells and suppression of normal hematopoiesis.1 With a 
median age of ~70 years at diagnosis,2 AML is most common in the elderly and its yearly 
incidence is expected to increase as the population ages.3 Current chemotherapeutic 
regimens lead to remission rates of 60-85%. However, relapse occurs in the vast majority of 
AML cases, resulting in a 5-year overall survival of 40% in patients <60 years of age, which 
even drops to 10% in elderly patients due the higher prevalence of bad risk cytogenetics 
and poor chemotherapeutic tolerance.4 Although allogeneic stem cell transplantation 
(allo-SCT) is potentially curative, mostly younger patients can benefit from this therapeutic 
option due to high association with transplant-related morbidity and mortality.5 Therefore, 
adjuvant and alternative treatment options are urgently needed.
Transfusion of allogeneic NK cells is a promising therapeutic approach for patients 
with AML. NK cells are major effector cells of the innate immune system and play a key 
role in control against virus infection and tumour immunosurveillance.6,7 In the setting 
of haploidentical allo-SCT, NK cell alloreactivity has proven to decrease relapse rate 
and improve survival among AML patients.8 Therefore, there is an emerging interest in 
exploiting adoptive NK cell transfer in the treatment of AML. Clinical studies reported so 
far showed that infusion of haploidentical NK cells derived from leukapheresis products 
resulted in objective clinical responses in high-risk AML patients,9,10 as well as long term 
remissions in childhood AML.11
However, further improvement of NK cell-based therapy is needed to increase the 
clinical effect. In this regard, NK cells generated ex vivo from haematopoietic progenitor 
cells (HPC) may have significant clinical benefits over enriched NK cells from adult donors, 
including the ability to choose an appropriate killer-cell immunoglobulin-like receptor 
(KIR)-ligand or KIR B haplotype alloreactive donor, as well as the capacity to reach high 
therapeutic dosages. Recently, we reported a GMP-compliant, cytokine/heparin-based 
culture protocol for the ex vivo generation of highly active NK cells from CD34+ HPC 
isolated from cryopreserved umbilical cord blood (UCB) units.12 Expansion in closed, 
large-scale bioreactors yields a clinically relevant dose of NK cells with high purity and 
cytolytic activity against AML cells in vitro.13
In the present study, we aimed at evaluating the anti-leukemic potential of UCB-
NK cells in vivo in terms of biodistribution, survival and cytotoxicity following adoptive 
transfer in NOD/SCID/IL2Rγnull (NSG) mice. Therefore, we established an 111Indium labelling 
protocol that enables specific and sensitive in vivo tracking of infused UCB-NK cells by 
single photon emission computed tomography (SPECT) imaging. Besides generating 
insight in UCB-NK cell trafficking, we demonstrated specific accumulation of UCB-NK 
cells in the bone marrow (BM) that matched their chemokine receptor profile. Moreover, 
we demonstrated that a single infusion of UCB-NK cells resulted in potent leukaemia 
cell growth inhibition and significantly improved mice survival. These findings strongly 
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support ex vivo-generated UCB-NK cells as promising immunotherapeutic products for 
the treatment of AML.
Materials and Methods
UCB-NK cell generation
UCB units were obtained at birth after normal full-term delivery after written informed 
consent with regard of scientific use from the cord blood bank of the Radboud university 
medical centre (Radboudumc, Nijmegen, The Netherlands). The use of UCB units was 
approved by the Radboudumc Institutional Review board. NK cells were generated 
from cryopreserved UCB-derived HPC as previously reported.12,13 Briefly, expanded 
CD34+ UCB cells were differentiated and further expanded using NK cell differentiation 
medium which consists of Glycostem Basal Growth Medium (GBGM®) for cord blood (Clear 
Cell Technologies) supplemented with 2% human serum (HS; Sanquin Blood Supply 
Foundation, Nijmegen, The Netherlands), low-dose GM-CSF (Neupogen), G-CSF, IL6 (both 
CellGenix) and a high-dose cytokine cocktail consisting of IL7, SCF, IL15 (all CellGenix) and 
IL2 (Proleukin®). The cell density was checked two times a week and adjusted to >1x106 
cells/ml by the addition of GBGM® NK cell differentiation medium. For experiments, 
CD56+CD3- UCB-NK cells were used at the end of the culture process with >90% purity, 
what was typically achieved within 3-4 weeks in GBGM® NK cell differentiation medium.
Flow cytometry
Cell numbers and expression of cell surface markers were determined by flow cytometry. 
Anti-human CD45-ECD (J.33) and CD56-PC7 (N901) antibodies (Beckman Coulter) were 
used to follow cell number and NK cell differentiation during culture using the Coulter 
FC500 flow cytometer (Beckman Coulter). The population of living CD45+ cells was 
determined by exclusion of 7AAD (Sigma) positive cells. For phenotypical analysis, UCB-NK 
cells were incubated with the appropriate concentration of antibodies for 30 min at 4°C. 
After washing, cells were resuspended in PBS/0.5% BSA and analysed using the Coulter 
FC500 or Cyan-ADP 9 color flow cytometers (Beckman Coulter). The following conjugated 
monoclonal antibodies were used: CCR2 (48607, R&D system), CCR5 (T21/8, eBioscience), 
CCR6 (TG7), CCR7 (G043H7), CXCR3 (G025H7), CXCR4 (12G5), CXCR6 (TG3), CX3CR1 (2A9-
1) and CD62L (DREG-56, all Biolegend).
In vitro cell migration assay
UCB-NK cells were resuspended in GBGM/2% HS and loaded into transwell inserts (105 
cells/well, 5 μm pore filter transwell, 24-well plate, Corning). The human chemokines CCL4, 
CCL20, CXCL10, CXCL11 and CXCL12 (all Immunotools) were diluted at 10-250 ng/ml and 
added to the lower compartment (600 μl/well) in triplicates. After 2 h at 37°C, inserts were 
removed; cells in lower compartments were collected, stained for CD56 and quantified by 
flow cytometry. Percentage of migrated cells was calculated as the number of CD56+ cells 
in the lower compartment divided by the total number of CD56+ loaded cells.
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Mice
NOD/SCID/IL2Rγnull (NSG) mice were originally purchased from Jackson Laboratories, 
and housed and bred in the Radboudumc Central Animal Laboratory. Male NSG mice 
were used from 6 to 12 weeks of age (weight was 20-30 g). All animal experiments 
were approved by the Animal Experimental Committee of the Radboudumc and were 
conducted in accordance with institutional and national guidelines under the university 
permit number 10300. 
NK cell labelling with 111Indium, SPECT-CT imaging and biodistribution analysis
UCB-NK cells were labelled with 111Indium-oxinate (111In; GE Healthcare) in PBS Tris 0.1 
M HCl, pH 7.4 for 15 min at RT at doses mentioned in the text. After incubation, cells 
were washed twice with PBS/2% HS and resuspended in PBS before use. Viability was 
assessed by trypan blue exclusion and cell-associated activity was quantified using a 
dose calibrator VDC-404 (Veenstra Instruments, The Netherlands). Lysates were obtained 
after three freezing/thawing cycles of 111In-NK cells previously resuspended in distilled 
water. Whole body scans of isoflurane gas anesthetized (2% in air) mice were acquired 
with a SPECT-CT dual-modality scanner (U-SPECT II, MiLabs) for 30-45 min using a 1.0 
mm diameter pinhole mouse collimator cylinder. Scans were reconstructed with MiLabs 
reconstruction software and analysed using Inveon Research Workplace software. For 
biodistribution analysis, mice were euthanized by cervical dislocation, tissues of interest 
were dissected, weighed, and analysed for their 111In content using a shielded 3-inch-
well-type gamma counter (Wizard; Pharmacia LKB). The 111In activity in each tissue was 
expressed as percentage of the injected dose (%ID) per gram of tissue and was normalized 
to the blood level. Values for the total blood and BM fraction were extrapolated according 
to physiological values, with blood being 6% of the total body weight, and one femur 
being 6.7% of the total BM fraction.14
Intra-femoral K562 model, Bioluminescence Imaging and UCB-NK cell adoptive transfer
The NK-sensitive leukaemia cell line K562 (ATCC) was cultured in Iscove’s modified 
Dulbecco’s medium (IMDM; Invitrogen) containing 50 U/ml penicillin, 50 µg/ml 
streptomycin and 10% fetal calf serum. Green fluorescent protein (GFP) and Luciferase 
expressing K562 cells (K562.LucGFP) were generated by stable transduction of parental 
cells with lentiviral particles LVP20 encoding the reporter genes under control of the 
CMV promoter (GenTech). To establish a preclinical AML xenograft model, adult NSG mice 
were injected in their right femur with 105 K562.GFPLuc cells (injection volume 5 μl), by 
insertion of a 25G Hamilton needle through the knee joint of isoflurane gas anesthetized 
mice. Using this procedure, leukaemia cell growth remained localized to BM up to 5 
weeks. Thereafter, tumour cells eventually overgrow outside the bone forming a palpable 
tumour. Mice were sacrificed (cervical dislocation) when the palpable tumour reached 1 
cm in diameter or when one of the following criteria was observed: severe weight loss, 
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poor coat and skin condition, static activity or paraplegia. Leukaemia load was monitored 
by bioluminescence imaging (BLI) following injection of Luciferine (3.5 mg per mouse, 
Caliper Life Science) using the IVIS system (Xenogen). Images were analysed using Living 
Image Software 2.5 (Xenogen). Leukaemia load was quantified in the region of interest 
with subtraction of background signal, and expressed as photons per second. For 
adoptive transfer, UCB-NK cells were resuspended in PBS and injected i.v. via the tail vein 
of adult NSG mice. Recombinant human IL15 (Miltenyi Biotech) was administrated intra-
peritoneally (i.p.) at the dose of 0.5 mg/mouse (i.e. 2.500 Units/mouse) the day of UCB-NK 
cell infusion and thereafter every 2-3 days for 2 weeks.
Statistical analysis
Statistical analyses were performed using Graphpad Prism 5 software. Biodistribution of 
111In-associated activity following 111In-NK cell infusion was compared to that observed 
after lysate or free 111In injection using one way-analysis of variance (ANOVA) and Dunnett’s 
multiple comparison tests. Two way-ANOVA followed by Bonferroni post-hoc test, and 
log rank Mantel Cox tests were used in anti-leukemic studies as indicated in the figure 
legends. Differences were considered to be significant for p values <0.05.
Results
Characterization of the homing receptor expression profile of UCB-NK cells
We reported previously that the cytokine-based culture system that we established allows 
generation of CD3-CD56+ NK cells with high purity, that express typical inhibitory and 
activating NK receptors and display similar cytotoxic gene expression profile to peripheral 
blood NK cells.15 To further characterize UCB-NK cell products and to investigate their 
biodistribution potential upon adoptive transfer, we examined the expression and 
functionality of a panel of receptors that were previously described to participate in the 
regulation of human NK cell trafficking in vivo.16,17 As shown in Figure 1A-B, the chemokine 
receptors CCR2, CCR5, CCR7, CXCR6 and CX3CR1 were virtually absent. However, high 
proportion of UCB-NK cells expressed CCR6 (52 ± 12%) and CXCR3 (65 ± 21%). Expression 
of CXCR4 as well as the adhesion molecule CD62L (L-selectin) were also detected typically 
on 10-20% of UCB-NK cells at the end of the culture process. Results obtained from in 
vitro migration assays were consistent with this chemokine receptor profile (Figure 1C). 
Notably, the proportion of CD56+ UCB-NK cells migrating in response to the chemokine 
CXCL12 was similar to level of CXCR4-expressing cells, and specific migration towards 
the chemokines CCL20 (CCR6 ligand), CXCL10 and CXCL11 (both CXCR3 ligands) were 
confirmed. These data indicate that UCB-NK cells functionally express CXCR4, what could 
trigger BM homing in response to its ligand CXCL12. In addition, data suggest that UCB-
NK cells have the capacity to migrate to inflamed tissues via the CXCR3/CXCL10-11 and 
CCR6/CCL20 axis.
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Figure 1. Homing receptor expression profile of UCB-NK cells. (A-B) The expression level of homing receptors 
was analysed by flow cytometry on UCB-NK cells at the end of the culture process. (A) Dot plots gated on CD56+ 
cells from one representative donor; (B) Summary of 6 different donors analysed. (C) The capacity of UCB-NK 
cells to respond in vitro to gradients (10 to 250 ng/ml) of the chemokines CCL4 (CCR5 ligand), CCL20 (CCR6 
ligand), CXCL10, CXCL11 (both CXCR3 ligand) and CXCL12 (CXCR4 ligand) was evaluated in transwell migration 
assays as described in materials and methods. Mean ± SEM of three independent experiments are shown, each 
performed with different UCB-NK cell donors. Migration towards specific chemokines was compared to non-
specific migration (0 ng/ml) using a one way-ANOVA followed by Dunnett’s multiple comparison post-hoc test, 
*p<0.05, **p<0.01, ***p<0.001.
Development of in vivo UCB-NK cell tracking
Next, we aimed to establish a method using 111In-oxinate as radiolabel and SPECT-CT 
imaging that could be exploited both at the pre-clinical level in mice and for clinical studies 
in humans, to monitor early distribution of UCB-NK cell following infusion in relation to 
anti-leukemic potency in BM. To address the feasibility of this methodology, increasing 
doses of UCB-NK cells previously labelled with 111In-oxinate (111In-NK cells; 2MBq of 111In-
oxinate was added per 106 cells and labelling efficiency was 55%) were injected i.v. into 
NSG mice. Whole body scans acquired 1 and 24 h after infusion showed that the 111In-
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activity first localized in the lungs, and thereafter redistributed to the spleen, liver and BM 
(Figure 2A). At 24h, liver and spleen were visible at all doses of infused 111In-NK cells, while 
the activity present in BM was detected only in mice injected with ≥ 5x106 111In-NK cells. 
To address the specificity of 111In-NK cell in vivo imaging, we also analysed the distribution 
of 111In-activity following injection of either a lysate obtained from 111In-NK cells or 111In-
oxinate (Figure 2B). In both cases, after 24h, the activity was mainly visualized in kidneys. 
Weak uptake of 111In was noticed in liver and lungs following injection of 111In-lysate and 
111In-oxinate, respectively.  
Figure 2. SPECT-CT imaging provides good sensitivity and specificity to track 111In-labelled UCB-NK 
cells in vivo. To address the feasibility of UCB-NK cell tracking in vivo, adult NSG mice were injected i.v. either 
with increasing doses of 111In-NK cells (1, 5 or 12 x106 111In-NK cells per mouse equivalent to 1, 5 and 12 MBq 
respectively, n=5 in total), with a lysate obtained from 111In-NK cells (111In-lysate, n=2) or with 111In-oxinate (n=3). 
(A) Representative whole body SPECT scans acquired 1 h and 24 h after injection of 111In-NK cells with major 
visualization of lungs (Lu), liver (Li), spleen (Sp, arrowhead) and bone marrow (BM, arrow). (B) Representative 
whole body SPECT scans acquired 24 h after injection of 111In-NK cell lysate or 111In-oxinate; kidneys (Ki), heart 
(He). (C) Quantitative biodistribution analysis performed 24 h after injection. For comparison, the relative 111In-
content of each tissue of interest was normalized to blood. Data are shown as mean ± SD. *p<0.05, **p<0.01, 
***p<0.001.
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After imaging, mice were euthanized, organs were collected, weighted, and used to 
analyse quantitatively the distribution of the 111In-activity as described in materials and 
methods. All tissues examined following injection of 111In-oxinate exhibited similar level of 
111In compared to that measured in blood, indicating that the 111In activity remained in the 
circulation, resulting in visualization of well perfused organs. In mice injected with 111In-
lysate, the activity mainly accumulated in the kidneys, representing ~20% of the injected 
dose (data not shown). Slightly enhanced 111In activity levels were also measured in liver 
and lymphoid organs. In contrast, following infusion of 111In-NK cells, the proportions of 
activity quantified in BM, spleen, liver and lungs were strongly increased compared to 
blood level. Values were also significantly higher compared to those determined following 
injection of 111In-lysate and 111In-oxinate (Figure 2C), indicating that the accumulation of 
111In activity in these organs could be attributed to the accumulation of 111In-NK cells. 
Notably, the distribution of 111In activity was similar at all doses of infused 111In-NK cells 
(Supplementary Figure 1). Moreover, human CD45+CD56+ NK cells were clearly identified 
in the same organs, except kidneys, by ex vivo flow cytometric analysis performed 24 
h after infusion of UCB-NK cells (Figure 3). All together, these data show that SPECT-CT 
imaging allows tracking of 111In-NK cells in vivo with good sensitivity and specificity, and 
that UCB-NK cells, after a brief period of retention in the lungs, rapidly traffic to the liver, 
spleen and BM.
A consistent proportion of UCB-NK cells accumulates in mouse BM following adoptive transfer
After demonstrating the feasibility of 111In-NK cell tracking in vivo, we aimed to determine 
quantitatively the biodistribution of UCB-NK cells in 2 independent experiments. To this 
end, we first optimized the labelling procedure by incubating increasing numbers of NK 
cells with 2 MBq 111In. Good 111In labelling efficiency and cell recovery were achieved using 
>4x106 cells (Figure 4A). Based on these findings, 0.4 MBq of 111In-oxinate was added per 
106 cells for subsequent experiments where labelling efficiency always exceeded 80%, cell 
viability >90% and cell recovery >95% (data not shown). In addition, this procedure did 
not affect the migration capacity of UCB-NK cells towards the prototypic BM-chemokine 
CXCL12 in vitro (Figure 4B). 
As observed in the pilot studies, we found the highest activity concentration in the 
spleen, followed by liver, BM and lungs at 24h after infusion. Taking into account total 
organ weights, nearly 70% (64.9 ± 2.1) of the ID was present in liver, while spleen and 
lungs contained 3.1 ± 1.2 %ID and 3.9 ± 1.9 %ID, respectively (Figure 4C). For BM, 0.32 ± 
0.05 %ID was quantified per femur (data not shown). Assuming that one femur accounts 
for 6.7% of the total BM in adult mouse,14 we estimated at ~5% the fraction of 111In-NK 
cells accumulating within 24 h in the total BM compartment. Accordingly, a homogenous 
111In-signal was visualized by SPECT-CT imaging in all bones (Figure 4D). These data 
indicate that a significant percentage of UCB-NK cells are able to migrate to the mouse 
BM following adoptive transfer. 
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Low dose human IL15 drives UCB-NK cell expansion in vivo
Next to BM homing, we aimed to evaluate the survival potential of UCB-NK cells 
following adoptive transfer. Indeed, clinical responses reported so far always occurred 
with concomitant donor NK cell persistence and even expansion within the first two 
weeks after infusion. Interestingly, conditioning regimens that allowed successful alloNK 
cell engraftment also resulted in transient elevation of endogenous IL15.9 Therefore, 
we examined UCB-NK cell survival potential upon adoptive transfer in NSG mice in 
Figure 3. Ex vivo flow cyto-
metric analysis confirmed 
trafficking of UCB-NK cells 
through lymphoid tissues, 
liver and lungs following 
adoptive transfer in NSG 
mice. Two adult NSG mice 
were infused i.v. with 10x106 
UCB-NK cells. The day after, 
mice were sacrificed, organs 
collected and used to prepare 
cell suspension for ex vivo flow 
cytometric analysis follow-
ing erythrocyte lysis. One ad-
ditional non-injected mouse 
was used as control. Pres-
ence of human CD45+CD56+ 
NK cells was confirmed in all 
examined tissues except kid-
neys. Dot plots gated on total 
living cells are shown.
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the presence of low dose IL15 support. In a first experiment, we observed that daily 
administration of IL15 mediated efficient expansion of infused UCB-NK cells in vivo 
(Supplementary Figure 2). In contrast to mice injected with UCB-NK cells alone, a clear 
population of human CD45+CD56+ cells could be visualized in mice co-injected with IL15, 
representing 3.5% of total leukocytes at day 7, which further increased till 4.5% at day 
14. Nevertheless, NK cell numbers rapidly declined after removal of IL15 (Supplementary 
Figure 2). We next intended to confirm these findings with a different UCB donor and to 
examine UCB-NK cell engraftment level in lymphoid tissues. To this end, mice received a 
single infusion of 5x106 UCB-NK cells, and percentages of circulating human NK cells were
Figure 4. Organ-distribution of UCB-NK cells following adoptive transfer. (A) For optimization of NK cell 
labelling procedure, increasing number of UCB-NK cells were incubated with 2MBq 111In. Graphs show mean 
± SD of three experiments performed each with a different UCB donor. Good labelling efficiency and cell 
recovery were achieved using >4x106 cells per 2 MBq. Subsequently (panels B-D), 0.4MBq 111In was added per 
106 UCB-NK cells to label. (B) The capacity of 111In-NK cells to migrate in response to the chemokine CXCL12 
was evaluated in vitro and compared to that of unlabelled UCB-NK cells. The same experimental procedure 
was employed to assess the transwell migration of unlabelled and 111In-NK cells as described in materials and 
methods, except that the proportion of 111In-labelled cells present in bottom chambers were quantified using 
a shielded 3-inch-well-type gamma counter (Wizard; Pharmacia LKB). (C) Biodistribution analysis of 111In-NK 
cells 24h after i.v. infusion, expressed as a percentage of injected activity per gram of tissue of interest or per 
organ. Combined results from two experiments expressed as mean ± SD (n=6) are shown. *Extrapolated values 
according to physiological parameters. (D) Representative 2D-reconstruction analysis of SPECT-CT illustrating 
the accumulation of 111In-NK cells (orange) in bones (grey).
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monitored in peripheral blood collected at 1, 7 and 14 days later. Here, NSG mice were 
given intermittent injections of IL15, thereby reducing the IL15 support compared to 
the first experiment. Consistent with previous observations, human NK cells were almost 
absent at day 7 in mice co-treated with PBS. In contrast, mice co-injected with IL15 
displayed stable levels of NK cells from day 1 to day 7, which even increased in 4 out 5 mice 
at day 14 (Figure 5A). In addition, significant percentages of UCB-NK cells were identified 
in spleen and BM by day 14 (Figure 5B). Moreover, examination of the NK cell phenotype 
in these tissues revealed high expression level of CD16 and KIR receptors, which were 
strongly increased compared to the infused UCB-NK cell product (Figure 5C). All together, 
these data demonstrate that low dose IL15 mediates efficient UCB-NK cell survival and 
expansion in vivo, and that further differentiation of UCB-NK cell products occurs rapidly 
following adoptive transfer.
Figure 5. Low-dose IL15 mediates efficient UCB-NK cell survival and expansion in vivo. Adult NSG 
mice were injected i.v. with 5x106 UCB-NK cells with or without supportive IL15. Recombinant human IL15 
was administered every 2-3 days for 2 weeks at the dose of 0.5 μg/mouse/injection, starting the day of UCB-
NK cell infusion. (A) Percentages of circulating human CD45+ cells in all CD45+ cells were quantified by flow 
cytometry at the indicated time points. Each line corresponds to one mouse. (B) Percentages of human CD45+ 
cells in all CD45+ cells quantified in spleen and bone marrow (leg bones) 2 weeks after UCB-NK cell infusion. 
(C) Expression of CD16 and CD158a/h,b,e on UCB-NK cells before and 2 weeks after infusion into NSG mice. 
Percentages were determined on human CD45+CD56+ NK cells isolated from spleen and bone marrow. Graphs 
show the mean ± SD of 5 mice.
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Figure 6. A single infusion of UCB-NK cells inhibits growth of BM-residing human leukaemia cells. The 
potential of UCB-NK cells to attack human leukaemia in vivo was evaluated in NSG mice bearing K562 intra-
femoral (IF) tumours. (A) Experimental study design: adult NSG mice were injected in their right femur with 
105 K562.LucGFP cells. The day after, mice were treated with 20x106 UCB-NK cells i.v. in combination with IL15 
administration (0.5 μg/mouse i.p. every 2-3 days for 14 days), or received PBS or IL15 alone as control (n=6 
per group). Tumour load was monitored by BLI from day 8 after K562.LucGFP cell inoculation and next every 
3-4 days for 2 weeks. At later time points, only mice with undetectable tumour load were imaged. (B) Two 
independent anti-leukemic studies were performed with similar outcomes. Tumour load per mouse measured 
at day 15 following K562.LucGFP cell IF injection from experiment 1 (black circles) and 2 (open circles). (C) BLI 
pictures acquired at day 15 after tumour cell IF injection, and (D) tumour load in time (mean ± SD, n=6 per 
group). **p<0.01 UCB-NK cells + IL15 vs. PBS and IL15. Data of experiment 2 are shown. (E) Time to first tumour 
detection by BLI and (F) mice survival analysed according to Mantel Cox test. One mouse from the IL15 group 
(experiment 1) died at day 19 after luciferine injection and was excluded from the survival analysis.
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Adoptive transfer of UCB-NK cells inhibits growth of BM-residing leukaemia cells in mice
Finally, to evaluate the cytolytic activity of UCB-NK cells in vivo, we developed a leukaemia 
xenograft model by injecting adult NSG mice with leukaemia cells intra-femorally (IF), 
therefore requiring BM homing by infused UCB-NK cells to achieve anti-leukemic response. 
For this, we used K562 leukaemia cells expressing Luciferase (K562.LucGFP cells) to allow 
longitudinal monitoring of tumour growth in living animals by bioluminescence imaging 
(BLI). In this model, mice received a single infusion of UCB-NK cells the day after K562.
LucGFP cell IF injection, in combination with low dose supportive IL15 (Figure 6A). A dose 
of 20x106 NK cells per mouse was defined based on biodistribution studies to approach an 
effector to target ratio of 1:1 in vivo. The anti-leukemic potential of UCB-NK cells to target 
K562.LucGFP cells was evaluated in two independent experiments with similar outcomes 
(Figure 6B). Comparable K562 cell engraftment was observed in both experiments and 
all control mice treated with PBS and IL15 except one displayed detectable IF tumours 
by day 15 (Figure 6B-C) In striking contrast, 8 out of 12 mice treated with UCB-NK cells 
had undetectable tumour load by day 15. Significant inhibition of K562.LucGFP cell 
progression following UCB-NK cells infusion was demonstrated by BLI in time (Figure 6D). 
Most importantly, a single infusion of ex vivo-generated UCB-NK cells in combination with 
low-dose IL15 prolonged survival of K562 IF injected mice of which 25% showed long-
term protection (Figure 6E-F). These results demonstrate that UCB-NK cells are functional 
following adoptive transfer, and that they are able to target and eliminate BM-residing 
leukaemia cells in vivo.
Discussion
To date, it is well established that NK cells mediate efficient graft-versus-leukaemia 
reactivity with improved control of relapse in AML patients following allo-SCT. This 
raises the interest in exploiting NK cells for adoptive immunotherapy, particularly as an 
adjuvant treatment approach to chemotherapy for elderly, high-risk and refractory AML 
patients. Most trials reported so far employed peripheral blood derived-NK cells enriched 
by CD3 depletion with or without CD56 selection from donor apheresis products, and 
showed that enriched NK cell infusions are well tolerated, without induction of GVHD or 
severe toxicity.9-11,18 Nevertheless, the clinical impact of NK cell-based therapy remains 
inconsistent and several issues need to be optimized to achieve clinical efficacy. In 
addition to conditioning regimens that prevent rapid graft rejection and supply of 
exogenous cytokines like IL2 supporting NK cell survival upon adoptive transfer, the purity, 
the activation and the number of cells that can be infused in patients are critical factors 
determining clinical response.9,11 Since, new methodologies are currently emerging to 
generate higher numbers of activated NK cells, including in vitro expansion of donor-
derived NK cells before infusion,19 as well as NK cell generation from CD34+ haematopoietic 
stem/progenitor cells.12,20,21 In particular, the availability of cryopreserved UCB units and 
the development of GMP-compliant culture systems constitute a very attractive approach 
NK-cells generated from UCB-progenitor cells target human leukaemia cells in NSG mice
5
111
to exploit the potential of NK cell-based adoptive immunotherapy, with generation of a 
clinically relevant dosages of UCB-NK cells with high purity and cytolytic activity in vitro.13
The present study was designed to pre-clinically evaluate the in vivo anti-leukemic 
potential of UCB-NK cells generated with our GMP-compliant culture system. To this end, 
we developed a mouse model in which human K562.LucGFP leukaemia cells are directly 
implanted into the femur of NSG mice, thus requiring BM-specific homing of infused UCB-
NK cells to achieve anti-tumour response. In this model, we showed that treatment with 
UCB-NK cells in combination with supportive IL15 potently inhibited progression of K562 
cells, thereby demonstrating that UCB-NK cells are functional in vivo and have the capacity 
to target leukaemia cells within BM upon adoptive transfer. Importantly, prolongation of 
mice survival including complete and persistent response in 25% of the mice was achieved 
following a single infusion of UCB-NK cells and in the presence of low dose IL15 support. 
Considering that complete protection against K562 cells in vivo was mostly reported 
following multiple NK cell infusions and/or prolonged high-dose IL2 administration,21-24 
we believe that our results nicely illustrates the therapeutic potential of UCB-NK cells in 
the clinic. In addition, biodistribution analysis showed that a relatively small proportion of 
our current UCB-NK cell product accumulates in one femur within 24h (~0.3% of 20x106 
cells, i.e. <1x105 UCB-NK cells per femur), suggesting that inhibition of leukaemia cell 
growth primarily happened at a low effector to target ratio what also illustrates the high 
cytolytic potential of ex vivo generated UCB-NK cells.
Our phenotypical analysis and in vitro migration studies support that UCB-NK cells can 
actively home to BM following adoptive transfer. Consistent expression of the chemokine 
receptor CXCR4 was detected on UCB-NK cells at the end of the culture process, and 
robust migration in response to its ligand CXCL12 was shown in vitro. Implication of the 
CXCR4/CXCL12 axis in regulating the migration of human T and NK cells to BM has been 
reported in several studies,25,26 including in human metastatic prostate cancer.27 Therefore, 
it is likely that UCB-NK cell homing to BM is CXCR4/CXCL12-dependent. Nevertheless, we 
also showed that UCB-NK cells display high expression of CXCR3 and CCR6, two receptors 
that could also regulate UCB-NK cell trafficking to inflamed tissues in vivo. Future studies 
are now warranted to demonstrate the role of the CXCR4/CXCL12 axis in UCB-NK cell 
homing to BM and to examine its implication in patients among other inflammatory 
pathways like CXCR3/CXCL10-11. Also, trafficking of adoptively transferred NK cells has 
not been addressed in leukaemia patients yet. Use of 111In for in vivo tracking of adoptively 
transferred NK cells has already been reported in patients with renal cell carcinoma and 
liver metastases,28,29 and at the pre-clinical level in xenograft mouse models of leukaemia.23 
Similar to our findings, early distribution of NK cells in the lungs, and later in the liver, 
spleen and eventually BM was visualized following systemic infusion. However, detailed 
organ distribution of NK cells as well as demonstration of the specificity of the visualized 
signal, particularly in BM, were not available. Here, we showed that 111In-based NK cell 
tracking provides good specificity and sensitivity, and will constitute a useful method to 
Chapter 5
5
112
study and correlate effective BM targeting with clinical response in patients.
We reported previously that UCB-NK cells generated with our GMP-compliant culture 
system display a relatively low expression level of CD16 and KIRs at the end of the culture 
process.12 However, we observed that the proportions of UCB-NK cells expressing these 
markers were strongly increased two weeks after adoptive transfer, indicating that UCB-NK 
cells can further differentiate in vivo into a more mature cell population. These data are in 
agreement with Huntington et al. who showed that rapid IL15 driven-transition of human 
CD56hiCD16-KIR- to CD56dimCD16+KIR+ NK cells occurs in vivo.30 Since KIR-ligand mismatch 
triggers NK cell alloreactivity towards AML, such phenotypic modifications might have 
important implications in patients. In that view, UCB-NK cell reactivity towards AML in vivo 
should be further addressed using HLA-expressing AML cells in our IF NSG model.
In conclusion, our results strongly support that UCB-NK cells constitute promising 
immunotherapeutic products to improve the treatment of AML, as demonstrated by their 
capability to migrate to BM and to inhibit progression of human leukaemia cells following 
adoptive transfer. In addition, we demonstrated efficient UCB-NK survival in vivo in the 
presence of low dose human IL15. Transient elevation of IL15 plasma levels was reported 
in AML patients following immunosuppressive Cy/Flu conditioning,9,10 what could favour 
in vivo expansion and maturation of UCB-NK cells as well as clinical responses following 
UCB-NK cell adoptive transfer. Since BM is the primary site of AML development and 
encloses niches essential for leukemic stem cells causing relapse,31 we believe that BM 
targeting is essential for elimination of minimal residual disease and induction of optimal 
and persistent clinical responses against AML. Strategies that aim at increasing BM-specific 
chemokine receptors, like CXCR4, on UCB-NK cells are now considered to enhance BM 
targeting. In addition, the methodologies that we report here for UCB-NK cell tracking and 
anti-leukemic effect monitoring will be instrumental to validate future findings and to fully 
exploit the potential of UCB-NK cells against AML and other hematological malignancies.
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Supplementary Figure 1. The biodistribution of 111In-NK cells upon adoptive transfer is reproducible 
between animals and independent of the dose of injected cells. Five adult NSG mice (mice M1 to M5) were 
infused i.v. with increasing number of 111In-NK cells (1MBq per 106 cells) and euthanized the day after for organ 
collection and biodistribution analysis. For comparison, proportions of activity quantified per gram of tissue of 
interest were normalized to blood.
Supplementary Figure 2. Low-dose IL15 mediates efficient UCB-NK cell survival and expansion in vivo. 
Adult NSG mice were injected i.v. with 10x106 UCB-NK cells with or without supportive IL15. Recombinant human 
IL15 was administered daily for 2 weeks at the dose of 0.5mg/mouse/injection, starting the day of UCB-NK cell 
infusion. Human NK cells were quantified weekly in peripheral blood by flow cytometric analysis. (A) Percentage 
of human CD45+CD56+ cells in blood of mice injected with UCB-NK cells alone (dotted line, n=5) or UCB-NK cells 
with IL15 (straight line, n=6) over time. (B) Representative dot-plots obtained 2 weeks after UCB-NK cell infusion.
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Abstract
Adoptive transfer of allogeneic natural killer (NK) cells represents a promising treatment 
approach against cancer, including acute myeloid leukaemia (AML). Previously, we 
reported a cytokine-based culture method for the generation of NK cell products with high 
cell number and purity. In this system, CD34+ hematopoietic progenitor cells (HPC) are 
expanded and differentiated into NK cells under stroma-free conditions in the presence of 
IL15 and IL2. Here, we show that combining IL15 with IL12 drives the generation of more 
mature and highly functional NK cells. Particularly, replacement of IL2 by IL12 enhanced 
the cytolytic activity and IFNγ production of HPC-NK cells towards cultured and primary 
AML cells in vitro, and improved anti-leukemic responses in NOD/SCID/IL2Rγnull (NSG) 
mice bearing human AML cells. Phenotypically, IL12 increased the frequency of NKG2A 
and Killer Immunoglobulin-like Receptor (KIR)-expressing HPC-NK cells, which were more 
responsive to target cell stimulation. In addition, NK15/12 cell products demonstrated 
superior maturation potential resulting in >70% positivity for CD16 and/or KIR within 
two weeks after infusion into NSG mice. We foresee that higher functionality and faster in 
vivo maturation will favour HPC-NK cell alloreactivity towards malignant cells in patients, 
making this cytokine combination an attractive strategy to generate clinical HPC-NK cell 
products for cancer adoptive immunotherapy.
Combining IL15 and IL12 for NK cells with superior maturation and anti-leukemic activity
6
119
Introduction
Adoptive transfer of natural killer (NK) cells is a novel, relatively non-toxic and promising 
treatment approach against cancer, including acute myeloid leukaemia (AML).1 In the 
context of allogeneic hematopoietic stem cell transplantation (HSCT), it has been well 
established that fast repopulating alloreactive NK cells mediate an efficient graft-versus-
leukaemia  reaction and improve control of relapse without causing graft-versus-host 
disease.2-4 Importantly, prolonged relapse-free survival has been demonstrated in 
allotransplanted AML patients in the setting of Killer Immunoglobulin-like Receptor (KIR)-
ligand mismatching between patients and allogeneic donors.5-7 In this situation, AML cells 
of the patient lack an inhibitory HLA-ligand for the allogeneic donor NK cells, resulting in 
the absence of inhibitory signal for NK cells and potent activation upon engagement of 
activating receptors. These clinical observations raised the interest in exploiting NK cell 
adoptive immunotherapy as an adjuvant treatment approach against AML, and in the 
non-transplant setting, adoptive transfer of allogeneic NK cells also demonstrated clinical 
activity in poor-prognosis AML patients,8, 9 as well as in childhood AML with induction of 
long-term remission.10 In these trials, NK cell infusions were given following fludarabine 
and cyclophosphamide conditioning, which resulted in a marked rise in endogenous IL15 
that favoured in vivo survival and expansion of infused NK cells in the majority of treated 
patients.8, 9
Although infusions with peripheral blood derived-NK cells appeared to be safe, NK 
cell enrichment from leukapheresis products yields relatively low NK cell numbers, with 
contaminating alloreactive T cells.11-14 To overcome these limitations, several methods have 
been explored to activate and expand NK cells before adoptive transfer.15-20 Alternatively, 
NK cells can be generated from hematopoietic progenitor cells (HPC).21-25 Previously, we 
reported a GMP-compliant, cytokine-based culture protocol for the ex vivo-generation 
of allogeneic NK cells from CD34+ HPC isolated from cryopreserved umbilical cord blood 
(UCB) units, bone marrow (BM) or G-CSF-mobilized blood (see ref23 and unpublished data). 
Purified CD34+ progenitor cells are expanded in closed, large-scale bioreactors to achieve 
clinically relevant doses of NK cell products, completely devoid of allogeneic T cells.25 In 
addition, pre-clinical studies conducted in NOD/SCID/IL2Rγnull (NSG) mice demonstrated 
that these HPC-NK cells have BM homing capacity, display IL15-driven in vivo expansion, 
and prolong survival of leukaemia-bearing mice.26
Currently, we generate HPC-NK cells under stroma-free conditions in the presence of 
IL15 and IL2. However, several other cytokines are known to promote NK cell development, 
activation and function.27-29 While IL15 plays a crucial role during NK cell development as 
well as in the survival and expansion of NK cells in vivo, recent studies also demonstrated 
that pre-activation with combinations of the cytokines IL12, IL15, and IL18 results in 
“priming” of memory-like NK cells with enhanced functional properties.30-32 Although the 
precise underlying mechanism remains unknown, this prime-boost strategy using distinct 
combinations of cytokines may pave the way to improved NK cell immunotherapeutic 
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strategies.
In the present study, we demonstrated that combining IL15 with low dose IL12 
drives the generation of more mature and highly functional HPC-NK cells. Particularly, 
replacement of IL2 by IL12 favours the development of KIR-expressing NK cells, which 
display superior IFNγ production and cytolytic activity against AML cells, in vitro and in 
vivo. Although enhancement of NK cell cytolytic functions were associated with ICAM-1 
upregulation on AML cells in vitro, HPC-NK cell products generated with IL15 and IL12 
demonstrated faster maturation potential in vivo compared to IL15/IL2 cultured NK cells, 
resulting in higher frequency of CD16+KIR+ alloreactive NK cells shortly after adoptive 
transfer. Altogether, our data support that combining IL15 with IL12 for the generation of 
clinical HPC-NK cell products is an attractive strategy to improve anti-leukemic response 
in patients.
Materials and Methods
HPC-NK cell generation
UCB units were obtained at birth after normal full-term delivery and written informed 
consent with regard of scientific use from the cord blood bank of the Radboudumc. NK 
cells were generated from cryopreserved UCB-derived HPC as previously reported.23, 
26 Briefly, expanded CD34+ cells were differentiated and further expanded using NK cell 
differentiation medium which consists of Glycostem Basal Growth Medium (GBGM®) for 
cord blood (Clear Cell Technologies) supplemented with 2% human serum (HS; Sanquin 
Blood Supply Foundation, Nijmegen, the Netherlands), 250 pg/ml G-CSF (Neupogen®; 
Amgen), 10 pg/ml GM-CSF, 50 pg/ml IL6 (both CellGenix) and a high-dose cytokine 
cocktail consisting of 20 ng/ml IL7, SCF, IL15 (all CellGenix) and 1000 U/ml IL2 (Proleukin®; 
Chiron). IL12 (Immunotools, specific activity of 3x106 U/mg) was used at a concentration 
of 200 pg/ml in conjunction with IL15, with or without IL2. Where indicated in the figure 
legends, HPC-NK cells were generated using the alternative Stem Cell Growth Medium 
(SCGM, Cellgenix) with the following modifications in the cytokine cocktail: 50 ng/ml 
IL15 and 70 pg/ml IL12 (Miltenyi Biotech, specific activity of 3x106 U/mg). The cell density 
was checked twice a week and adjusted to >1.5x106 cells/ml by the addition of NK cell 
differentiation medium. For experiments, CD56+CD3- HPC-NK cells were used at the end 
of the culture process with >80% purity, which was typically achieved within 3-4 weeks in 
NK cell differentiation medium.
Cell lines and reagents
The K562, THP-1, and KG-1a cell lines (ATCC) were cultured in Iscove’s modified Dulbecco’s 
medium (IMDM; Invitrogen) containing 50 U/ml penicillin, 50 µg/ml streptomycin and 
10% fetal calf serum (FCS; Integro). Recombinant human IFNγ and TNFα (both 2x107 U/
mg; Immunotools) were used at concentrations as indicated in the figure legends.
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Flow cytometry
Anti-human CD45 (J33; Beckman Coulter) and CD56 (HCD56; Biolegend) antibodies 
were used to follow cell number and NK cell differentiation during culture using the 
Coulter FC500 flow cytometer (Beckman Coulter). The population of living CD45+ cells 
was determined by exclusion of 7AAD positive cells (Sigma). Phenotypical analysis were 
performed using the Coulter FC500 or Cyan-ADP 9 colour cytometers (Beckman Coulter) 
and the following conjugated monoclonal antibodies: CD3 and NKG2A (clones UCHT1 
and Z199 respectively, both from Beckman Coulter), CD158a/h, b and e (clones HP-MA4, 
DX27, and DX9 respectively), CD16 (3G8), CD62L (DREG-56), CXCR3 (G025H7), CXCR4 
(12G5), NKG2D (1D11), NKp46 (9E2), TRAIL (RIK-2), FasL (NOK-1; all Biolegend), and DNAM-
1 (DX11; BD Bioscience).
Cellular assays
Flow cytometry-based cytotoxicity assays were performed as described previously with 
minor modifications.23 Briefly, CFSE-labelled target cells were resuspended in IMDM/10% 
FCS to a final concentration of 1-3x105/ml. HPC-NK cells were washed with PBS and 
resuspended in GBGM/2% HS to a final concentration of 1-10x105/ml. Target cells were 
co-cultured with effector cells at different E:T ratios in 96-wells flat-bottom plates. NK and 
target cells alone were plated as controls. After overnight incubation at 37°C, cells were 
harvested and the number of viable target cells was quantified by flow cytometry. Target 
cell survival was calculated as follows: % survival = (absolute no. viable CFSE+ target cells 
co-cultured with NK cells / absolute no. viable CFSE+ target cells cultured in medium)*100. 
The percentage of specific killing was 100 - % survival. NK cell co-cultures with primary 
AML cells were supplemented with IL3 (50 ng/ml; Cellgenix), SCF (20 ng/ml; Immunotools), 
Flt3L (20 ng/ml; Cellgenix), G-CSF (20 ng/ml; Amgen) and IL15 (5 ng/ml). ICAM-1 blocking 
antibody (clone SM89) was used with the dilution 1:100. NK cell degranulation and IFNγ 
production were determined upon stimulation with K562 cells at an E:T ratio of 1:1. 
Anti-CD107a (H4A3; BD Biosciences) was added in a 1:100 dilution at the start of the co-
culture, and Brefeldin A (1 ng/µl, BD Biosciences) was added 1h later. Cells were collected 
the day after, stained for cell surface markers, then treated with fixation/permeabilization 
buffer (eBioscience), and stained for intracellular IFNγ (clone B27; BD Biosciences). Flow 
cytometric analysis was performed with exclusion of dead cells with Fixable Viability Dye 
(eBioSciences) and using unstimulated cells as control.
Cytokine production analysis
Cytokine production by target cell-stimulated NK cells was measured in the supernatant 
of the co-cultures by enzyme-linked immunosorbent assay (ELISA) according to 
manufacturer’s instructions. In these assays, a fixed number of 5x104 HPC-NK cells were 
plated at an E:T ratio of 1:1 or 2:1, as indicated in the figure legend, with target cells in a 
total volume of 200 µl. ELISA kits for IFNγ, TNFα and Granzyme B were purchased at Pierce 
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Endogen, Mabtech, and Sanquin respectively, and TMB microwell peroxidase substrate 
system was from KPL. Absorbance was measured at 450 nm with a Multiscan MCC/340 
ELISA reader (Titertek).
RNA extraction and real-time PCR quantification
Total RNA was isolated using Quick-RNA Miniprep kit (Zymo Research) according to 
the manufacturer’s instructions. Next, cDNA was synthesized using M-MLV-reverse 
transcriptase (Invitrogen) in a standard reaction after which real-time PCR was performed 
using Taqman Gene expression assays (Applied Biosystems): PRF1 (Hs99999108); GZMB 
(Hs01554355); EOMES (Hs00172872); TBX21 (Hs00203436). Expression levels were 
calculated relative to GAPDH (Hs02758991) using the ΔΔCt method. 
HPC-NK cell adoptive transfer, intra-femoral THP-1 model and bioluminescence imaging
NSG mice originally purchased from Jackson Laboratories were housed and bred in 
the Radboudumc Central Animal Laboratory. NSG mice were used from 6 to 12 weeks 
of age at the start of the experiment (weight was 20-30 g). All animal experiments were 
approved by the Animal Experimental Committee of the Radboudumc and conducted 
in accordance with institutional and national guidelines under the university permit 
number 10300. In adoptive transfer studies, HPC-NK cells were resuspended in PBS and 
injected intravenously via the tail vein. Recombinant human IL15 (Miltenyi Biotech) 
was administrated subcutaneously at the dose of 0.5 mg (2500 units) per mouse every 
2-3 days starting the day of HPC-NK cell infusion. For ex vivo-flow cytometric analysis, 
mice were sacrificed and cells were isolated from spleen, bone marrow and liver using 
erythrocyte lysis solution or lympholyte-M (Cedarlane). Preclinical xenograft models 
were established using the K562 and THP-1 cells previously engineered to express the 
GFP and Luciferase reporter genes (K562.GFPLuc and THP1.GFPLuc cells). Efficient AML 
cell engraftment was achieved using 105 K562 and 2x104 THP-1 cells injected in the right 
femur of isoflurane gas anesthetized mice (injection volume = 5 µl). Tumour load was 
monitored by bioluminescence imaging (BLI) as previously described.26
Statistical analysis
Statistical analyses were performed using Graphpad Prism 5 software. Student t-tests, 
one- and two-way analysis of variance (ANOVA) were used when appropriate as indicated 
in the figure legends. Differences were considered to be significant for p values <0.05.
Results
Replacement of IL2 by IL12 in combination with IL15 allows generation of HPC-NK cells with 
higher NKG2A, CD16 and KIR expression
Because of its NK-potentiating effect, we have examined the influence of IL12, in 
combination with IL15 and IL2, on the generation and functionality of HPC-NK cells. To this 
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Figure 1. High numbers of CD56+CD3- HPC-NK cells can be generated in the presence of IL12 without 
IL2. (A) Representation of the culture system used for the ex vivo-generation of HPC-NK cells in the presence 
of IL15 (20 ng/ml), with addition of IL2 (1000 U/ml) and/or IL12 (200 pg/ml) from day 14 onward during the 
differentiation phase. (B) Kinetics of CD56 acquisition upon HPC-NK cell differentiation and (C) fold expansion of 
total CD45+ cells (mean ± SD of 3 culture-wells). One representative donor is shown. (D) Relative fold expansion 
of NK15/12 cells to NK15/2 cells. A summary of 7 donors (mean ± SD) is shown. (E-F) The phenotype of HPC-NK 
cells was examined at the end of the culture process (day 38-42) by flow cytometry. One representative donor 
(E) and a summary of 7 donors (F, mean ± SD) are shown. ***p<0.001, paired student t test.
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end, IL12 was introduced in our culture system from day 14 onwards at low concentration 
which had no impact on the purity of the final product (Figure 1A-B). Although addition of 
IL12 reduced the expansion rate of the total cells, this effect was limited when combining 
IL15 with IL12 only (Figure 1C-D). In addition, this cytokine combination led to interesting 
phenotypical changes compared to the NK15/2 cell product (Figure 1E-F). Replacement of 
IL2 by IL12 resulted in higher percentages of CD56+ cells expressing NKG2A and inhibitory 
KIRs (combined CD158a/h, b, and e staining). Despite variability between donors, a 
slightly increased percentage of CD16+ NK cells was noticed in NK15/12 compared 
to NK15/2 cells. Notably, NK15/12 cell products showed slightly lower levels in CD56 
expression at the end of the culture process (CD56 MFI: 152 ± 10.7 vs. 124.2 ± 9.0, NK15/2 
vs. NK15/12 respectively, data not shown), but this was not related to a specific NK cell 
subset. We also found higher percentages in CD62L positivity. Expression of the activating 
receptors NKG2D, natural cytotoxicity receptors and DNAM-1 were similar in all NK cell 
cultures analysed at the end of the process (data not shown). For these reasons, further 
investigations were concentrated on comparing NK15/2 and NK15/12 cells.
Combining IL15 with IL12 generates HPC-NK cells with enhanced cytolytic activity against AML 
in vitro and in vivo
Next, we examined the impact of IL12 on HPC-NK cell reactivity towards leukaemia 
cells. Although both NK cell products showed high cytolytic activity against the NK-
sensitive K562 cells, increased killing of MHC class I-positive AML cells THP-1 and KG-1a 
was measured with NK15/12 cells (Figure 2A). Enhanced reactivity towards target cells 
was confirmed by elevated levels of granzyme B produced by NK15/12 compared to 
NK15/2 cells (Figure 2B). Levels of IFNγ secretion were also increased with NK15/12 cells 
(Figure 2C), while production of TNFα was relatively low and similar for both NK products 
(Figure 2D). Most importantly, higher susceptibility of patient-derived primary AML cells 
to NK15/12-mediated killing was demonstrated at low effector-to-target ratio, including 
differentiated M4-M5 AMLs as well as more immature CD34+ M1-M2 AMLs (Figure 2E, 
Supplementary Figure 1; for AML patient characteristics see Supplementary Table 1).
To further compare the anti-leukemic potential of NK15/2 versus NK15/12 cells, 
adoptive transfer studies were designed in adult NSG mice challenged in their right femur 
with luciferase-expressing leukaemia cells (day 0). We reported previously that HPC-NK 
cells generated in the presence of IL15 and IL2 efficiently inhibited progression of BM-
residing K562 cells in vivo.26 Using this model, a single infusion of NK15/2 or NK15/12 
cells exerted similar effect (Figure 3A-B). Therefore, new studies were designed in a 
more stringent model using the MHC-I+ THP-1 cells. In this model, the effect of a single 
HPC-NK cell infusion was not immediately apparent as at day 7, all mice showed clear 
tumour cell engraftment with no difference between experimental groups. However after 
2 weeks, progression of THP-1 cells was significantly reduced following treatment with 
NK15/12 cells (Figure 3E). Next, to slow down THP-1 cell progression in vivo and to prolong
Combining IL15 and IL12 for NK cells with superior maturation and anti-leukemic activity
6
125
Figure 2. Combining IL15 with IL12 enhanced the cytolytic activity and the IFNγ production capacity 
of HPC-NK cells towards AML. The functionalities of HPC-NK cell products were assessed after overnight 
coculture with target cells. (A) Percentage killing of K562, THP-1 and KG-1a cells at increasing E:T ratio. 
Combined results (mean ± SEM) of 7 independent experiments, each performed in triplicates with different 
HPC-NK cell donors, are shown. (B-D) Granzyme B, IFNγ, and TNFα levels were determined by ELISA in coculture 
supernatants of 5x104 NK cells with target cells at a E:T ratio of 1:1. Means ± SEM of 5 donors are shown. (E) 
Percentage killing (mean ± SD) of patient-derived primary AML cells (E:T ratio 3:1). The cytolytic activity of 
HPC-NK cells derived from donor I (undetermined HLA-C type) was addressed using CFSE-based cytotoxicity 
assay, while viable AML cells were identified by flow cytometry using 7AAD and CD33/CD34/CD56 markers 
with donor II (HLA-C group C1/C2). Statistical analysis was performed using a two way ANOVA (with repeated 
measurements in panels A-D), *p<0.05, **p<0.01, ***p<0.001.
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Figure 3. Infusion of NK15/12 cell products improves anti-leukemic response in THP1-bearing NSG 
mice. The anti-leukemic potential of a single infusion of NK15/2 versus NK15/12 cell infusion was compared in 
vivo, in adult NSG mice injected in their right femur with K562.LucGFP cells (A-B) or THP1.LucGFP cells (C-H). (A) 
Experimental study design in K562-bearing mice, and (B) tumour load in time (mean ± SD, n=6 per group, two-
way ANOVA). (C-E) Effect of a single NK cell infusion applied the day after THP-1 cell IF injection. Combined data 
from 2 independent experiments (n=7-9 per group per experiment) are shown. (C) Experimental study design. 
(D) Tumour load measured in each mouse at day 7, 11, and 14 after IF THP-1 cell injection. (E) Fold increase in the 
tumour load between day 7 and day 14. Mean ± SD, one-way ANOVA. (F-H) Effect of multiple NK cell infusions 
in cyclophosphamide-conditioned mice. Data from one experiment are shown (n=8-9 per group), where HPC-
NK cells were generated using SCGM and selected for partial KIR/ligand mismatch (UCB HLA type: Bw4, C1/C2, 
THP-1 HLA type: Bw6, C1/C1). (F) Experimental study design. (G) Tumour load progression overview. Mean ± 
SD, two-way ANOVA with repeated measures. (H) Fold increase in the tumour load between day 6 and day 21. 
Mean ± SD, one-way ANOVA. *p<0.05, **p<0.01.
the treatment period, conditioning of THP1-bearing mice using cyclophosphamide was 
introduced in our study, and an equivalent amount of HPC-NK cells was administered as 3 
infusions with 3-4 days interval (Figure 3F). In line with previous findings, the anti-leukemic 
effect of NK cell infusions was visible from day 10 onwards. More importantly, treatment 
with NK15/12 cells significantly reduced tumour load compared to NK15/2 cell products 
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until day 21 (Figure 3G-H). Analysis of peripheral blood confirmed NK cell persistence up 
to 2 weeks after adoptive transfer, and showed similar levels of circulating NK cells in both 
groups of mice (data not shown). All together, these data demonstrate that combining 
IL15 with IL12 drives the generation of HPC-NK cells with enhanced cytolytic activity 
against AML cells, in vitro and in vivo.
Combining IL15 with IL12 favours development of more mature and highly functional 
NKG2A+KIR+ NK cells
Next, we aimed to understand how IL12 influenced the increased killing activity of HPC-
NK cells. Besides similar expression of activating receptors, we could not identify any 
significant difference in the cytolytic machinery between both NK cell products. At the 
protein level, NK15/2 and NK15/12 cells displayed comparable expression of perforin and 
granzyme B (data not shown), as well as TRAIL and FasL (Figure 4A). Gene expression profiles 
of perforin and granzyme B were also similar, as well as those for the transcription factors 
Eomesodermin and TBX21 (Figure 4B), which were described as important modulators 
of NK cell maturation, function and exhaustion.33,34 Thereafter, we examined NK cell 
reactivity at the single cell level upon overnight stimulation with K562 cells. As shown in 
Figure 4C-D, a small but significant increase of CD107a+ degranulating cells was noticed 
within NK15/12 cells. More strikingly, the fraction of IFNγ-producing cells was strongly 
augmented. In accordance with the levels of IFNγ detected in co-culture supernatants, 
IFNγ-positivity was almost absent in NK15/2 cells while a clear population of CD107a+ IFNγ+ 
cells was visualized in all tested NK15/12 cell products. Interestingly, examination of NK 
cell phenotype in combination with IFNγ production showed enrichment of responsive 
cells within the NKG2A+KIR+ population (Figure 4E-F), supporting the conclusion that IL12 
favors the development of more mature and highly functional NK cells.
Higher cytolytic activity of NK15/12 cells is associated with superior IFNγ production capacity 
and ICAM-1 upregulation on AML in vitro
With respect to the level of KIRs expressed on NK15/2 and NK15/12 cells, the data 
described above could suggest that enhanced AML killing relied on differential KIR-
mediated alloreactivity of HPC-NK cells. However, increased cytolytic activity of NK15/12 
cells was consistent in vitro, irrespective of the HLA type of AML cells including against 
the C1/C2/Bw4-positive KG-1a cells as well as patient-derived AML blasts (Figure 2, 
Supplementary Figure 1). In a recent study, Sun and colleagues established a direct link 
between cytokine production and cytolysis of NK cells, as a result of IFNγ/TNFα-induced 
upregulation of Intercellular Adhesion Molecule 1 (ICAM-1) on tumour cells.35 To address 
this possibility, we first examined the expression level of adhesion molecules on AML cell 
lines. As illustrated in Figure 5A, we found a dose-dependent up-regulation of ICAM-1 
on THP-1 and KG-1a cells 24h following incubation with IFNγ and TNFα. For comparison, 
basal expression of LFA-3 was high in both AML cell lines and remained unchanged under
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Figure 4. Replacement of IL2 by IL12 favors the development of more mature and highly functional 
KIR+ NK cells. (A-B) Representative expression level of TRAIL and FasL on CD56+ HPC-NK cells. (B) Relative gene 
expression of the cytolytic mediators perforin (PRF1) and granzyme B (GrzB), as well as the transcription factors 
eomesodermin (EOMES) and t-bet (TBX21). Mean ± SD of two HPC-NK cell donors are shown, one generated 
with GBGM and the second one using SCGM. (C-D) Percentages of degranulating and IFNγ-producing NK cells 
were determined upon overnight stimulation with K562 cells at E:T ratio 1:1 and in the presence of low dose IL15 
(5 ng/ml). Percentages of CD107+ and IFNγ+ cells were determined with subtraction of signals measured with 
unstimulated cells. One representative experiment (C) and a summary of 10 donors (D, mean ± SEM) are shown. 
(E-F) The IFNγ production capacity of NK15/12 cells was examined within different subsets identified using 
NKG2A and KIRs differentiation markers. One representative donor (E) and a summary of 4 donors (F, mean ± 
SEM) are shown. Differences were analyzed using a paired t-test (D) or a one-way ANOVA (F), *p<0.05,**p<0.01.
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Figure 5. IFNγ-mediated ICAM-1 upregulation on AML cells strengthen NK cell cytolytic activity. (A) 
Expression of ICAM-1 and LFA-3 on AML cell lines after 24h culture with increasing concentrations of IFNγ and 
TNFα. (B) Expression profile of CD11a on NK15/2 and NK15/12 cells at the end of the culture process. Histograms 
from one representative HPC-NK cell donor out of three analyzed are shown. (C) Overnight THP-1 and KG-1a 
cell killing by NK15/2 vs. NK15/12 cells, or NK15/2 cells in the presence of 1000 pg/ml recombinant IFNγ (E:T ratio 
3:1, mean ± SD). (D) Inhibition of HPC-NK cell killing in the presence of anti-ICAM-1 antibody (10 µg/ml). (E-G) 
Coculture experiments of NK15/2 or NK15/12 cells with patient-derived primary AML cells were performed at 
E:T ratio 2:1 and in the presence of low dose IL15 (5 ng/ml) for 24, 48 and 72h. (E) Relative ICAM-1 expression 
level on AML cells and (F) relative killing (mean ± SD) of AML cells in time upon coculture with NK cells. (G) 
Expression of CD11a measured at 48h on HPC-NK cells upon coculture with AML cells. Data shown in (E-G) were 
obtained with AML#7 cells. Statistical analysis was performed using a one-way ANOVA (C) and student t test (D, 
F), **p<0.01, ***p<0.001, p<0.0001.
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inflammation. Moreover, NK15/2 and NK15/12 cells expressed similar level of CD11a (Figure 
5B), supporting the idea that enhanced killing capacity of NK15/12 cells could rely on their 
potency to strengthen their LFA-1/ICAM-1 mediated-interaction with target cells through 
inflammatory cytokine release. Accordingly, addition of recombinant IFNγ increased 
killing of AML cells by NK15/2 cells (Figure 5C), while ICAM-1 blocking inhibited NK cells 
activity (Figure 5D). Thereafter, we examined ICAM-1 expression on primary AML cells. 
In line with previous results, up-regulation of ICAM-1 was observed upon inflammation 
as well as in the presence of HPC-NK cells (data not shown). More interestingly, analysis 
of ICAM-1 levels and relative NK-killing in time supported the contribution of ICAM-1 
upregulation in AML cell susceptibility to NK cells. Particularly, ICAM-1 upregulation was 
more pronounced in the presence of NK15/12 cells at 48 and 72h of co-culture (Figure 
5E). This was accompanied with a progressive increase in AML cell killing by NK15/12 
cells (Figure 5F) while both NK cells showed sustained expression of CD11a (Figure 5G). 
In addition, preferential lysis of the ICAM-1hi AML cells was visualized using blasts from 
a second AML patient (Supplementary Figure 2). In these experiments, differential IFNγ 
production towards primary AML cells was confirmed, but treatment with inflammatory 
cytokines alone did not result in any significant upregulation of NK activating ligands on 
AML cells (Supplementary Figure 3). All together, these data strongly support that IL12 
enhances HPC-NK cell cytolytic activity through higher IFNγ-production capacity.
HPC-NK15/12 cell products display faster maturation potential in vivo
Next to the impact of IL12 on HPC-NK cell functionalities in vitro, we showed that infusion of 
NK15/12 cells resulted in superior anti-leukemic activity in vivo compared to NK15/2 cells. 
If this effect was not attributed to a difference in HPC-NK cell survival and/or expansion in 
vivo, we wondered whether NK15/2 and NK15/12 cells would behave the same in terms of 
activation and maturation. To address this question, mice were infused with either NK15/2 
or NK15/12 cells and sacrificed one week later for ex vivo-flow cytometric analysis. As shown 
in Figure 6A, both NK15/2 and NK15/12 cells showed high and sustained expression of 
various activation markers including NKG2D, NKp46 and DNAM-1, as well as CXCR3, which 
is, among others, an important chemokine receptor for NK cell recruitment to tumour 
and inflammation sites.36 In contrast, differences were found within NK cell maturation 
markers. Notably, increased levels of CD16 and KIRs expressing-NK cells were measured 
1 week after infusion (Figure 6B). Relative to the infused NK cell products, NK15/12 cells 
experienced CD16 acquisition to the same extent as NK15/2 cells. However, percentages 
of circulating KIR+ NK15/12 cells were significantly higher compared to NK15/2 cells (17.3 
± 0.3 vs. 40.9 ± 4.0 %, respectively), resulting in higher frequencies of KIR+CD16+ cells in the 
spleen (Figure 6C), as well as in liver and bone marrow of infused mice (data not shown). To 
further characterize the kinetics of NK cell maturation in vivo, NK15/12 cells were infused 
into NSG mice and phenotyped 1, 7, or 14 days later. Interestingly, the percentages of 
CD16 and KIR single-positive cells remained stable in time (Figure 7A). However, the 
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proportion of CD16+KIR+ NK cells strongly increased to progressively replace CD16-KIR- NK 
cells, suggesting concomitant acquisition of CD16 and KIRs expression on immature HPC-
NK cells in vivo. In line with this, no difference in proliferation capacity between each NK 
cell subsets was found (data not shown). Moreover, although a discrete NKG2A-KIR+ NK 
cell population appeared by day 7-14, expression of NKG2A remained high with > 70% 
positivity at all time-points (Figure 7B-C). All together, these data indicate that, in addition 
to sustained expression of activating receptors, HPC-NK cells generated with IL15 and IL12 
undergo rapid in vivo maturation, what might favour their alloreactivity towards AML cells 
following adoptive transfer in situation of KIR-ligand mismatches.
Figure 6. HPC-NK cell products generated in the presence of IL12 display faster maturation in vivo. 
NK15/2 or NK15/12 cells were infused into adult NSG mice (5x106) in combination with low dose IL15 support. 
One week later, mice were sacrificed and ex vivo-flow cytometric analysis was performed on cells isolated from 
spleen, liver, and bone marrow (BM). (A) Representative expression of the activating receptors NKG2D, NKp46 
and DNAM-1 as well as CXCR3 on NK15/2 and NK15/12 cells before infusion and isolated from spleen one week 
after adoptive transfer. (B) Percentages of CD16 and KIRs-expressing NK cells before infusion and one week 
after adoptive transfer. Combined results from two experiments (n=4-6 mice per group per experiment) are 
shown. Means ± SEM. **p<0.01, two-way ANOVA. (C) Representative dot plots of CD16 and KIR expression on 
CD56+ cells isolated from spleen of mice injected with NK15/2 or NK15/12 cells.
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Figure 7. NK15/12 cells undergo concomitant CD16 and KIR acquisition in vivo with sustained NKG2A 
expression. NK15/12 cells (5x106) were infused into adult NSG mice in combination with IL15 support. Ex vivo-
flow cytometric analysis was performed on cells isolated from spleen 1, 7, and 14 days after adoptive transfer 
(n=4 per time point). (A) Percentages of NK cell subsets identified using CD16 and KIR differentiation markers 
in time. **p<0.01, ***p<0.001, one-way ANOVA. (B) Percentages (mean ± SD) of NK cell subsets identified using 
NKG2A and KIR differentiation markers in time. (C) Representative dot plots of KIR, NKG2A, and CD16 expression 
on human CD56+ cells of the infused product and splenocytes isolated at day 1 and 14.
Discussion
In the past decade, adoptive transfer of allogeneic NK cells gained attention as a promising 
adjuvant treatment approach against cancer including AML. Thereby, a great number of 
reports described new methodologies to achieve higher NK cell number and activation. 
Particularly, expansion and differentiation of HPCs allows generation of clinically 
applicable NK cell products with high purity and functionality.25 Nevertheless, we and 
others have observed that NK cells generated under stroma-free cultured conditions using 
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IL15 and IL2 have low surface expression of CD16 and only a subset (5-10%) expresses 
KIRs,23, 37 raising the question about NK cell potency and alloreactivity following adoptive 
transfer. Moreover, clinical studies reported so far showed that adoptively transferred 
allogeneic NK cells have a relatively short lifespan in patients. In view of the transient 
elevation of endogenous IL15, which facilitates in vivo expansion after lympho-depleting 
chemotherapy, as well as host immune T cell recovery and consequent rejection of the 
partially HLA-matched allogeneic NK cells, it might be beneficial to maximize NK cell 
alloreactivity towards AML shortly following adoptive transfer. 
In the present study, we demonstrated that more mature and highly functional HPC-
NK cells can be generated under stroma-free conditions by replacement of IL2 for IL12. 
Importantly, NK15/12 cells showed higher cytolytic activity against both cultured and 
patient-derived primary AML cells. Although IL12 reduces the cell expansion rate during 
the differentiation phase, high numbers of HPCs can be isolated from UCB units and 
efficiently expanded using our culture process, thereby allowing generation of clinically-
relevant dose of NK cells to treat patients. In addition, we showed that IL12 favours the 
generation of CD16 and KIR-expressing NK cells, resulting in the rapid development of 
hyper-responsive CD16+KIR+NK cells following adoptive transfer. In line with the study of 
Hsu and colleagues, demonstrating that NK cell responsiveness follows a clear hierarchy 
with respect to NKG2A and inhibitory KIRs expression pattern,38 we foresee that faster 
maturation potential of NK15/12 cells in vivo will trigger more potent HPC-NK cell 
alloreactivity towards AML. Accordingly, superior anti-leukemic activity of NK15/12 cell 
products was demonstrated in vivo in situation of partial KIR-ligand mismatch. Moreover, 
a recent study reported that hypo-responsiveness of unlicensed NK cells lacking KIR 
expression for self HLA could be reversed upon CD16 engagement.39 This supports that 
concomitant CD16 and KIR acquisition observed among NK15/12 cells will favour HPC-
NK cell potency and provides a rationale to explore allogeneic HPC-NK cell adoptive 
transfer in combination with therapeutic antibodies to exploit tumour-targeted antibody-
dependent cell-mediated cytotoxicity. 
As a known potentiating effect of IL12 on NK cells,27 we also demonstrated higher 
IFNγ production capacity of NK15/12 cell products compared to IL15/IL2 generated cells. 
Expression of the IL12 receptor CD212 was detected early on NK progenitor cells and 
all along ex vivo NK cell differentiation (data not shown), supporting that in our system 
IL12 has a direct effect on HPC-NK cell functions. Notably, use of IL12 in combination 
with IL2 during the differentiation phase also increased the functionalities of HPC-NK 
cell products (data not shown). Nevertheless, this cytokine combination had a stronger 
impact on ex vivo NK cell expansion compared to IL12 alone. It also resulted in limited 
increased KIR expression (data not shown), suggesting that both IL12 and IL2 influence NK 
cell maturation and KIR acquisition. Likewise, previous studies described that exposure to 
IL12 resulted in upregulation of CD62L on NK cells,40 and more recently, that expression 
of CD62L identified a unique subset of polyfunctional NK cells with enhanced IFNγ 
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production and proliferation capacity upon viral infection in vivo.41 In the present study, 
although increased frequencies of CD62L+ cells were observed using IL12, differences in 
functionality could not be identified within this subset. Therefore, the mechanisms by 
which IL12 influences NK cell maturation and/or proliferation could be further investigated.
In conclusion, we showed that replacement of IL2 by IL12 in our culture process allows 
generation of HPC-NK cell products with enhanced cytolytic activity and IFNγ production 
towards AML, as well as superior maturation potential and anti-leukemic activity in vivo. 
We foresee that higher functionality and faster CD16 and KIR acquisition will trigger 
more potent HPC-NK cell alloreactivity towards malignant cells in patients, making the 
combination of IL15 and IL12 an attractive strategy to generate clinical HPC-NK cell 
products for cancer adoptive immunotherapy.
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AML FAB subtype Origin % CD34+ HLA-C group
1 M4-M5 BM 0 N/A
2 M4-M5 BM 7 N/A
3 M4 BM 20 N/A
4 M5 BM 25 C1/C2
5 M1 BM 85 C1/C2
6 M2 BM 85 C1/C1
7 M2 BM 70 C2/C2
8 M4-M5 BM 3 C1/C2
9 M5 BM 20 C1/C2
Supplementary Table 1. Characteristics of AML patient samples. 
N/A, not analyzed
Supplementary Figure 1. 
Generation of HPC-NK cells using 
the alternative SCGM. HPC-NK 
cells were generated from CD34+ 
progenitors using SCGM using 
the same cytokine cocktails as 
described in materials and methods 
except that IL15 and IL12 were added 
at 50 ng/ml and 0,07 ng/ml during 
the differentiation respectively. 
(A) Kinetics of CD56 acquisition 
upon HPC-NK cell differentiation. 
One representative donor out of 
3 analyzed is shown. (B) Specific 
killing (mean ± SD) of AML cells by 
NK15/2 and NK15/12 cell products 
generated from 2 HLA-typed HPC 
donors and using SCGM culture 
medium. N/D, not detected; N/A, 
not analyzed.
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Supplementary Figure 2. ICAM-1 upregulation triggers NK cell reactivity towards AML. (A) Flow 
cytometric analysis of ICAM-1 levels on CD33+ AML cells cultured for 48h in medium alone (N/T) or in the 
presence of IFNγ and TNFα (5 ng/ml and 1.25 ng/ml respectively). (B) Expression level of ICAM-1 on primary 
AML cells upon coculture with HPC-NK cells. AML cells were identified by flow cytometry using CD33 and CD45 
markers. Non viable cells were excluded using Sytox blue. Representative dot plots obtained with AML#2 are 
shown. (C) Relative killing of AML cells in time upon coculture with HPC-NK cells (mean ± SD, Student t test). 
Supplementary Figure 3. NK15/12 cells have higher IFNγ production capacity towards patient-derived 
AML blasts. (A) Coculture experiments of NK15/2 or NK15/12 cells with patient-derived primary AML cells were 
performed at E:T ratio 2:1 and in the presence of low dose IL-15 (5 ng/ml) for 24, 48 and 72h. IFNγ levels measured 
in coculture supernatants are shown. Means ± SEM obtained with 3 different AMLs (AML#1, 2, and 7). (B) The 
expression level of various inhibitory/activating ligands on AML blasts was analyzed at 48h in the presence of 
5 ng/ml IFNγ and 1.25 ng/ml TNFα. AML cells were identified by flow cytometry using CD33 and CD45 markers. 
Non viable cells were excluded using Sytox blue. Data presented in B were obtained using AML#2.
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Abstract
Allogeneic stem cell transplantation (allo-SCT) can be a curative therapy for patients 
suffering from haematological malignancies. The therapeutic efficacy is based on donor-
derived CD8+ T cells that recognize minor histocompatibility antigens (MiHAs) expressed by 
patient’s tumour cells. However, these responses are not always sufficient, and persistence 
and recurrence of the malignant disease is often observed. Therefore, application of 
additive therapy targeting haematopoietic-restricted MiHAs is essential. Adoptive transfer 
of MiHA-specific CD8+ T cells in combination with dendritic cell (DC) vaccination could be 
a promising strategy. Though effects of DC vaccination in anti-cancer therapy have been 
demonstrated, improvement of DC vaccination therapy is needed, as clinical responses 
are limited. In this study we investigated the potency of Program Death Ligand (PD-L) 1 
and 2 silenced DC vaccines for ex vivo priming and in vivo boosting of MiHA-specific CD8+ 
T cells responses. Co-culturing CD8+ T cells with MiHA-loaded DCs resulted in priming 
and expansion of functional MiHA-specific CD8+ T cells from the naive repertoire, which 
was augmented upon silencing of PD-L1 and -L2. Furthermore, DC vaccination supported 
and expanded adoptively transferred antigen-specific CD8+ T cells in vivo. Importantly, 
the use of PD-L silenced DCs improved boosting and further expansion of ex vivo primed 
MiHA-specific CD8+ T cells in immunodeficient mice. In conclusion, adoptive transfer of ex 
vivo primed MiHA-specific CD8+ T cells in combination with PD-L silenced DC vaccination, 
targeting MiHAs restricted to the haematopoietic system, is an interesting approach to 
boost GVT immunity in allo-SCT patients and thereby prevent relapse.
PD-L silenced dendritic cells boost the expansion of MiHA-specific CD8+ T cells in NSG mice
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Introduction
Allogeneic stem cell transplantation (allo-SCT) can be a curative therapy for patients 
suffering from high-risk haematological malignancies.1-3 Donor-derived CD8+ T cells play 
an important role in the therapeutic effect of this treatment, the so called graft-versus-
tumour (GVT) reaction. These CD8+ T cells can be directed against minor histocompatibility 
antigens (MiHAs), that are human leukocyte antigen (HLA)-bound peptides derived from 
polymorphic genes that differ between patient and donor.4, 5 Importantly, a selective 
GVT-response occurs when the expression of these MiHAs is restricted to haematopoietic 
tissues.0 Previously, we showed that patients transplanted with a stem cell graft from a 
MiHA-mismatched donor (patient expressing the MiHA, whereas the donor does not), 
have an improved relapse-free survival (RFS).7 This RFS was especially increased in patients 
in whom MiHA-specific CD8+ T cells could be detected. However, these responses are 
infrequent and persistence or recurrence of the malignant disease is often observed. This 
emphasizes the need to further boost GVT-selective MiHA-specific CD8+ T cell responses 
in allo-SCT patients.
One of the current additive treatment options is donor lymphocyte infusion (DLI). 
However, this non-selected donor T cell product contains only a limited number of naive 
T cells recognizing haematopoietic-restricted MiHAs that are able to contribute a specific 
GVT-effect. Moreover, T cells present in the DLI can also recognize polymorphic antigens 
expressed by healthy host tissues, thereby causing graft-versus-host disease (GVHD),8, 9 the 
major cause of morbidity and mortality post allo-SCT. Therefore, adoptive T cell therapy 
with purified and expanded donor CD8+ T cells selective for MiHAs restricted to the 
haematopoietic system could lead to a more efficacious GVT-effect without promoting 
GVHD.
T cell responses can be initiated, supported, and boosted by dendritic cells (DCs). These 
professional antigen presenting cells can activate T cells upon presentation of a peptide 
in concordance with co-stimulatory signals, which is dependent on the balance between 
co-inhibitory and co-stimulatory interactions. Two of the co-inhibitory ligands involved 
in this process are Program Death Ligand (PD-L) 1 and -L2. We have shown previously 
that their receptor, Program Death (PD)-1, is highly expressed on MiHA-specific CD8+ T 
cells after allo-SCT, possibly due to chronic antigen exposure as observed in chronic viral 
infections.10 This high PD-1 expression was involved in the functional inhibition of MiHA-
specific CD8+ T cells. Importantly, we demonstrated that interference with this pathway 
resulted in enhanced expansion of MiHA-specific CD8+ T cells of allo-SCT patients in 
vitro.10-12 Either by using blocking antibodies against PD-1 or PD-L1,10 or by silencing 
the inhibitory ligands PD-L1 and -L2 on DCs, which results in more stimulatory DCs, we 
augmented the expansion of MiHA-specific CD8+ T cells of allo-SCT patients in vitro. As 
PD-1/PD-L1 blocking antibodies early after allo-SCT might increase the risk for GVHD,13 
adoptive transfer of tumour-reactive T cells in combination with DC vaccination would 
be a safer adjuvant therapeutic approach early post allo-SCT. These DCs can maintain 
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and expand the adoptively transferred MiHA-specific CD8+ T cells which will contribute 
to the reduction of the tumour load and generation of an immunological memory to 
control relapse. Though some clinical responses of DC vaccination in anti-cancer therapy 
have been demonstrated, improvement of DC vaccination therapy is needed.14-19 By 
augmenting the stimulatory capacity of DCs, via silencing of the co-inhibitory ligands PD-
L1 and -L2, we aim to superiorly boost and augment adoptively transferred MiHA-specific 
CD8+ T cell responses in vivo, and thereby improve survival. In this study, we show that 
using monocyte-derived DCs, functional MiHA-specific CD8+ T cells can be primed and 
expanded in vitro, which is augmented by silencing the co-inhibitory ligands PD-L1 and 
-L2 on the DCs. Moreover, we demonstrate in immunodeficient mice that DC vaccination 
can boost the expansion of adoptively transferred MiHA-specific CD8+ T cells, in which 
PD-L silenced DCs show their superior stimulatory potential.
Materials and Methods
Donor material and MiHA genotyping
Peripheral blood mononuclear cells (PBMCs) were isolated from HLA-A2 and -B7 positive 
buffy coats (Sanquin Blood Supply Foundation, Nijmegen, the Netherlands) after written 
informed consent. PBMCs were genotyped for the MiHAs HA1,20 HA2,21 LRH1,22 and 
ARHGDIB23 with the KASPar assay system (KBioscience, Hoddesdon, UK), a fluorescence-
based competitive allele-specific PCR using non-labeled primers. Details of this method 
are available at http://www.kbioscience.co.uk.
siRNAs targeting PD-L1 and PD-L2
PD-L1 and PD-L2 siRNAs were kindly provided by dr. Anna Borodovsky from Alnylam 
Pharmaceuticals, and produced as described previously.12, 24 The duplex sequences 
were as follows: PD-L1, 5’AGAccuuGAuAcuuucAAAdTsdT-3’   (sense), 5’-UUUGAAAGuAU-
cAAGGUCUdTsdT-3’ (anti-sense); PD-L2, 5’-AuAAcAGccAGuuuGcAAAdTsdT-3’ (sense), 
5’-UUUGcAAACUGGCUGUuAUdTsdT-3’(anti-sense). As a negative control a siRNA duplex 
for Luciferase was used, with the sequence 5’-cuuAcGcuGAGuAcuucGAdTsdT-3’ (sense) 
and 5’-UCGAAGuACUcAGCUcAGCGuAAGdTsdT-3’ (anti-sense). Small case represent 2’-O-
methyl modified residues.
DC culture and PD-L silencing 
Monocytes were isolated from PBMCs via plastic adherence in tissue culture flasks 
(Greiner Bio-One, Alphen a/d Rijn, the Netherlands). Intermediate DCs were generated 
by culturing monocytes in X-VIVO15 medium (Lonza, Verviers, Belgium) supplemented 
with 2% human serum (HS; PAA laboratories, Pasching, Austria), 500 U/ml interleukin 
(IL)4, and 800 U/ml Granulocyte macrophage colony-stimulating factor (GM-CSF, both 
Immunotools, Friesoythe, Germany). After 3 days, intermediate DCs were supplemented 
with fresh medium and cytokines, or were transferred to 6-wells plates and further 
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cultured at 0.5 x 106/ml X-VIVO15 supplemented with 2% HS, 500 U/ml IL4, and 800 U/
ml GM-CSF. At day 7, maturation was induced in X-VIVO15/2% HS containing 5 ng/ml 
IL1ß, 15 ng/ml IL6, 20 ng/ml tumour necrosis factor (TNF)α (all Immunotools), and 1 µg/
ml Prostaglandin E2 (PGE2), Pharmacia & Upjohn, Bridgewater, NJ, USA). At day 9, mature 
DCs were harvested, phenotyped, and used in experiments. PD-L1/L2 were silenced using 
siRNAs, delivered via standard methods as described previously11, 12 (and Roeven et al, 
Journal of Immunotherapy, accepted for publication). Previously, we showed that PD-L1/
L2 siRNA silencing did not affect expression of the cell surface markers CD14, CD80, CD83, 
CD86, CCR7, MHC-I and -II.12
Priming of MiHA-specific CD8+ T cells
Peripheral blood lymphocytes (PBLs), CD8+ T cells, naive or effector memory CD8+ T (Tn 
and Tem respectively) cells were used in MiHA-specific CD8
+ T cell priming experiments as 
indicated. CD8+ T cells were isolated using MACS microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) according to the manufacturer’s guidelines. To isolate Tn or Tem 
cells, CD3+CD8+CD45RA+CCR7+ and CD3+CD8+CD45RA-CCR7- cells were sorted after CD8 
MACS isolation using the FACS Altra (Beckman Coulter, Fullerton, CA, USA). Priming was 
performed by co-culturing PBLs, CD8+, Tn or Tem cells with mature PD-L silenced or control 
siRNA treated DCs, loaded with 5 µM MiHA-peptide. Cells were cultured for 7 days in 
IMDM/10% HS at a T cell:DC ratio of 1:0.1. At day 2 and 5, IL2 (50 U/ml, Chiron CA, USA) 
and IL15 (5 ng/ml, Immunotools) were added. At day 7, T cells were analyzed by flow 
cytometry, and when indicated re-stimulated for an additional week. 
Flow cytometry
Phenotype and maturation state of DCs were analyzed by staining with the following 
antibodies against: PD-L1 (clone MIH1), PD-L2 (clone MIH18, both from Becton Dickinson, 
Franklin Lakes, NJ, USA) and isotype control IgG1 (Dako). Cytomegalovirus (CMV), LRH1, 
HA1, HA2, and ARHGDIB-specific CD8+ T cells were detected by staining cells with tetramers 
containing the corresponding peptide (CMV.B7: RPHERNGFTVL; LRH1.B7: TPNQRQNVC; 
HA1.A2: VLHDDLLEA; HA2.A2: YIGEVLVSV; ARHGDIB.B7: LPRACWREA). Tetramers were 
kindly provided by prof. dr. Frederik Falkenburg (Department of Hematology, Leiden 
University Medical Center, Leiden, the Netherlands). Cells were incubated with 0.15-0.2 
μg APC and PE labeled tetramer for 15 min at room temperature. Subsequently, cells 
were labeled with antibodies against the surface markers: mouse CD45 (clone 30-F11, 
Biolegend, San Diego, CA), human CD45 (clone J33, Beckman Coulter), CD8 (clone 3B5, 
Life Technologies, Grand Island, NY), CD3 (clone UCHT1, Biolegend), CD45RA  (clone 
2H4LDH11LDB9, Beckman Coulter), CCR7 (clone 150503, R&D Systems), and CD28 
(Biolegend) for 30 min at 4°C. After washing with PBS/0.5% bovine serum albumin (BSA; 
Sigma, St Louis, MO, USA), cells were resuspended in washing buffer containing 1:5000 
Sytox Blue (Life Technologies) to discriminate dead cells, and analyzed using the Cyan-
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ADP 9 color analyzer or the Gallios (both Beckman Coulter). Analysis was performed using 
Summit (Dako) and Kaluza software (Beckman Coulter).
MiHA-specific CD8+ T cell functionality assay
Primed MiHA-specific CD8+ T cells were tested for their IFNγ production upon peptide-
rechallenge. Therefore, cells were restimulated overnight with MiHA-peptide (5 µM) in the 
presence of Brefeldin A (1 µg/ml, BD Biosciences). The following day, extracellular staining 
by MiHA-tetramers, and antibodies recognizing CD3 and CD8 was performed, followed 
by intracellular staining for IFNγ. For this, cells were resuspended in 4% paraformaldehyde 
(PFA), and incubated for 10 min at RT. Then, cells were incubated in 0.1% saponin (Sigma) 
buffer containing 10% fetal calf serum (Integro, the Netherlands) for 10 min at RT. This was 
followed by intracellular staining for anti-CD137 (clone 41BB, Biolegend) and anti-IFNγ 
(clone B27, BD Biosciences) for 30 min at 4°C after which cells were fixed in 1% PFA and 
measured on the Gallios flow cytometer.
Antigen-specific CD8+ T cell expansion in vivo by DC vaccination
NOD/SCID/IL2Rγnull (NSG) mice were originally purchased from Jackson Laboratories, and 
housed and bred in the Radboud university medical center (Radboudumc) Central Animal 
Laboratory. Female NSG mice were used from 6 to 20 weeks of age. All animal experiments 
were approved by the Animal Experimental Committee of the Radboudumc and were 
conducted in accordance with institutional and national guidelines, permit number 
10300. Mice were i.v. injected with 10-15 x 106 (cultured) PBLs containing antigen-specific 
CD8+ T cells and weekly vaccinated with 0.25-0.5 x 106 peptide-loaded autologous control 
or PD-L silenced DCs (i.p.). To support antigen-specific CD8+ T cells, 0.5 μg recombinant 
human IL15 (Miltenyi, i.e. 2500 units) was administered i.p. every 2-3 days when indicated. 
At indicated time points, mice were sacrificed and organs were analyzed for presence of 
antigen-specific CD8+ T cells by flow cytometry. 
Statistical analysis
The data was analyzed using Graphpad Prism 4. Statistical significance was analyzed using 
a student t-test or One- way Analysis of Variance (ANOVA) followed by a Bonferroni post-
hoc test as indicated in the figure legends. p<0.05 was considered to be significant.
Results
Highly efficient priming and expansion of MiHA-specific CD8+ T cells by PD-L silenced DCs
Previously, we showed that PD-L silenced DCs augment expansion of MiHA-specific 
CD8+ effector-memory cells from transplanted patients.11, 12 To study the potency of PD-L 
silenced DCs in the expansion of MiHA-specific CD8+ T cells from the naive repertoire, in 
vitro priming experiments were performed using CD8+ T cells from MiHA-negative donors.
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Donor MiHA
MiHA-specific
CD8+ T cells*
1 HLA-A2.HA1 0.009%
2 HLA-A2.HA1 0.009%
3 HLA-A2.HA1 0.011%
4 HLA-A2.HA1 0.017%
4 HLA-A2.HA2 0.031%
5 HLA-B7.LRH1 0.017%
6 HLA-B7.LRH1 0.001%
6 HLA-B7.ARHGDIB 0.036%
7 HLA-B7.ARHGDIB 0.071%
These T cells were co-cultured with MiHA peptide-loaded HLA-A2+ or B7+ DCs, and weekly 
analyzed by flow cytometry. At day 7, we observed an average of 0.02% MiHA-specific 
CD8+ T cells in the cultures (Figure 1A-B and Table 1). Phenotypical analysis of these T cells 
showed high expression of the co-stimulatory molecule CD28 (Figure 1C). In addition, the 
functionality of these T cells was determined by overnight peptide rechallenge followed 
by intracellular staining for IFNγ. Upon this antigen-specific stimulation, we observed 
production of IFNγ, but only in cells expressing the activation marker CD137 (Figure 1D). 
Within this activated T cell population, 59% of the cells produced IFNγ, indicating high 
functionality of the expanded MiHA-specific CD8+ T cells. Combined, this showed the 
feasibility of this method using DCs to ex vivo prime and generate highly functional MiHA-
specific CD8+ T cells.
Next, we investigated whether PD-L silenced DCs would be more effective in priming 
MiHA-specific CD8+ T cells. Therefore, we co-cultured CD8+ T cells with peptide-loaded 
control or PD-L silenced DCs. Though MiHA-specific CD8+ T cells could be expanded by 
control DCs, the use of PD-L silenced DCs strongly augmented the expansion of MiHA-
specific CD8+ T cells within 2 weeks of culture (Figure 1E). This resulted in a 10-fold increase 
in the absolute number of MiHA-specific CD8+ T cells (Figure 1F). These data show the 
superior potency of PD-L silenced DCs in the priming and expansion of MiHA-specific 
CD8+ T cells from MiHA-negative donors.
To exclude that this observation could be attributed to the expansion of antigen-
experienced MiHA-specific CD8+ effector memory T cells developed during pregnancy,25 
both naive and effector memory CD8+ T cells were sorted from a MiHA- donor, after which 
they were co-cultured with MiHA-peptide loaded control or PD-L silenced DCs. Again, 
highly efficient MiHA-specific CD8+ T cell priming was observed, but only in co-cultures 
that started with naive T cells (Figure 2A). In co-cultures containing effector memory T 
cells, no MiHA-specific CD8+ T cells could be expanded. Although MiHA-specific CD8+ T 
cells primed from the naive repertoire by control DCs could be expanded to 1.6% cell 
responses from the naive repertoire in 2 weeks, the use of PD-L silenced DCs resulted 
in augmented numbers of MiHA-specific CD8+ T cells (Figure 2A). Notably, these cells
Table 1. Primed MiHA-specific CD8+ T cells.
*Percentage of total CD8+ T cells
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Figure 1. Priming of functional MiHA-specific CD8+ T cells is enhanced by PD-L silenced DCs. CD8+ T 
cells were co-cultured with MiHA-peptide loaded allogeneic DCs and analyzed at day 7 by flow cytometry 
for the presence of MiHA-specific CD8+ T cells. (A) Representative FACS plot of 2 independent cultures. The 
numbers in the FACS plots represent the percentage of MiHA-specific CD8+ T cells within the total CD3+CD8+ T 
cell population. (B) Combined data of 9 independent cultures. (C) Representative FACS plot of CD28 expression 
(black) on MiHA-specific CD8+ T cells at day 7 of culture, isotype control in grey. The numbers in the FACS plots 
represent mean fluorescence intensity (MFI). One out of 4 independent cultures is shown. (D) Representative 
FACS plot of cultured cells at day 7, which were o/n re-stimulated with peptide followed by intracellular staining 
for IFNγ and CD137. The number in the FACS plots represent the percentage of IFNγ+ cells within CD137hi CD8+ 
T cells. (E-F) CD8+ T cells were cultured for two consecutive weeks with HA-1 peptide loaded PD-L silenced 
or control DCs (relative expression: PD-L1 6%, PD-L2 23%), and analyzed at day 14 by flow cytometry for the 
presence of MiHA-specific CD8+ T cells. FACS plot (E) and absolute cell numbers (F) of cultures with control or 
PD-L silenced DCs, n=1.
Figure 2. MiHA-specific CD8+ T cell priming and expansion from the naive repertoire is augmented 
by PD-L silenced DCs. Naïve (N, CD45RA+CCR7+) and effector memory (EM, CD45RA-CCR7-) CD8+ T cells were 
sorted and cultured for two consecutive weeks with HA-1 peptide-loaded PD-L silenced or control DCs (relative 
expression: PD-L1 7%, PD-L2 12%). The percentage (A) and cumulative numbers (B) of HA-1-specific CD8+ T cells 
obtained after stimulation with PD-L silenced or control DCs. 
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expanded to more than 40% of MiHA-specific CD8+ T cells after one week of re-stimulation. 
Together this resulted up to 20-fold increase in MiHA-specific CD8+ T cells after two weeks 
of culture (Figure 2B). These data show the superior potential of PD-L silenced DCs in the 
priming and expansion of MiHA-specific CD8+ T cell responses from the naive repertoire.
Expansion of antigen-specific T cells by DC vaccination in NSG mice
To investigate the stimulatory capacity of PD-L silenced DCs on supporting and boosting 
adoptively transferred T cells in vivo, we generated a  mouse model in which NSG mice 
were injected with PBLs containing antigen-experienced CD8+ T cells. Subsequently, 
mice were vaccinated weekly with peptide-loaded DCs. These mice received no, one, 
two, or three DC vaccinations at weekly intervals, and mice were sacrificed one week 
after their last vaccination. Mice receiving no DC vaccination were sacrificed at the end 
of the experiment, similar to the group receiving three DC vaccines. Engraftment of the 
adoptively transferred human cells increased in time from 0.02 ± 0.09 x 106/ml at week 
1 to 8.7 ± 7.4 x 106 human cells/ml at week 3 in peripheral blood (PB, mean ± SD, Figure 
3A). In addition, in spleen we observed an increase from 2.2 ± 1.3 to 110 ± 58 x 106 human 
cells. This human engraftment reflected the increase in CD8+ T cell numbers in both PB 
and spleen (Figure 3B). Notably, the DC vaccinations did not affect engraftment levels or 
consistency, as similar numbers were observed between mice receiving no or three DC 
vaccinations. Though in some mice receiving only one DC vaccination low numbers of 
CMV-specific CD8+ T cells could be detected, levels were generally below the detection 
limit (data not shown). With increasing engraftment of human cells in time, boosted CMV-
specific CD8+ T cells could be clearly detected in mice receiving three DC vaccinations. In 
these mice, a CMV-specific CD8+ T cell population was detected up to 0.75% of the total 
CD8+ T cell compartment in both spleen and PB. The absolute CMV-specific CD8+ T cells 
number in DC vaccinated mice was 56 ± 66 x 103 in spleen and 6.0 ± 4.7 x 103/ml in PB 
(Mean ± SD, Figure 3C-D), which already in these two organs was 31 times higher than 
the infused number of CMV-specific CD8+ T cells, showing robust expansion of antigen-
specific CD8+ T cells in vivo. In mice receiving no DC vaccination, CMV-specific CD8+ T cells 
were undetectable at time of analysis (day 21). These data demonstrate that this mouse 
model can be used to evaluate DC-mediated expansion of adoptively transferred antigen-
specific CD8+ T cells in a humanized setting. 
PD-L silenced DCs enhanced expansion of adoptively transferred MiHA-specific CD8+ T cell 
To study the stimulatory potentency of PD-L silenced DCs in vivo, we first confirmed the 
stability of the silencing under inflammatory conditions. For this, we co-cultured DCs in 
the presence of IFNγ. Additionally, as the mouse model includes IL15 injections to support 
the survival and expansion of antigen-specific T cells, the effect of this low-dose IL15 was 
also investigated. For this, PD-L silenced DCs were generated, expressing only 5.4% of PD-
L1 and 1.4% of PD-L2 compared to their control DCs (Supplementary Figure 1A). After 48
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hours of culture in the presence of IFNγ and/or IL15, flow cytometry analysis revealed no 
effects on expression of PD-L1 or -L2 on either PD-L silenced or control DCs (Supplementary 
Figure 1B). Concluding, silencing of PD-L on DCs results in a co-stimulatory phenotype 
which is stably retained under inflammatory conditions.
Next, we addressed the potency of PD-L silenced DCs to superiorly boost the expansion 
of adoptively transferred MiHA-specific CD8+ T cells in vivo. Therefore, MiHA-primed PBLs 
Figure 3. CMV-specific CD8+ T cell expansion by DC 
vaccination in vivo. Peripheral blood lymphocytes 
containing 2000 CMV-specific CD8+ T cells were 
injected in NSG mice and stimulated with no (Ctrl), one, 
two, or three peptide loaded (5 µM) DC vaccinations at 
weekly intervals. Mice were sacrificed 7 days after their 
last DC vaccination or at the end of the experiment 
(Ctrl). Peripheral blood and spleen were analyzed by 
flow cytometry for human CMV-specific CD8+ T cells. 
Engraftment of human cells (A) and CD8+ T cell (B). 
Statistical analysis was performed using an One way 
ANOVA followed by a Bonferroni post-hoc test. (C) 
Representative FACS plot of CMV-specific CD8+ T cells 
after three DC vaccinations. The numbers in the FACS 
plots represent the percentage of CMV-specific CD8+ 
T cells within the total CD3+CD8+ T cell population. (D) 
Percentage and absolute cell numbers of CMV-specific 
CD8+ T cells of mice non-vaccinated, or vaccinated 
three times. Statistical analysis was performed using an 
one-tailed student t-test. *p<0.05, **p<0.01, ***p<0.001.
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were injected in NSG mice followed by weekly vaccinations with either control or PD-L 
silenced DCs (Figure 4A). After three weeks mice were sacrificed. We observed similar 
engraftment levels of human CD45+ and CD8+ T cells in mice vaccinated with control or 
PD-L silenced DCs (Supplementary Figure 2). During the experiment no signs of GVHD 
were observed, as weights of the mice were stable and no differences in fur appearance, 
activity, or statue were noticed between control and PD-L silenced DCs (data not shown). 
Interestingly, while mice vaccinated with control DCs showed only low levels of MiHA-
specific CD8+ T cells (0.06% ± 0.11%), PD-L silenced DCs expanded the MiHA-specific CD8+ 
T cell numbers up to 1.5% in PB (0.53% ± 0.60%, p=0.046, Figure 4B-C). Also in spleen this 
increase in MiHA-specific CD8+ T cells by PD-L silenced DCs was observed, though did not 
reach significance (0.09% ± 0.10% in case of control DCs vs. 0.32% ± 0.32%, in case of PD-L 
silenced DCs, p=0.058). Nevertheless, absolute numbers of MiHA-specific CD8+ T cells were 
significantly augmented in mice vaccinated with PD-L silenced DCs, in both spleen and PB 
(83 ± 129 vs. 590 ± 440/ml in PB, p=0.011; and 1.1 x 104 ± 1.5 x 104 vs. 4.8 x 104 ± 4.0 x 104 
in spleen, p=0.031, Figure 4B-C). This resulted in a 4 versus 17-fold expansion of the MiHA-
specific CD8+ T cells in control DC versus PD-L silenced DC treated mice, respectively. This 
demonstrated that PD-L silenced DCs exhibit enhanced stimulatory capacity to boost the 
expansion of adoptively transferred MiHA-specific CD8+ T cells in vivo.
Discussion
Despite the curative potential of allo-SCT, many patients relapse. In previous studies, we 
have demonstrated that the frequencies of productive T cell responses in these patients 
are inadequate. This emphasizes the need for additive therapy to improve GVT immunity, 
and consequently overall survival of patients suffering from haematological malignancies. 
To reduce the risk for GVHD, these additive therapies should exploit MiHA-specific CD8+ 
T cells recognizing antigens expressed solely by the haematopoietic system. By this, 
selective GVT-immunity could be boosted without promoting GVHD.
Currently, additive T cell therapy can be given post allo-SCT as DLI. Yet, these non-
selected donor lymphocytes contain only few tumour-reactive T cells, while a substantial 
percentage of T cells could contribute to the life-threatening complication GVHD. Ex vivo 
priming of donor lymphocytes would enrich the DLI for GVT-specific MiHA-specific CD8+T 
cells. Although priming of MiHA-specific CD8+ T cells can occur during pregnancy,25 the 
MiHA-specific CD8+ T cell responses in our assays most likely emerged from the naive 
T cell repertoire, as confirmed by the absence of MiHA-specific CD8+ T cell responses in 
case effector memory T cells were used as starting material. Notably, the extent of the ex 
vivo primed MiHA-specific CD8+ T cell responses varied between donors, probably due 
to variation in precursor frequencies between donors and different MiHAs.26, 27 In this
manuscript, we are the first to demonstrate that the use of PD-L silenced DCs in these ex 
vivo cultures greatly enhanced the priming and expansion of MiHA-specific CD8+ T cell 
responses. Notably, we recently demonstrated that ex vivo priming of the MiHA-specific
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CD8+ T cells for adoptive T cell transfer could be further improved by retaining these cells 
in an early memory state using a selective Akt-inhibitor during ex vivo culture.28
DC vaccination is a strong tool to boost adoptively transferred MiHA-specific CD8+ T 
cells. To improve the activation and expansion of these tumour-reactive T cells by DC-
based stimulation, one can interfere with the co-inhibitory PD-1/PD-L pathway. Though 
recent papers showed clinical effects of PD-1 blockade in solid tumours and after 
autologous stem cell transplantation without causing severe side effects,29-31 speculations 
have been made on the risk of these blocking antibodies on GVHD. Addition of PD-1/PD-
Figure 4. PD-L silenced DCs 
enhanced MiHA-specific CD8+ T cell 
expansion in vivo. (A) HA1-primed 
PBLs containing 2900 HA1-specific T 
cells were injected in NSG mice and 
vaccinated three times with control 
or PD-L silenced (relative expression: 
PD-L1 13.1%, PD-L2 10.5%) DCs at 
weekly intervals. Mice were sacrificed 
at day 21, and peripheral blood 
and spleen were analyzed by flow 
cytometry for human HA-1-specific 
CD8+ T cells. (B) Representative FACS 
plot of HA1-specific CD8+ T cells in 
spleen after control or PD-L silenced 
DC vaccinations. The numbers in the 
FACS plots represent the percentage 
of HA1-specific CD8+ T cells within 
the CD3+CD8+ T cell population. (C) 
Percentages within CD8+ T cells, and 
absolute levels of HA1-specific CD8+ T 
cells in peripheral blood and spleen. 
Each dot represents a single mouse, 
n=6 mice per group. Statistical 
analysis was performed using a one-
tailed student t-test.
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L1 blocking antibodies to the activated immune system  early after allo-SCT could further 
release the brake on all activated T cells, resulting in the induction and aggravation of 
GVHD. Therefore, we believe that PD-L silenced DCs is a safer way to interfere with the 
PD-1/PD-L pathway in the allo-SCT setting, and thereby potently augment the activation 
and expansion of MiHA-specific CD8+ T cells. The use of DC vaccinations to boost tumour-
reactive T cells is a safe and feasible application as shown in several DC vaccination trials in 
cancer patients.32 Applying adoptive transfer of haematopoietic-restricted MiHA-specific 
CD8+ T cells in combination with potent PD-L silenced DC vaccines could augment GVT-
immunity and thereby prevent relapse and improve survival.
We previously showed the potential of PD-L silenced DCs in the expansion of 
MiHA-specific CD8+ effector-memory T cells in vitro.11,12 In this paper, we are the first 
to demonstrate that PD-L silenced DC are also superior in boosting antigen-specific 
CD8+ T cells in vivo. Moreover, in addition to our superior expansion, Pen et al recently 
showed improved cytokine production of T cells upon interference with the PD-1/PD-L1 
pathway.33 This was also shown by Lesterhuis et al, who demonstrated that upon down-
regulation of PD-L1 and -L2 expression on DCs by platinum-based chemotherapeutics, 
antigen-specific T cells show enhanced proliferation and Th1 cytokine secretion.34 In 
addition, DNA vaccination of soluble PD-1, which interfered with the natural PD-1/PD-
L1 interaction, resulted in an increased functionality and anti-tumour effect in mice.35 
More promising, Ge et al showed that the use of a PD-L1 blocking antibody during ex vivo 
priming of antigen-specific T cells and subsequent DC vaccination, resulted in a better 
cytokine production and expansion of these T cells in vitro, and an improved anti-tumour 
effect in vivo.36 All together, these observations illustrate the potency of PD-L silenced DCs 
with adoptive transfer of MiHA-specific CD8+ T cells, which should be further explored 
for improving an anti-tumour effect in a relevant tumour therapy model. However, first 
a robust and appropriate isolation method to purify ex vivo primed MiHA-specific CD8+ T 
cells before adoptive transfer into tumour-bearing mice should be set-up. This could be 
performed by the Streptamer technique obtaining viable MiHA-specific CD8+ T cells for 
adoptive immunotherapy.37
Our current data illustrate a novel additive value of our approach in relation to previous 
reports. This therapeutic strategy would  especially be attractive for clinical exploration 
in patients who lack productive tumour-reactive T cell responses. The combination of 
adoptive transfer of ex vivo primed MiHA-specific CD8+ T cells with PD-L silenced DCs 
vaccines targeting haematopoietic-restricted MiHAs, would greatly contribute to better 
GVT-immunity without inducing detrimental GVHD. This pre-emptive therapy could 
prevent relapse and thereby improve survival in allo-SCT patients. Furthermore, our 
strategy could be broadly exploited towards tumour-antigen or virus-specific CD8+ T cells 
in cancer and viral infections.
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Supplementary Figure 1. Stable PD-L silencing on dendritic cells. (A) Representative FACS plots of PD-L1 
and PD-L2 expression on control (black) or PD-L silenced (grey) DCs at the end of their maturation culture. White 
histogram represent isotype control staining. The numbers in the FACS plots represent the mean fluorescence 
intensity (MFI). (B) These DCs were subsequently cultured in maturation medium with or without IFNγ (100 U/
ml) and/or IL15 (5 ng/ml) for 2 days. MFI of PD-L1 and PD-L2 expression are corrected for isotype control.
Supplementary Figure 2. Engraftment levels of human cells after adoptive T cell transfer and 
vaccination with control or PD-L silenced DCs in NSG mice. PBLs were primed using HA-1-loaded DCs 
for 7 days, after which NSG mice were injected with 10 x 106 cells. Then they were vaccinated three times 
with control or PD-L silenced (relative expression: PD-L1 13%, PD-L2 11%) DCs at weekly intervals. Mice were 
sacrificed at day 21. (A) Percentage and (B) absolute numbers of human CD45 (% of total human and mouse 
CD45+ cells) and CD8+ T cells (% within human CD45+ cells). Each dot represents a single mouse, n=6 mice per 
group. Statistical analysis was performed using an one-tailed student t-test.
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Abstract
Effective T cell therapy against cancer is dependent on the formation of long-lived, stem 
cell-like T cells with the ability to self-renew and differentiate into potent effector cells. 
Here, we investigated the in vivo existence of stem cell-like antigen-specific T cells in 
allogeneic stem cell transplantation (allo-SCT) patients, and their ex vivo-generation for 
additive treatment post-transplant. Early after allo-SCT, CD8+ Tscm cells targeting minor 
histocompatibility antigens (MiHAs) expressed by recipient tumour cells were non-
detectable, emphasizing the need for improved additive MiHA-specific T cell therapy. 
Importantly, MiHA-specific CD8+ T cells with an early CCR7+CD62L+CD45RO+CD27+ 
CD28+CD95+ memory-like phenotype and gene signature could be expanded from 
naive precursors by inhibiting Akt-signalling during ex vivo-priming and expansion. This 
resulted in a MiHA-specific CD8+ T cell population containing a high proportion of stem 
cell-like T cells, compared to terminal differentiated effector T cells in control cultures. 
Importantly, these Akt-inhibited MiHA-specific CD8+ T cells showed a superior expansion 
capacity both in vitro as well as in immunodeficient mice, and induced a superior anti-
tumour effect in intrafemural multiple myeloma-bearing mice. These findings provide a 
rationale for clinical exploitation of ex vivo generated Akt-inhibited MiHA-specific CD8+ T 
cells in additive immunotherapy to prevent or treat relapse in allo-SCT patients.
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Introduction
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative 
therapy for high-risk haematological  malignancies.1-3 The therapeutic effect is attributed 
to the graft-versus-tumour (GVT) response, during which donor-derived CD8+ T cells 
become activated by recipient minor histocompatibility antigens (MiHAs) presented on 
dendritic cells (DCs).4 Subsequently, these activated CD8+ T cells expand, and differentiate 
into effector cells that kill MiHA-positive tumour cells. However, persistence and recurrence 
of the malignant disease is often observed, indicating that insufficient GVT-immunity is 
induced. This suboptimal anti-tumour CD8+ T cell response might be due to lack of robust, 
long-lived, and high quality memory T cell function.5 
The current strategy to enhance GVT-responses post allo-SCT is the adoptive transfer 
of polyclonal donor T cells, known as donor lymphocyte infusion (DLI).3,6,7 However, 
this non-selected donor T cell product contains a limited number of T cell precursors, 
recognizing hematopoietic-restricted MiHAs and/or tumour-associated antigens (TAA), 
that are able to contribute to the GVT-effect. Moreover, it contains T cells recognizing 
polymorphic antigens expressed by healthy host tissues, thereby causing graft-versus-
host disease (GVHD), the major cause of morbidity and mortality post allo-SCT.8 Therefore, 
adoptive T cell therapy with purified and expanded donor CD8+ T cells, selective for 
MiHAs restricted to the hematopoietic system, could lead to a more efficacious GVT-
effect without promoting GVHD. Nevertheless, current ex vivo expansion protocols for 
generating MiHA-specific CD8+ T cells concomitantly results in effector memory T (Tem) cells 
and terminal differentiated effectors.9,10 It has been described that these subsets comprise 
the least potent cells for adoptive T cell therapy due to their poor proliferative capacity, 
lack in maintaining robust responses over time and vulnerability to exhaustion.11-13 Stem 
cell memory T (Tscm) cells and central memory T (Tcm) cells would be more favourable 
populations for MiHA-based adoptive immunotherapy after allo-SCT. Especially Tscm cells, 
have enhanced proliferation, self-renewal, and multipotency.12,14 Importantly, these long-
lived Tscm cells have the plasticity to differentiate into Tcm and Tem, that rapidly acquire 
effector functions after antigenic re-exposure. In addition, a recent publication by Graef 
et al showed the stem cell properties of Tcm cells.
15 As the proliferative and differentiation 
capacity of these subsets is retained, they provide a better chance to generate long-term 
anti-tumour T cell responses and ultimately elimination of all residual malignant cells.11
The PI3K-Akt-mTOR pathway plays an important role in regulating CD8+ T cell 
metabolism and differentiation.16 Upon signalling via the TCR, co-stimulatory molecules, 
and cytokine receptors the PI3K-Akt pathway is activated, resulting in downstream 
activation of the mTOR complex-1 and cytoplasmic sequestration of Forkhead box 
protein O1 (Foxo1). Multiple lines of evidence indicate that sustained activity of Akt 
and mTOR drives T cells towards terminally differentiation. For instance, increased 
activation of Akt by IL12,17 expression of a constitutively active form of Akt,18 and deletion 
of Foxo1,19 have all been shown to promote the formation of KLRG1+ effector T cells. 
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Therefore, as constitutively active Akt induces terminal differentiation, we hypothesized 
that pharmacological inhibition of the Akt pathway could inhibit the differentiation of 
CD8+ T cells. In this study, we demonstrate that by inhibiting the Akt pathway we can 
generate highly potent MiHA-specific CD8+ T cells ex vivo. These Akt-inhibited CD8+ T cells 
showed superior expansion potential upon removal of the Akt-inhibitor, which results in 
a superior anti-tumour effect in mice. Using hematopoietic-restricted MiHAs, this strategy 
is expected to be a safe and potent additive T cell therapy after allo-SCT.
Materials & Methods 
Patient and donor material
PBMCs were isolated using Ficoll-Hypaque gradient (Healthcare, WI, USA) from buffy 
coats of healthy donors, selected for HLA-A2 or -B7 positivity (Sanquin Blood Supply 
Foundation, Nijmegen, the Netherlands) or from PB samples of patients at several time 
points after allo-SCT. Allo-SCT patients were treated as described previously.20 Briefly, 
patients underwent HLA-matched allo-SCT for a haematological  malignancy following 
(non)-myeloablative conditioning regimens. After conditioning, patients received a partial 
T cell-depleted graft, with 0.5 ± 0.3 × 106 CD3+ T cells/kg (mean ± SD). GVHD prophylaxis 
consisted of cyclosporine A only. Patients and healthy donors had given their written 
informed consent, which was approved by the Radboudumc Institutional Review Board.
In vitro Akt-inhibitor VIII treatment and priming of MiHA-specific T cells
CD8+ cells were selected using CD8 microbeads (MACS Miltenyi Biotec, Germany) according 
to the manufacture protocol and were resuspended in Roswell Park Memorial Institute 
(RPMI; Gibco Invitrogen) medium supplemented with 10% fetal calf serum (FCS; Integro, 
the Netherlands) or Human Serum (HS, PAA laboratories). Next, cells were stimulated 
with (PD-L 1/2 siRNA-silenced) DCs, generated as described previously.21,22 These were 
loaded with 5 µM MiHA-peptide (HA1, VLHDDLLEA23; ARHGDIB, LPRACWREA24) in medium 
without serum for 30 minutes at 37°C and were added to the culture with a DC:T cell 
ratio of 1:10 to1:20. Cell cultures were supplemented with 50 U/ml IL2 (Chiron, Emeryville, 
CA, USA), 5 ng/ml IL7 (Immunotools), and 5 ng/ml IL15 (R&D systems, MN, USA). When 
indicated, 8 µM Akt-inhibitor VIII (IC50 = 58 nM, 210 nM, and 2.12 µM for Akt1, Akt2, and 
Akt3 respectively, Merck Millipore, Germany) or DMSO as control was added. Medium, 
including cytokines and Akt inhibitor was refreshed every 2-3 days, and MiHA-specific T 
cell cultures were weekly re-stimulated with DCs and analysed by flow cytometry.
Flow cytometry
To analyse surface markers, cells were resuspended in PBS + 0.5% BSA, stained with 0.2 μg 
of PE and APC-labelled tetramers containing the MiHA-specific peptide for HA1.HLA-A2, 
ARHGDIB.HLA-B7, HY.HLA-A2 (FIDSYICQV), HY.HLA-B7 (SPSVDKARAEL), CMV.HLA-A2 
(NLVPMVATV), or CMV.HLA-B7 (RPHERNGFTVL), and incubated for 15 minutes in the dark 
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at RT. For additional markers, cells were labelled with following antibodies: CD3 (UCHT1, 
Biolegend, CA, USA), CD8 (3B5, Invitrogen, CA, USA), CD45RO (UCHL1, Beckman Coulter 
CA, USA), CCR7 (G04H7, Biolegend), CD27 (O323, eBioscience), CD28 (IM2071U, Beckman 
Coulter), CD45RA (H100, Biolegend), CD62L (DREG56, Biolegend), CD95 (4B2, Beckman 
Coulter), CD127 (A019D5, Biolegend), CXCR4 (12G5, Biolegend). Labelling was performed 
at 4˚C in the dark for 30 and measured on the Cyan-ADP nine color analyser (Beckman 
Coulter), FACS ARIA, or Gallios (Beckman Coulter). Analysis was performed using Summit 
(DAKO) or Kaluza (Beckman Coulter) software.
RNA extraction and real-time PCR quantification
RNA of FACS purified MiHA-specific CD8+ T cells was extracted using Quick-RNA Microprep 
kit (Zymo Research) according to the manufacturer’s instructions. cDNA was synthesized 
using M-MLV-reverse transcriptase (Invitrogen) in a standard reaction after which real-time 
PCR was performed using following Taqman Gene expression assays (Applied Biosystems): 
Bcl6 (Hs00153368); EOMES (Hs00172872); FOXO1 (Hs01054576); GZMB (Hs01554355); 
ID2 (Hs04187239); ID3 (Hs00954037); IFNG (Hs00989291); KLRG1 (Hs00929964); PRDM1 
(Hs00153357); PRF1 (Hs99999108); TBX21 (Hs00203436); TCF7 (Hs00175273). Expression 
levels were calculated relative to GAPDH (Applied Biosystems; 4326317E-1010038) using 
the ΔΔCt method, and expressed relative to control cultures.
Functionality assays
After 14 days of priming, cells were cultured in IMDM + 10% HS supplemented with 
50 U/ml IL2, 5 ng/ml IL7, and 5 ng/ml IL15, and stimulated with MiHA-loaded (5 µM) 
irradiated 174CEM.T2 (T2) cells25 in a T2:T cell ratio of 1:10. Medium and cytokines were 
refreshed every 2-3 days. At day 7, flow cytometery analysis was performed to determine 
MiHA-specific CD8+ T cell numbers. To determine functionality, rechallenged cells were 
stimulated overnight with MiHA peptide (5 µM) in the presence of anti-CD107a (H4A3, 
Biolegend). And Brefeldin A (added after 1 hour, 1 ng/µl; BD biosciences). The next day, 
cells were stained for extracellular surface markers and resuspended in 4% PFA for 10 min 
at RT. Then, cells were incubated in 0.1% saponin (Sigma) buffer containing 10% FCS for 
10 min at RT, followed by intracellular staining for anti-CD137 (41BB, Biolegend) and anti-
IFNγ (B27, BD biosciences) for 30 min at 4°C, after which cells were fixed in 1% PFA and 
measured on the Gallios. 
Flow cytometry-based cytotoxicity assays were performed using CFSE-labelled 
(1.5µM) tumour and EBV cell lines, in which 18,000 target cells were co-cultured with 
3,000 MiHA-specific T cells in IMDM+10% HS. U266, UM6, UM9, and patient or donor EBV-
LCL cell lines were cultured in IMDM+10% FCS. UM6 cultures were supplemented with 
22.5 ng/ml IL6 (Immunotools). Target cells alone were used as controls. After overnight 
incubation at 37°C, cells were harvested and viable target cells were quantified by flow 
cytometry. Killing percentage was calculated as follows: 100 - (absolute no. viable CFSE+ 
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target cells co-cultured with T cells / absolute no. viable CFSE+ target cells cultured without 
T cells)*100.
In vivo evaluation of proliferative, self-renewal capacity and anti-tumour effect of MiHA-
specific CD8+ T cells
NOD/SCID/IL2Rγnull (NSG) mice, originally purchased from Jackson Laboratories, were 
housed and bred in the Radboudumc Central Animal Laboratory. Female mice were 
used from 6 to 20 weeks of age. All animal experiments were approved by the Animal 
Experimental Committee of the Radboudumc and were conducted in accordance with 
institutional and national guidelines, permit number 10300. The tumour model was 
created by injection of 105 luciferase expressing UM9 multiple myeloma  cells (UM9.Luc) 
in the right femur (IF) of mice by insertion of a 25G Hamilton needle through the knee 
joint. Tumour cell growth was monitored weekly by bioluminescence imaging (BLI) as 
described previously.26 Signals >3 x 104 were considered specific. Mice with high tumour 
load at day 7 due to misinjection of the needle (so tumour cells are not injected in the 
bone) and outliers were excluded to create homogeneous groups. Mice were i.v. injected 
with (MACS-enriched) primed CD8+ T cells, containing equal numbers of MiHA-specific 
CD8+ T cells, and CD4+ T cells were co-infused to support engraftment. Then, mice were 
weekly vaccinated with 0.5 x 106 autologous PD-L KD DCs, loaded with MiHA peptide (i.p.). 
To support survival of MiHA-specific T cells, 0.5 μg rhIL15 (i.e. 2.500 Units, Miltenyi) was 
administered i.p. every 2-3 days for 3 weeks. Peripheral blood and spleens were analysed 
by tetramer staining using flow cytometry. Mice were sacrificed when the palpable 
tumour reached 1 cm in diameter or when one of the following criteria was met: severe 
weight loss, poor coat and skin condition, static activity or paraplegia.
Statistical analysis
The data was analysed using Graphpad Prism 4.0. Statistical significance was analysed 
using a (paired) t-test, One- or Two-way Analysis of Variance (ANOVA), followed by a 
Bonferroni post-hoc test as indicated in the figure legends. p<0.05 was considered 
significant.
Results
Low frequency of circulating Tcm and Tscm cells in allo-SCT patients
Human memory T cells with stem cell-like characteristics have been identified among 
antigen-experienced CD8+ T cells in healthy donors. To investigate the existence of Tscm 
cells relatively early after allo-SCT, we analysed PBMCs of allo-SCT patients and healthy 
donors by flow cytometry. CD8+ T cell subsets were divided in Tn, Tscm, Tcm, and Tem cells, 
based on expression of CD45RO, CCR7, CD27, and CD95 (Supplementary Figure 1 and 
Figure 1A). As shown previously by us,27,28 most CD8+ T cells displayed the Tem phenotype 
after allo-SCT (Table 1, Figure 1B). While in healthy controls 27.0 ± 18.4% of the CD8+ T 
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Figure 1. Low CD8+ Tscm in patients after 
allo-SCT. CD8+ T cells of healthy donors 
(HD, ○, n=6) and allo-SCT patients (allo-
SCT, ●, n=8-9) were analyzed for their 
differentiation status by flow cytometry. 
(A) Representative plot showing subset 
discrimination. (B) Summary of memory 
subsets within CD8+ T cells. (C-D) Tscm cells within Tn-like cells gated as shown in A (C) or as CD95
hi (D) in HD and 
allo-SCT patients. (E) Memory subsets within antigen-specific T cells in healthy donor (CMV, n=6) and allo-SCT 
patients (CMV, n=5; and MiHA, n=3). Tn, naive T cells; Tscm, stem cell memory T cells; Tcm, central memory T cells; 
Tem, effector memory T cells; ND, non-detectable. Statistical analysis was performed using a Two-way ANOVA (B 
and E) followed by a Bonferroni post-hoc test, or a one-tailed student t-test (C-D). *p<0.05, ***p<0.001.
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cells were Tn cells, post allo-SCT it contained less than 0.7 ± 1.1% Tn cells. Similarly, Tscm 
levels accounted for not more than 0.1 ± 0.2% in allo-SCT patients compared to 1.1 ± 0.4% 
within the CD8+ T cell population of healthy controls. This was despite the observation that 
in allo-SCT patients the population of Tscm cells was increased within the Tn-like population 
compared to healthy controls (Figure 1C), as shown previously by Cieri et al.29 This was also 
observed when Tscm cells were defined as CD95
hi within Tn-like cells, resulting in >85% Tscm 
cells within Tn-like CD8
+ T cells post allo-SCT (Figure 1D). 
Antigen-experienced CD8+ T cells mostly display a Tcm and Tem phenotype, though Tscm 
cells have been described to be present within this population.14,29,30 We determined the 
composition of CMV- and MiHA-specific CD8+ T cells as described above. Similar to total 
CD8+ T cells, MiHA- as well as CMV-specific CD8+ T cells of allo-SCT patients contained a 
higher frequency of Tem cells, compared to CMV-specific T cells of healthy donors (Figure 
1E). Furthermore, CMV- and MiHA-specific T cells in allo-SCT patients contained lower 
levels of Tcm cells compared to healthy donors. Although Tscm cells could be clearly detected 
in CMV-specific CD8+ T cells of healthy controls and some allo-SCT patients, the MiHA-
specific T cell population did not contain detectable levels of stem cell-like memory T cells. 
Altogether, these data emphasize the need to apply adjuvant approaches to increase the 
frequency of long-lived, tumour-reactive stem cell-like T cells post-transplant.
Generation of stem cell-like MiHA-specific CD8+T cells by inhibiting Akt-signalling 
Since constitutively active Akt induces terminal T cell differentiation, we studied whether 
pharmacological inhibition of the Akt-pathway could inhibit ex vivo differentiation of 
CD8+ T cells and favor the generation of stem cell-like T cells. To set up culture conditions 
for optimal expansion of stem cell-like T cells, we first stimulated CD8+ Tn cells with anti-
CD3/CD28 beads in the presence of combinations of the cytokines IL2, IL7, and IL15 
shown to be involved in memory and Tscm generation.
29,31-33 Though variation was seen 
between cultures, no clear effect on T cell differentiation was observed with any of the 
cytokine combination (Supplementary Figure 2). Next, stimulations were performed in 
the presence or absence of Akt-inhibitor VIII that selectively inhibits Akt1/Akt2 activity. 
We observed a delay in proliferation (Supplementary Figure 3), but most importantly, Akt-
inhibited CD8+ T cells showed reduced differentiation as manifested by higher expression 
of CD45RA and CCR7 as compared to control cultures (Supplementary Figure 3).
Next, we investigated whether MiHA-specific CD8+ T cells with an early differentiated 
phenotype could be generated using the Akt-inhibitor. Therefore, we stimulated purified 
CD8+ T cells from a MiHA-negative donor (co containing naïve MiHA-specific CD8+ T cells 
precursors), with MiHA-peptide loaded autologous DCs in the presence or absence of 
the Akt-inhibitor. At day 7 and 14 after stimulation, the presence of MiHA-specific CD8+ T 
cells and their differentiation phenotype was analysed. While the frequency of expanded 
MiHA-tetramer+ CD8+ T cells between the Akt-inhibited and non-inhibited cultures varied 
in the different experiments (n=4; mean ± SEM of control 0.30 ± 0.53 vs. Akt-inhibited 
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cultures 0.14 ± 0.10 at day 14) (Figure 2A), the overall numbers of MiHA-specific CD8+ T 
cells at day 7 and 14 were comparable (Figure 2B). As expected for control conditions, a 
vast majority of MiHA-specific CD8+ T cells expressed CD45RO with no detectable levels 
of CCR7 after 2 weeks of culture (Figure 2C&E). Interestingly, inhibition of the Akt-pathway 
inhibited significantly T cell differentiation, as these T cells dominantly displayed a Tcm-like 
CCR7+CD45RO+ phenotype (p<0.01, Figure 2C&E). While an average ± SE of 72 ± 7% of Akt-
inhibited MiHA-specific CD8+ T cells at day 7 of culture had a CCR7+CD45RO+ phenotype, 
this was 27 ± 12% in the culture without Akt-inhibitor (p<0.01). After restimulation with 
peptide-loaded DCs and culturing up to 14 days, 39 ± 11% of expanded Akt-inhibited 
cells MiHA-specific CD8+ T cells vs. only 8 ± 3% without Akt inhibitor, displayed the 
CCR7+CD45RO+ phenotype. This was also reflected in the MFI of CCR7 in Akt-inhibited 
MiHA-specific CD8+ T cells, which was higher compared to control cultures (p=0.03 on day 
7 and p=0.06 on day 14, Figure 2D).
To further analyse the level of T cell differentiation of the Akt-inhibited cells, additional 
phenotypical and gene analyses were performed. Interestingly, we observed that CD62L 
and CD28, two surface markers expressed by less differentiated T cells, were expressed 
on Akt-inhibited MiHA-specific CD8+ T cells to a higher level compared to controls (Figure 
2F). Furthermore, CD95, as well as IL7Rα (CD127), and CXCR4, which are highly expressed 
on stem cell-like CD8+ T cells, were expressed in higher amounts on Akt-inhibited cells. 
To determine T cell differentiation at the transcriptional level, control and Akt-inhibited 
MiHA-specific CD8+ T cells were FACS sorted, and gene expression analysis was performed 
by Q-PCR. Consistent with the phenotypic data, we found that genes encoding several 
transcriptional regulators involved in the generation and maintenance of long-lived 
memory cells, including TCF7, FOXO1, ID3, and BCL614,34 were higher expressed in Akt-
inhibited compared to control MiHA-specific CD8+ T cells (Figure 2G). Conversely, EOMES, 
ID2, and KLRG1, transcriptional regulators implicated in effector T cell differentiation 
and  senescence,14,35 were expressed at lower levels upon inhibition of the Akt-pathway. 
Interestingly, comparing ex vivo expanded Akt-inhibited CD8+ T cells with natural 
occurring T cell subsets, the expression of TCF7 and KLRG1 was found to be between Tn
 
Figure 2. Inhibiting Akt-signaling during priming reserved T cell differentiation of MiHA-specific CD8+  T 
cells. CD8+ T cells were cultured with peptide-loaded DCs for 7 days with or without 8 µM Akt-inhibitor. Medium 
containing cytokines and Akt-inhibitor was refreshed every 2-3 days. Flow cytometry analysis was performed 
at day 7 and 14 to determine T cell differentiation of the MiHA-specific CD8+ T cells. (A) Representative tetramer 
staining on day 14 of culture. (B) Expansion of MiHA-specific T cells, calculated from an estimated precursor 
frequency of 1:107, (n=4). (C) Representative staining for T cell differentiation based on CCR7 and CD45RO 
expression, gated on MiHA-specific CD8+ T cells. (D) Median fluorescence intensity (MFI) of CCR7 expression 
of MiHA-specific CD8+ T cells, relative to control (n=4). (E) Differentiation determined as in C, of MiHA-specific 
CD8+ T cells at day 7 and 14 of culture (n=4). (F) Additional phenotypical analysis of MiHA-specific CD8+ T cells 
on day 14 of culture in the absence (white) or presence (black) of 8 µM Akt-inhibitor. (G-H) MiHA-specific CD8+ 
T cells, cultured for 14 days in the absence or presence of 8 µM Akt-inhibitor, were FACS purified followed by 
PCR analysis. Two cultures of independent donors are shown, dashed line: 3 vs. 60%, and solid line: 20 vs. 41% 
CCR7+CD45RO+ cells in control and Akt-inhibited MiHA-specific CD8+ T cells respectively. Statistical analysis 
was performed using a Two-way ANOVA (E) followed by a Bonferroni post-hoc test, or paired student t-test (D).
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and Tcm cells (Supplementary Figure 4). Surprisingly, the effector-associated transcription 
factors PRDM1 and TBX21, which encode Blimp1 and T-bet respectively,35 were 
expressed in higher amounts in Akt-inhibited CD8+ T cells. Possibly, as all these genes 
are connected, feedback loops are responsible for this observation.34 Consistently with 
the higher expression of PRDM1 and TBX21, we found that Akt-inhibited MiHA-specific 
CD8+ T cells had increased mRNA expression of the effector molecules IFNg and PRF1 
(Figure 2H). Combined, these data show that inhibition of Akt-signalling reserves T cell 
differentiation of ex vivo generated MiHA-specific CD8+ T cells but simultaneously favors 
the establishment of some effector gene features.
Akt-inhibited MiHA-specific CD8+ T cells have superior expansion capacity
To determine whether the presence of effector-traits had detrimental impact on the 
stemness of Akt-inhibited MiHA-specific CD8+ T cells, we evaluated the proliferative 
capacity upon restimulation after withdrawal of the Akt-inhibitor. Therefore, primed 
CD8+ T cells were restimulated with T2 cells loaded with the MiHA-peptide. This antigen-
reencounter resulted in profound expansion of MiHA-specific CD8+ T cells, while 
stimulation with non-loaded T2 cells induced minimal proliferation (Figure 3A-B). Notably, 
MiHA-specific CD8+ T cells primed in the presence of the Akt inhibitor showed significantly 
more expansion compared to control (29 vs. 5 fold expansion, range 8-59 vs. 3-8, Figure 3A-
B). Importantly, this resulted in profound increase in the number of MiHA-specific CD8+ T 
cells from Akt-inhibited cells after rechallenge (p<0.01, Figure 3C), indicating that the high 
levels of PRDM1 were insufficient to instruct a program of replicative senescence in Akt-
inhibited cells. Next, we sought to determine whether the higher expression of TBX21 and 
effector molecules in Akt-inhibited MiHA-specific CD8+ T cells would confer the functional 
advantages to these cells following antigen restimulation. Degranulation by CD107a 
was clearly observed for the CD137hi cells, which was equal for both MiHA-specific CD8+ 
T cells of control cultures and those primed in the presence of the Akt-inhibitor (Figure 
3D-E). In addition, for both cultures IFNγ production was observed within the CD137hi 
cells upon peptide stimulation (Figure 3F-G). Interestingly, a trend towards higher IFNγ 
production was observed for MiHA-specific CD8+ T cells primed in the presence of the 
Akt-inhibitor compared to controls, suggesting that higher TBX21 and IFNγ mRNA levels 
following priming in the presence of the Akt-inhibitor might provide functional benefits. 
Subsequently, we tested whether the rechallenged Akt-inhibited MiHA-specific T cells 
could also recognize endogenously processed antigen on target cells. Therefore, MACS-
enriched ARHGDIB-specific T cells, which were rechallenged from Akt-inhibited T cells, 
were co-cultured with various target cells. This showed that the multiple myeloma cell lines 
UM6 and UM9, which endogenously express the MiHA ARHGDIB, were highly susceptible 
to killing (Figure 3H). In addition, killing of EBV-transformed cell lines was observed upon 
endogenous antigen or after loading ARHGDIB-peptide. These findings demonstrate 
that priming of MiHA-specific CD8+ T cells in the presence of the Akt-inhibitor resulted in 
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Figure 3. Enhanced expansion capacity of 
functional Akt-inhibited MiHA-specific CD8+ T 
cells in vitro. MiHA-specific CD8+ T cells, cultured 
for 14 days in the absence or presence of 8 µM Akt-
inhibitor, were rechallenged with peptide-loaded T2 
cells and cultured for 7 days without Akt-inhibitor. 
Medium with cytokines was refreshed every 2-3 
days. Flow cytometry analysis was performed at 
day 7 to determine MiHA-specific T cell numbers. 
(A) Representative tetramer staining on day 14 of 
priming and after 7 days of rechallenge. (B) Relative 
expansion to input of MiHA-specific CD8+ T cells during rechallenge of 3 independent donors, mean + SEM. 
(C) Expansion of MiHA-specific CD8+ T cells, calculated from an estimated precursor frequency of 1:107, during 
priming and rechallenge of 3 independent donors, mean + SEM. (D-G) Rechallenged cells were stimulated 
o/n with 5 µM peptide and stained for CD107a, IFNγ, and CD137. Representative plots of CD137 and CD107a 
(D) or IFNγ (F) staining within CD8+ T cells. Percentages represent CD107a+ or IFNγ+ cells within CD137hi cells. 
Percentage of (E) CD107a+ or (G) IFNγ+ within CD137hi cells was analyzed for two independent cultures, mean 
+ SEM. Statistical analysis was performed using a Two-way ANOVA followed by a Bonferroni post-hoc test. (H) 
Killing of CFSE-labeled target cell lines with or without endogenous ARHGDIB-expression or peptide-loading, 
by MACS-enriched ARHGDIB-specific T cells (45% ARHGDIB-specific CD8+ T cells) derived from a rechallenged 
Akt-inhibited culture, n=3. **p<0.01, ***p<0.001
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unique CCR7+CD45RO+ stem cell-like T cells with superior proliferation capacity and high 
functional activity upon in vitro re-exposure. 
Akt-inhibited MiHA-specific CD8+ T cells show enhanced expansion potential in vivo
To test the in vivo expansion potential of Akt-inhibited MiHA-specific CD8+ T cells, ex vivo 
generated CD8+ T cells containing equal numbers of MiHA-specific T cells were injected in 
NOD/SCID/IL2Rγnull (NSG) mice (Figure 4A). At time of adoptive transfer, MiHA-specific CD8+ 
T cells of the control culture were >90% CCR7-CD45RO+, while still 35% of the Akt-inhibited 
MiHA-specific CD8+ T cells displayed a stem cell-like CCR7+CD45RO+ phenotype (Figure 
4B-C). Autologous CD4+ T cells were co-infused to support engraftment, and peptide-
loaded DC vaccination was given weekly to boost the activation and outgrowth of MiHA-
specific CD8+ T cells. After 3 weeks, mice were sacrificed and spleen and peripheral blood 
(PB) were analysed for the presence of MiHA-specific CD8+ T cells. Tetramer+ cells could be 
detected in PB and spleen of mice injected with either control or Akt-inhibited cultured 
cells (Figure 4D). Consistent with our in vitro observations, we found more robust MiHA-
specific CD8+ T cell expansion in PB and spleen of mice injected with Akt-inhibited cells 
(Figure 4D; p=0.05 and p=0.01 respectively). Notably, in PB and spleen alone we already 
observed up to 8 and 37 times more MiHA-specific CD8+ T cells than infused, versus only 
0.4 and 7 times in PB and spleen of control mice. These findings clearly demonstrates the 
superior in vivo expansion potential of the Akt-inhibited MiHA-specific CD8+ T cells. 
To investigate the self-renewal potential of the Akt-inhibited MiHA-specific CD8+ 
T cells, we analysed the phenotype of the cells after in vivo rechallenge. For both 
cultures, most in vivo expanded MiHA-specific CD8+ T cells displayed the CCR7-CD45RO+ 
phenotype. However, within the in vivo expanded Akt-inhibited MiHA-specific CD8+ T 
cells obtained from spleen, there was still a clear population detectable expressing both 
CCR7 and CD45RO (Figure 4E). Interestingly, the absolute number of CCR7+CD45RO+ 
MiHA-specific CD8+ T cells per spleen was more pronounced following adoptive transfer 
of Akt-inhibited CD8+ T cells (average ± SD: 332 ± 92 in control vs. 4066 ± 2587 in mice 
infused with Akt-inhibited MiHA-specific CD8+ T cells. p=0.03). Finally, we evaluated the 
functionality of the in vivo expanded MiHA-specific CD8+ T cell in vaccinated mice. While in 
spleens of mice injected with non-inhibited T cells no clear CD137+ nor IFNγ+ T cells could 
be detected (data not shown), clear CD137 up-regulation was observed within the splenic 
cell population of mice infused with Akt-inhibited MiHA-specific CD8+ T cells (Figure 4F). 
Within these CD137+ activated CD8+ T cells, around 60% produced IFNγ, reflecting the 
high functionality of these cells. Collectively, in this immunodeficient mouse model we 
demonstrate that Akt-inhibited MiHA-specific CD8+ T cells exhibit a superior proliferative 
potential, possible self-renewal capacity, and are highly functional upon antigen re-
encounter.
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Figure 4. Akt-inhibited MiHA-specific CD8+ T cells show enhanced expansion capacity in 
immunodeficent mice. (A) CD8+ T cells, containing equal amounts (5500) of MiHA-specific T cells, cultured for 
14 days in the absence or presence of 8 µM Akt-inhibitor, were infused in NSG mice. Equal numbers of CD4+ T 
cells (3 x 106) were co-infused to support engraftment, resulting in a CD4:MiHA-specific T cells ratio of 1:490. 
Mice were weekly vaccinated with DCs and supported with IL15 every 2-3 days. At day 21, mice were sacrificed 
and peripheral blood (PB) and spleen were analysed by flow cytometry for the presence of MiHA-specific 
CD8+ T cells. (B) Tetramer staining and (C) differentiation consistency of cultured cells prior to infusion. (D) 
Representative tetramer staining and absolute numbers of MiHA-specific CD8+ T cells in PB and spleen, n=10 
mice per group. (E) T cell differentiation phenotype of control and Akt-inhibited MiHA-specific CD8+ T cells 
after in vivo rechallenge, of each group one representative mouse out of 3 is shown. (F) IFNγ production of Akt-
inhibited MiHA-specific CD8+ T cells after in vivo rechallenge and o/n peptide stimulation, two independent 
mice are shown. Percentages represent IFNγ+ cells within CD137hi cells. Statistical analysis was performed using 
a one-tailed student t-test.
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Superior anti-tumour effect by Akt-inhibited MiHA-specific T cells
To test the anti-tumour potency of our Akt-inhibited MiHA-specific T cells, mice were 
intrafemurally injected with UM9.Luc multiple myeloma cells, which endogenously express 
the HLA-B7-restricted MiHA ARHGDIB (Figure 5A). The next day, mice were treated with no, 
control or Akt-inhibited ARHGDIB-specific CD8+ T cells. To effectively boost the anti-tumour 
response of the adoptively transferred ARHGDIB-specific CD8+ T cells, mice were weekly 
vaccinated with DCs, therefore providing effective antigenic stimulation in the presence 
of appropriate co-stimulation. Tumour growth in bone marrow was monitored in time 
via Bioluminescence Imaging (BLI). Non-treated mice displayed growth of the tumour, 
resulting in a detectable tumour in all mice at day 21 and further progression at day 28 
and 35 (Figure 5B-C). Interestingly, at day 28, two out of 9 mice treated with control MiHA-
specific CD8+ T cells were still tumour-free, and the average tumour load was significantly 
lower compared to non-treated mice (p<0.05). But more strikingly, mice treated with Akt-
 
Figure 5. Superior anti-tumour effect of Akt-inhibited MiHA-specific CD8+ T cells. (A) NSG mice were 
injected intrafemurally (IF) with UM9 multiple myeloma cells expressing luciferase. At day 1 mice were treated 
with 50.000 MACS-enriched MiHA-specific CD8+ T cells after culture with (17% CCR7+CD45RO+, n=8) or without 
Akt-inhibitor (12% CCR7+CD45RO+, n=9). To support engraftment, CD4+ T cells (0.3 x 106) were co-infused, 
resulting in a CD4:MiHA-specific T cells ratio of 1:6. Mice were weekly vaccinated with DCs, and received IL15 
every 2-3 days. Non-treated mice (n=8) only received IL15. From day 7 to day 35 bioluminescence imaging 
(BLI) was performed weekly to determine the tumour load, after which mice were monitored for survival. 
(B) BLI images at day 35 and (C) quantified signal corrected for background of the tumour-injected femur in 
time. Statistical analysis was performed using an Two-way ANOVA followed by a Bonferroni post-hoc test. (D) 
Mice survival analysed according to Mantel Cox test, significance shown compared to no treatment. *p<0.05, 
***p<0.001.
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inhibited MiHA-specific CD8+T cells showed clear delay in tumour growth, with 4 out of 8
mice tumour-free at day 28. Their tumour load was significantly lower compared to non-
treated (p<0.001) as well as control treated mice (p<0.05) at day 28 and day 35. Moreover, 
mice were followed for survival, in which non-treated mice died from day 60 onwards, with 
a median survival of 66 days (Figure 5D). Mice treated with control T cells had a prolonged 
median survival to 71 days (p<0.05). Interestingly, mice treated with Akt-inhibited T cells 
survived significantly longer, with a median survival of 98 days, and 4 out of 8 mice were 
still alive at the end of the experiment (day 100, p<0.001). These findings indicate the 
superior anti-tumour effect of Akt-inhibited MiHA-specific CD8+ T cells.
Discussion
Donor-derived CD8+ T cells are the main contributors to an effective GVT-effect post allo-
SCT. Therefore, it is highly important that these CD8+ T cells are effective in creating a 
robust memory response, resulting in long-lasting anti-tumour immunity. As published 
previously by us27,28 and shown in this study, circulating CD8+ T cells in cancer patients 
following allo-SCT display mainly a terminally differentiated Tem phenotype, with only low 
levels of CD8+ Tn cells and early differentiated memory subsets present. Although we could 
verify the increase in the highly functional Tscm population within Tn-like cells as described 
by Cieri et al,29 these CD8+ Tscm cells contributed only minimally to the total CD8
+ T cell 
population due to the low Tn-like cell numbers. The potentially suboptimal memory pool 
was even more severe within antigen-experienced CD8+ T cells as MiHA-specific CD8+ 
T cells post allo-SCT contained undetectable levels of Tscm cells. Therefore, we speculate 
that this may result in short anti-tumour reaction, which can be improved by applying 
additional post-transplant adoptive MiHA-based CD8+ T cell therapy.
As relapse remains a major problem after allo-SCT,36 development of adjuvant 
immunotherapy’s is essential. One of the current treatment options consists of non-selected 
DLI, of which only a relative low number of naive precursors is targeting hematopoietic-
restricted MiHAs to mount selective GVT-responses. Therefore, development of adoptive 
T cell therapy based on the transfer of enriched MiHA-specific CD8+ T cells targeting 
hematopoietic-restricted antigens could greatly enhance GVT-responses in the absence 
of GVHD.37 However, ex vivo expansion and culture of these MiHA-specific precursor cells 
using current protocols results in terminally differentiated effector T cells that probably 
show low anti-tumour potency.11,14 In this study, we aimed to generate MiHA-specific CD8+ 
T cells with limited T cell differentiation.
Although we could confirm efficient inhibition of T cell differentiation by mimicking 
Wnt-signalling as was described by Gattinoni et al,12,14 the block of proliferation observed 
in these cultures resulted in inefficient priming and expansion of MiHA-specific CD8+ T 
cells (Supplementary Figure 5). Various targets within the Akt-pathway, like inhibiting 
mTOR with rapamycin, could be potentially interesting to generate antigen-specific T 
cells with an early-memory phenotype. However, similar to TWS119, the concentration 
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of rapamycin required for significant inhibition of T cell differentiation might also 
dramatically inhibits T cell growth as it has been shown that rapamycin robustly inhibits 
T cell proliferation.38,39 Alternatively, we observed inhibition of Akt-signalling did not 
strongly interfere with expansion of MiHA-specific CD8+ T cells, which therefore could 
be used for clinical generation of additive tumour-specific T cell therapy. The strategy to 
inhibit Akt resulted in ex vivo expansion of CD8+ T cells displaying a minimally differentiated 
phenotype compared to control cultures without Akt-inhibition both in phenotype and 
gene expression. Interestingly, the effector-associated genes PRDM1 and TBX21 were 
elevated in Akt-inhibited cells compared to controls. Possibly, feedback regulations have 
exerted this effect, as multiple of these transcriptional factors including Blimp1, T-bet, 
EOMES, TCF7, and ID2, have been shown to interact closely.34 In addition, this observed 
expression of TBX21 could also explain the higher IFNγ in these cells, as a critical role of 
TBX21 has been described in the formation of IFNγ producing T cells.40 Although Akt-
inhibited MiHA-specific CD8+ T cells appeared to have some increased effector-traits, 
KLRG1 expression was much lower compared to non-inhibited T cells and found between 
the natural-occurring Tn and Tcm subsets.
Importantly, our Akt-inhibited CD8+ T cells were superior in proliferation, which 
resulted in highly functional effector cells. This superior proliferation capacity observed 
by Akt-inhibited T cells could be caused by a combination of less replicative senescence 
characteristics, higher expression of co-stimulatory molecules such as CD28, as well as 
increased expression of cytokine receptors like the IL7Rα. For instance, it has been shown 
that T cells expressing higher levels of the IL7Rα survive and proliferate better than IL7Rαlow 
T cells following antigen-stimulation, both in human T cells as well as mouse models.41,42 
Importantly, possible self-renewal potential of Akt-inhibited CD8+ T cells was observed as 
after 3 weeks of in vivo boosting with peptide-loaded DC vaccines. Although secondary 
adoptive transfer studies will give more insight in the true self-renewal potential of our T 
cells, our data suggest long-lived memory formation, and restimulation potential of the 
Akt-inhibited MiHA-specific T cells. 
All together, Akt-inhibition on MiHA-specific CD8+ T cells resulted in a superior anti-
tumour effect against the multiple myeloma cell line UM9. As the IF injection in our 
human tumour xenograft mouse model results in tumour growth in the natural myeloma 
habitat, we showed here that our Akt-inhibited MiHA-specific CD8+ T cells are not only 
more functional in vivo, but may also more efficiently home to the bone marrow via their 
increased expression of CXCR4.43,44 In conclusion, inhibiting Akt-signalling during the ex 
vivo priming, expansion, and culture of MiHA-specific CD8+ T cells gives rise to potent 
tumour-reactive T cells. These Akt-inhibited MiHA-specific CD8+ T cells have stem cell-like 
properties resembling traits of Tcm and Tscm cells. Therefore, infusion of Akt-inhibited MiHA-
specific CD8+ T cells in allo-SCT patients could mount a potent GVT-reaction, especially 
by when targeting hematopoietic-restricted MiHAs, a specific GVT effect without GVHD 
could be boosted. This could prevent relapse of haematological  tumours after allo-SCT. 
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Furthermore, our strategy to inhibit Akt-signalling during the generation of antigen-
specific T cells, could be broadly exploited for the generation of tumour-antigen or 
virus-specific stem cell-like CD8+ T cells for adoptive immunotherapy in cancer and viral 
infections. 
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Supplementary Figure 1. Gating strategy for flow cytometry to determine T cell differentiation subsets. 
CD8 T cells were analysed for their differentiation by flow cytometry. (A) Cells were first gated on singlets (Pulse 
width), live CD3+ T cells (CD3 versus Sytox Blue), and small lymphocytes (FS versus SS). T cell differentiation 
subsets of CD3+CD8+ T cells were then discriminated based on CCR7 and CD45RO. Tn-like defined as CD45RO
-
CCR7+CD27+ and divided in Tn and Tscm cells based on the CCR7/CD95 differentiation pattern, of which the gate 
was set on total CD8+ T cells. (B-C) Antigen-specific T cells were identified using double tetramer staining, 
which were analysed for their differentiation subsets as described in A. Representative example given for (B) 
CVM and (C) HY-specific CD8+ T cells. FS, forward scatter, SS, side scatter, Tn, naive T cells; Tscm, stem cell memory 
T cells; Tcm, central memory T cells; Tem, effector memory T cells; ND, non-detected.
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Next page - Supplementary Figure 3. Reserved CD8+ T cell differentiation by inhibition of Akt signalling 
following polyclonal stimulation. Tn cells were FACS purified (CD3+CD8+CCR7+CD45RO-) after which they 
were stimulated with CD3/CD28 beads (beads:T cell ratio of 3:1, Invitrogen) in the presence of IL2 (50 U/ml), 
IL7 (5 ng/ml), and IL15 (5 ng/ml), and 0, 2, 4, or 8 µM Akt-inhibitor. Cells were labelled with PBSE at day 0 to 
determine proliferation. Flow cytometry analysis was performed at day 3 and 7. Medium containing cytokines 
and Akt-inhibitor was refreshed every 2-3 days. (A) To determine proliferation, cells were labelled at the start 
of the culture with Pacific Blue succinimidyl ester (PBSE, Invitrogen) prior to culturing. For this, cells were 
incubated with 0.12 mg/ml PBSE for 10 minutes at 37˚C. Labelling was stopped by 2 minute incubation with 
FCS at RT. Representative plots of PBSE signal on cells cultured with no (grey) or 8 µM Akt-inhibitor (black). (B) 
Combined data of PBSE signal and (C) absolute cell numbers of cultures with no (dashed), 2 (light grey), 4 (dark 
grey), or 8 µM (black) Akt-inhibitor. Representative experiment is shown, n=3. (D) Representative plots of cells 
cultured with no (grey) or 8 µM Akt-inhibitor (black), and combined data of cells cultured with no (white), 2 
(light grey), 4 (dark grey), or 8 µM (black) Akt-inhibitor for CCR7, CD45RA, and CD95 expression. Representative 
experiment is shown, n=3. (E) Additional phenotypical analysis at day 7 of cells cultured with no (grey) or 8 
µM Akt-inhibitor (black), independent experiment from A-D. Numbers represent median fluorescent intensity 
(MFI). Statistical analysis was performed using an One- (CCR7, CD45RA, CD95) or Two- (PBSE, Cell number) way 
ANOVA followed y a Bonferroni post-hoc test, compared to control cultures. *p<0.05, **p<0.01, ***p<0.001.
Supplementary Figure 2. Effects of cytokines on T cell 
differentiation. Tn cells were FACS purified after which they were 
stimulated with CD3/CD28 beads (bead-T cell ratio, 3:1) in the 
presence of combinations of IL2 (50 U/ml), IL7 (5 ng/ml), and IL15 (5 
ng/ml). Flow cytometry analysis was performed at day 7. Medium 
with cytokines was refreshed every 2-3 days. Cell numbers and 
expression of CCR7, CD45RA, and CD95 in triplicates. Statistical 
analysis to compare cell numbers was performed using a Two-
way ANOVA. Expression of CCR7, CD45RA, and CD95 was analysed 
by a One-way ANOVA followed by a Bonferroni post-hoc test. MFI, 
median fluorescence intensity. *p<0.05, ***p<0.001.
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Supplementary Figure 3. Reserved CD8+ T cell differentiation by inhibition of Akt signalling following 
polyclonal stimulation. Legend see previous page.
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Supplementary Figure 5. Incompetent 
priming of MiHA-specific T cells in the 
presence of TWS119 due to inhibition of 
proliferation. (A) Tn cells were FACS purified 
after which they were stimulated with CD3/
CD28 beads (bead-T cell ratio, 3:1) in the 
presence or absence of 7 µM TWS119. Absolute 
cell numbers at day 7 of culture. Statistical 
analysis was performed using a one-tailed 
student t-test. (B-E) CD8+ T cells were cultured 
with peptide-loaded DCs for 7 days with no, 
3, 5 or 7 µM TWS119. Flow cytometry analysis 
was performed at day 7 and 14 to determine T 
cell differentiation of the MiHA-specific T cells. 
(B) Total CD8+ T cell numbers during culture. 
(C) Representative flow cytometry staining 
for T cell differentiation using CD45RO and 
CD62L, and tetramer staining to determine 
the presence of MiHA-specific T cells on day 
14, of cells cultured without (control) or in the 
presence of 7 µM TWS119. (D) Percentage and 
(E) absolute cell number of MiHA-specific T 
cells at day 14 of culture. *p<0.05
 
Supplementary Figure 4. Reserved T cell differentiation on TCF7 and KLRG1 expression in Akt-inhibited 
MiHA-specific CD8+ T cells. MiHA-specific CD8+ T cells cultured for 14 days in the absence or presence of 8 µM 
Akt-inhibitor, were FACS purified (n=2). Tn (CD45RO
-CCR7+), Tcm (CD45RO
+CCR7+), and Tem (CD45RO
+CCR7-) from 
2 healthy donors were FACS purified. All samples were analysed for expression of TCF7 and KLRG1 by qPCR. 
Expression levels were calculated relative to GAPDH, and expressed relative to control cultures and Tem cells 
(expression both at 1).
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General aspects
Patients suffering from haematological malignancies are treated with chemotherapy, 
radiotherapy, and/or molecular targeted drugs. Additionally, patients can receive an 
allogeneic stem cell transplantation (allo-SCT), which is a powerful form of cellular 
immunotherapy. The ultimate goal of allo-SCT is to induce a potent and long lasting anti-
tumour immune response that prevents relapse and cures the disease.1,2 Though allo-
SCT was initially developed to rescue patients with lethal bone marrow ablation due to 
high-dose chemotherapy, it has been demonstrated that the success of allo-SCT relies 
predominantly on the response of the transplanted donor immune system against the 
residual patient’s malignant cells. Donor-derived Natural Killer (NK) and T cells can trace, 
recognise, and destroy malignant cells, known as the graft-versus-tumour (GVT) reaction. 
Each of these immune cells recognizes its target via different molecular mechanisms. NK 
cells are activated based on the balance between inhibitory and activating signals.3-6 In 
the setting of an inhibitory killer immunoglobulin receptor (KIR)-ligand mismatch, less 
inhibitory signals are presented by patient cells to donor NK cells.7 In addition, loss or 
down-regulation of human leukocyte antigen (HLA) Class I (HLA-I) molecules by malignant 
cells also results in a lack of inhibitory signal.8 Moreover, malignant cells can up-regulate 
stress-inducible NK cell activating ligands, which combined can result in NK cell activation 
and subsequent killing of the patient’s malignant cells. On the other hand, T cells target 
cells that express a specific HLA-peptide complex that matches with their T cell receptor. 
Although allo-SCT is most often performed in a HLA-matched setting, single nucleotide 
polymorphisms (SNPs), which differ between patient and donor can result in a mismatch in 
HLA-presented minor histocompatibility antigens (MiHAs).9 If these MiHAs are expressed 
specifically by haematopoietic cells, a specific graft-versus-tumour (GVT) reaction can 
occur. However, MiHAs with a broad expression pattern can induce expansion of donor 
T cells targeting healthy tissues, which can cause the detrimental graft-versus-host 
disease (GVHD).10,11 This major drawback is associated with high transplantation-related 
mortality (TRM), which limits the therapeutic feasibility of allo-SCT. Though this therapy is 
potentially curative, relapse remains a problem. Improved clinical results could arise from 
therapeutic immune interventions which aim for the prevention of GVHD, and control 
progression of the malignancy. Additive anti-tumour therapies, which should not increase 
the risk for GVHD, could focus on donor effector cells which contribute to the GVT effect, 
like the tumour-reactive T and NK cells.
Targeting IL17-producing T cells to prevent GVHD 
Donor-derived T cells can recognise patient’s cells based on the expression of various 
MiHAs. Whether the expression of this MiHA is broad or restricted to the haematopoietic 
system, determines the balance between a selective GVT-response or detrimental GVHD. 
In the case of GVHD, effector T cells recognise MiHAs expressed on healthy tissues, causing 
severe damage to the GVHD-prone organs such as the skin, liver, gastrointestinal tract, and 
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lungs.10,11 The current treatment option for GVHD is the use of general immunosuppressive 
drugs like cyclosporine A and mycophenolate mofetil, which is not favourable, as 
systemic immune suppression predisposes the patient to an increased risk of infections 
and tumour relapse.12 More importantly, GVHD is not always halted by these drugs, and 
damage to the organs involved can be fatal for the patient. To prevent GVHD or develop 
new treatment strategies, it is essential to understand the immune mechanisms involved 
in this complication. In Chapter 2, we discuss the role of a relatively new T cell subset, 
namely IL17-producing T cells, in the initiation and pathophysiology of GVHD. CD4+ Th17 
and CD8+ Tc17 cells, named after their production of the pro-inflammatory cytokine 
IL17, have been associated with the initiation and progression of several autoimmune 
disorders like rheumatoid arthritis.13,14 Recently, several studies have been performed that 
show their involvement in GVHD. For instance, several knockout mouse models have been 
to demonstrate the role of IL17, next to IFNγ, in (xenograft) GVHD. Furthermore, levels of 
IL17-producing T cells have been determined post allo-SCT via different methods (e.g. 
IL17 production, CCR6 and/or CD161 expression), and associated with the occurrence 
of GVHD. Nevertheless, data remains limited and sometimes contradictory. To get more 
insight, we studied the role of these cells in two studies, investigating different aspects of 
these cells. 
In Chapter 3, we studied the correlation between SNPs in the Th/Tc17-linked genes 
IL23 receptor (IL23R) and CCR6 and the occurrence of GVHD. We were unable to confirm 
the previously published correlation between GVHD and the SNP rs11209026 in IL23R. We 
believe that the reason we could not confirm this genetic association can be attributed to 
partial ex vivo T cell depletion in all of our transplants, opposed to Elmaagacli et al. who 
did not perform T cell depletion.15 As T cell depletion affects the reconstitution of T cells 
and post-transplant immunosuppressive treatment, IL23, implicated in differentiation 
and expansion of Th/Tc17 cells, could be differently involved. However, studying a second 
gene prominent in the IL23/Th17 pathway, we found that a tagSNP around (rs2301436), 
and a SNP located in CCR6 (rs3093023), correlated with the occurrence of chronic GVHD. 
As two SNPs in CCR6 and its linkage disequilibrium can influence the expression of this 
chemokine receptor,16 it is likely that the SNPs found to be correlated to GVHD result in a 
different migration potential of Th/Tc17 cells.
Whether Th/Tc17 cells migrate and play a role on site in GVHD-affected tissues has been 
studied via various approaches, for instance by determining the levels of circulating Th17 
cells in GVHD-affected patients. In Chapter 4, we found using the well-established Th/Tc17 
lineage-identifier CD161, a correlation between reduced levels of circulating CD161+CD4+ 
and CD161hiCD8+ T cells and the occurrence of GVHD. Moreover, we showed the migration 
potential of these CD161-expressing T cells to inflamed tissues via the CCR6-CCL20 axis, 
as well as the presence of CCL20 in GVHD-affected tissues. Via the expression of CCR6, we 
then revealed the presence of these T cells in GVHD-affected tissues. The reduced levels 
of the CD161-expressing T cells, and their presence in GVHD-affected tissues indicate 
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their role in the initiation and/or the development of GVHD. Especially the significantly 
decreased frequency of CD161-expressing T cells that was observed in peripheral blood 
(PB) samples 3 months after allo-SCT from patients who developed chronic GVHD later on, 
indicates their involvement in the initiation of the disease. Moreover, the cytokine IL1β, 
elevated after conditioning of the patient, was shown to increase expression of CCL20 in 
GVHD-prone organs, as well as to boost IL17-production of CD161-expressing T cells.17,18 
Migration of CCR6+CD161-expressing T cells to the GVHD-prone tissues could therefore 
result in elevated IL17 production, priming the GVHD response and further enhancing 
CCL20 production, thereby recruiting other immune effector cells that harm healthy 
tissue cells.
As further discussed in Chapter 2, several factors influence the expansion, 
differentiation and activation of IL17-producing T cells, and their potential role in the 
initiation of GVHD. For instance, different dendritic cell (DC) subsets, like plasmacytoid DCs 
and DC NK lectin group receptor (DNGR)1+ myeloid DCs have the capability to stimulate 
Th/Tc17 responses through the release of cytokines. The pivotal cytokines IL1β, IL6, IL23, 
and TGFβ, which are known to drive differentiation and expansion of IL17-producing T 
cells, are highly elevated in patients after allo-SCT. In addition, potent activators of these 
DC subsets are motifs that are released upon tissue damage, and microbes exposed 
during allo-SCT. These motifs aggravate the Th/Tc17 response via the activation of distinct 
pathogen recognition receptor (PRR)s, thereby initiating and perpetuating GVHD. A more 
comprehensive understanding of the factors and DC subsets driving the IL17-pathway 
will contribute to the development and testing of novel therapeutic approaches for the 
prevention of GVHD. 
Various interventions can be investigated for the prevention and/or treatment of 
GVHD by targeting the IL17-pathway (Figure 1). One could think of selective depletion 
of specific cell subsets in the graft or in the patient. This could either be Th/Tc17 cells 
themselves, by targeting for instance CD161, or different DC subsets such as pDCs 
or DNGR1+ DCs, to prevent Th/Tc17 activation. Also in vivo manipulation of Th/Tc17 
differentiation could be applied using small molecule inhibitors targeting RORγt, which is 
an essential transcription factor in Th/Tc17 development. Interference with the activation 
of Th/Tc17 cells is another strategy to prevent GVHD, where inhibitors of various PRRs 
could be explored. A very promising approach is the blockade of specific cytokines. Here, 
cytokines involved in Th/Tc17 differentiation can be neutralized, like IL23 by Ustekinemab 
(IL12/IL23 blocking antibody), or IL1β signalling by Canakinumab (IL1β antibody) or 
Anakinra (IL1R antagonist). Finally, targeting IL17 itself could be achieved using anti-IL17 
(Ixekizumab) or anti-IL17 receptor (Brodalumab). Combined these strategies could inhibit 
the differentiation, activation, proliferation and functionality of Th/Tc17 cells, which might 
lead to prevention of GVHD. Although much new prevention strategies seem promising, 
further investigations are warranted. Still many questions remain to be answered on the 
role of different lymphocytes subsets, including Th/Tc17, in acute GVHD. Nevertheless, the
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insights we now gain rapidly on the IL17-producing T cells open up new ways that need 
exploration for the prevention and treatment of GVHD. Selective GVHD prevention will 
reduce treatment-related mortality, and importantly increase quality of life of allo-SCT 
patients.
Figure 1. Appealing immunological interventions to boost GVT and prevent GVHD. GVHD, graft-
versus-host disease; DC, dendritic cell; PRR, Pattern Recognition Receptor; Allo-SCT, allogeneic stem cell 
transplantation; CsA, cyclosporine A; KIR, Killer immunoglobulin receptor; MiHA, minor histocompatibility 
antigen; CIM, co-inhibitory molecule; HSPC, haematopoietic  stem/progenitor cell. 
Adoptive NK cell therapy for treatment of haematological malignancies
Currently, it is well established that donor-derived NK cells mediate graft-versus-tumour 
reactivity with improved control of relapse in acute myeloid leukaemia (AML) patients 
following allo-SCT. This raised the interest in exploiting allogeneic NK cells for adoptive 
immunotherapy, either as an adjuvant treatment approach to chemotherapy for high-
risk and refractory AML patients, or as post-transplant infusions boosting GVT-immunity. 
Most trials reported so far employed PB derived-NK cells, enriched by CD3-depletion with 
or without CD56 selection from donor aphaeresis products. These studies showed that 
enriched donor NK cell infusions are well tolerated, without induction of GVHD or severe 
toxicity. Nevertheless, the clinical impact of NK cell-based therapy remains inconsistent 
and several issues need to be optimized to achieve better clinical efficacy. In order to 
facilitate multiple donor NK cell infusions, we employed a novel strategy through the 
development of a GMP-compliant culture protocol for generating higher numbers of 
activated NK cells from CD34+ haematopoietic stem/progenitor cells (HSPCs).
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In Chapter 5, we demonstrated that ex vivo-generated HSPC-NK cells can efficiently 
migrate to distinct lymphoid tissues, including the bone marrow in NOD/SCID/IL2Rγnull 
(NSG) mice. HSPC-NK cells can migrate via the CXCR4/CXCL12 axis, which is expressed 
by bone marrow stromal cells, as well via CXCR3, responding the inflammatory-driven 
chemokines CXCL9-11. SPECT-CT imaging and ex vivo biodistribution analyses showed 
that ~6.5% of the infused 111In labelled NK cells migrate to the bone marrow. This indicates 
that these cells can target the area of interest as therapy for haematological malignancies. 
The in vivo anti-leukemic potential of HSPC-NK cells was shown in our intrafemural tumour 
mouse model, where K562 leukaemia cells are directly implanted into the femur of NSG 
mice. This showed bone marrow-specific homing of the infused HSPC-NK cells to achieve 
this anti-tumour response. We observed that treatment with HSPC-NK cells, in combination 
with supportive IL15 administration, potently inhibited progression of K562 cell growth. 
Importantly, prolonged survival, including a complete and persistent response in 25% of 
the mice, was achieved following a single infusion of HSPC-NK cells. This illustrated that 
HSPC-NK cells are a promising immunotherapeutic cell product to improve the treatment 
of AML, as demonstrated by their capability to migrate to bone marrow and to inhibit 
progression of human leukaemia cells following adoptive transfer in mice.
Although HSPC-NK cells showed promising effects in Chapter 5, improvement of NK 
cell therapy is essential to target high-risk leukaemias. This is especially important as ex 
vivo generated HSPC-NK cells have low surface expression of CD16 and only a subset 
expresses full KIR maturation. Moreover, so far clinical studies in the non-transplant 
setting reported that adoptively transferred allogeneic NK cells have a relatively short 
lifespan in patients. Due to the transient elevation in endogenous IL15, which facilitates 
in vivo expansion after lymphodepleting chemotherapy, as well as host immune T cell 
recovery, the partially HLA-matched allogeneic NK cells will be rejected. For that reason, 
it would be preferable to maximize NK cell alloreactivity towards AML shortly following 
adoptive transfer. Therefore, we investigated the potential of HSPC-NK cells generated in 
the presence of IL12 in Chapter 6 as this cytokine was described to enhance functional 
properties. We demonstrated that replacement of IL2 by IL12 results in superior cytolytic 
activity and maturation potential of ex vivo-generated HSPC-NK cells. Importantly, these 
NK15/12 cells showed higher potency against both cultured and primary AML cells. In 
addition, IL12 favoured the generation of CD16- and KIR-expressing NK cells, resulting 
in the rapid development of hyper-responsive CD16+KIR+ NK cells following adoptive 
transfer. This faster maturation potential of NK15/12 cells in vivo will trigger more potent 
HSPC-NK cell alloreactivity towards AML. Moreover, IL12 significantly enhanced the 
interferon (IFN)γ production capacity of HSPC-NK cells, which improved the anti-leukemic 
activity in vitro and in vivo, possibly via improved cell adhesion by ICAM-1. We foresee that 
higher functionality and faster CD16 and KIR acquisition will trigger more potent NK cell 
alloreactivity towards malignant cells in patients, making the combination of IL15 and 
IL12 an attractive strategy to generate clinical HSPC-NK cell products with superior anti-
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tumour potency following adoptive transfer.
The essential improvement of NK cell therapies to treat high-risk leukaemias can be 
addressed via different strategies. First of all, donor HSPC-NK cell therapy could be applied 
following allo-SCT. These fully HLA-matched NK cells, generated from donor stem cells 
would not be rejected and this prolonged persistance of NK cells would boost the GVT-
effect. Interestingly, it has been recently reported that rapid donor NK cell chimerism after 
HLA-matched SCT is associated with improved relapse-free survival.19 To create this setting, 
NK cells should be generated from bone marrow and G-CSF mobilised CD34+ progenitor 
cells. Preliminary in vitro studies performed in our group focus on the development of both 
HSPCs from mobilized blood or umbilical cord blood derived-NK cells which shows that 
HSPC-NK cells could be attractive for adoptive immunotherapy against multiple myeloma 
(MM, Roeven et al, submitted), as well as epithelial ovarian carcinoma (Hoogstad et al, 
unpublished data). Exploiting new protocols for the generation of NK cells from different 
stem cell sources creates new therapeutic options for various cancer patients (Figure 1). 
Since bone marrow is the primary site of AML development, and contains niches 
essential for leukemic stem cells causing relapse, we believe that bone marrow targeting 
is essential for elimination of minimal residual disease and induction of optimal and 
persistent clinical responses against AML. Therefore, strategies that improve bone marrow-
homing of NK cells are an interesting topic to enhance clinical efficacy. One could aim 
at increasing the expression of bone marrow-specific chemokine receptors, like CXCR4, 
on NK cells which could enhance bone marrow homing. Recent work in our lab shows 
that expression of CXCR4 can be increased by addition of low dose glucocorticoids to the 
culture (Cany et al, in preparation). On the other hand, treatments to enhance expression of 
bone marrow-homing ligands would also improve this approach. Enhanced bone marrow 
homing would result in more efficient targeting of the haematological malignancies.
Next to increased bone marrow-homing, enhanced activation of the NK cells could also 
improve efficiency of HSPC-NK cell therapy. Combination therapy with for instance the 
anti-KIR antibody Lirilumab would decrease inhibitory signals to the NK cells by blockade 
of inhibitory KIRs on the tumour target cells. This will increase activation of NK cells, and 
thereby augment killing of malignant cells. Alternatively, the expression of activating 
signals on target cells could be increased. The hypomethylating DNA methyltransferase 
inhibitors Azacitidine and Decitabine not only have an anti-cancer effect themselves, 
but could also up-regulate stress-induced activating ligands on the targeted tumour 
cells (Cany et al, in preparation). This enhanced expression would be beneficial to NK 
cell adoptive therapy, as higher activation could be initiated in this situation. Therefore, 
combination therapy with either anti-KIR antibodies, Azacitidine or Decitabine could be 
interesting to target persistent malignant cells.
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Adoptive transfer of tumour-reactive T cells combined with DC vaccination 
as anti-cancer therapy
As haematopoietic-restricted MiHA-specific CD8+ T cells could mount a specific response 
against the malignant cells of the patient without inducing GVHD, boosting these cells 
is an interesting strategy for additive therapies. One of the current treatment options to 
prevent or treat relapse after allo-SCT consists of non-selected donor lymphocyte infusion 
(DLI). Only a relatively low number of naive precursors of the infused cells are capable 
of targeting haematopoietic-restricted MiHAs. Therefore, development of adoptive 
T cell therapy based on the transfer of enriched MiHA-specific CD8+ T cells targeting 
haematopoietic -restricted antigens could greatly enhance GVT-responses in the absence 
of GVHD. For that reason, we investigated in Chapter 7 the ex vivo-generation of MiHA-
specific CD8+ T cells, and the potency of DC vaccination to boost these responses in vivo. 
We show that co-cultures of monocyte-derived DCs with T cells from a MiHA-negative 
donor results in the expansion of MiHA-specific CD8+ precursor T cells within 7 days. These 
cells are highly functional, as analysed by expression of the co-stimulatory molecule CD28, 
and IFNγ and degranulation responses to peptide-restimulation. We showed previously, 
that expansion of antigen-specific effector/memory T cells was more superior when using 
PD-L silenced DCs. Silencing of PD-L1 and PD-L2 results in a more stimulatory phenotype 
of the DC, which also showed to be more effective in the expansion of MiHA-specific CD8+ 
naive precursor T cells. Next, we investigated the potential of PD-L silenced DC vaccination 
in boosting the expansion of MiHA-specific CD8+ T cells in vivo. In our immune deficient 
NSG mice, we generated a model of adoptive transfer of human T cells with weekly DC 
vaccination. We showed that DC vaccination is essential in the expansion and survival 
of antigen-specific T cells. Using PD-L silenced DCs, the expansion of MiHA-specific CD8+ 
T cells was augmented, resulting in more MiHA-specific CD8+ T cells in both peripheral 
blood and spleen after three DC vaccinations. 
Recent studies demonstrate the potential of boosting tumour-reactive CD8+ T cells 
by interference with the co-inhibitory PD-1/PD-L pathway using blocking antibodies. 
This strategy could also be used to improve in vivo expansion of MiHA-specific CD8+ T 
cells after allo-SCT. Importantly, the clinical effects of PD-1 blockade in solid tumours and 
after autologous stem cell transplantation are remarkable, without causing severe side 
effects.20,21 However, speculations have been made on the risk of these blocking antibodies 
on GVHD induction, as early after allo-SCT the immune system is heavily activated. T cells, 
stimulated by increased cytokine levels could be activated and target one of the many 
antigens presented by healthy tissues, due to conditioning-induced tissue damage. 
Addition of blocking antibodies could further release the brake on these T cells, resulting 
in the induction and aggravation of GVHD. Therefore, we believe that exploiting PD-L 
silenced DCs is a safer way to interfere with the PD-1/PD-L pathway, and thereby potently 
augment the activation and expansion of MiHA-specific CD8+ T cells in allo-SCT patients. 
Next to the PD-1/PD-L pathway, there are many more inhibitory interactions between 
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T cells and their targets. We showed previously that also blockade of BTLA on T cells 
results in an enhanced outgrowth of MiHA-specific CD8+ T cells.22 Interestingly, we found 
that while some patient’s T cells respond efficiently to PD-1 blockade but not to BTLA 
blocking, others have more benefit of BTLA blockade. So far, no clear indications could 
be found which patients would benefit from which therapy. This strongly accentuates 
the need for more research on the role of different co-inhibitory molecules (CIMs) in 
the setting of allo-SCT. This could be used to determine a strategy in silencing CIMs on 
DCs to most efficiently boost MiHA-specific CD8+ T cell responses. This knowledge could 
either gathered by determining the most dominant CIMs in MiHA-specific CD8+ T cell 
responses, or by indentifying a personalized medicinal strategy to target CIMs in each 
patient according to their optimal treatment protocol. Applying adoptive transfer of 
haematopoietic -restricted MiHA-specific CD8+ T cells in combination with potent CIM-
silenced DC vaccines could augment GVT-immunity and thereby prevent relapse and 
improve survival in allo-SCT patients.
Currently, different sources are used in the field of DC vaccinations. Recent research 
explores the use of natural occurring DC subsets collected by aphaeresis of the patient, 
instead of the traditionally used monocyte-derived DCs. It was postulated that these DC 
subsets are better stimulators and could mediate better anti-tumour immunity.23,24 In 
addition, combination of different subsets (e.g. pDCs and mDCs) is under investigation. 
As different subsets are activated by different triggers, combined therapy could boost 
responses on both ends. However, aphaeresis of these DCs from patients results in only 
low cell numbers. Therefore, we and others, explored the possibility of ex vivo-generated 
DC subsets from haematopoietic progenitor cells.25,26 However, although these new 
strategies could create potent therapies, they are laborious and costly. An ‘off-the-shelve’ 
product which could be given to each patient would be more cost-effective. For that 
reason, in vivo targeting of DCs in the patient via specific molecules is appealing. One 
could think of artificial DCs, ‘loaded’ with peptide and activating agents, or particles which 
target DC-specific markers and carry siRNAs to silence CIMs.27-29 In the coming years these 
new therapies will demonstrate their potential (Figure 1).
When generating MiHA-specific CD8+ T cells ex vivo, an important aspect of the 
generated product is T cell differentiation. Following antigenic stimulation of naive T (Tn) 
precursor cells, proliferation and differentiation is initiated into the early memory subsets, 
stem cell memory T (Tscm) cells and central memory T (Tcm) cells, and the later arising 
subsets, effector memory T (Tem) cells and effector T (Teff) cells. Compared to Tn cells in 
response to an initial activation, the general hallmark of memory T cells is their ability to 
mount a faster and stronger proliferative response to antigen re-encounter. Conversely, 
although terminally differentiated Teff cells show potent anti-tumour killing activity, most 
of them die after a single act of duty. While the early memory Tscm and Tcm cells possess not 
only higher proliferative capability, they are also capable of differentiating into the later 
effector T cell subsets. Most importantly, they have a high self-renewal capacity which is 
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less profound in the more differentiated T cell subsets. This makes early memory T cells the 
most favourable subset for therapeutic approaches.
In Chapter 8 we reported that post allo-SCT only few early memory cells are present. This 
potentially suboptimal memory pool was even more fierce within antigen-experienced 
CD8+ T cells, as MiHA-specific CD8+ T cells post allo-SCT contained undetectable levels 
of Tscm cells. Therefore, we speculate that this may result in short-term anti-tumour 
responses, which can be improved by applying additional post-transplant adoptive MiHA-
based CD8+ T cell therapy. Generation of a MiHA-specific CD8+ T cell product containing 
early memory cells was therefore explored, showing the potency of inhibition of the 
Akt-pathway. Akt-inhibition during the ex vivo-generation of MiHA-specific CD8+ T cells 
resulted in a restrained T cell differentiation as determined by expression of naive-like 
transcription factors (e.g. TCF7) and phenotypical markers (e.g. CCR7). These Akt-inhibited 
T cells were highly functional upon re-stimulation with a superior expansion capacity 
and possible self-renewal capacity both in vitro as well as in our DC vaccination mouse 
model. Although secondary adoptive transfer studies will give more insight in the true 
self-renewal potential of our T cells, our data suggest long-lived memory formation, and 
restimulation potential of the Akt-inhibited MiHA-specific T cells. Importantly, adoptive 
transfer of Akt-inhibited MiHA-specific CD8+ T cells, followed by DC vaccination, resulted 
in an augmented anti-tumour effect compared to control MiHA-specific CD8+ T cells. 
Intrafemural MM-bearing mice treated with Akt-inhibited CD8+ T cells showed a delay 
in tumour growth, as well as improved survival. In conclusion, inhibiting Akt-signalling 
during the ex vivo priming, expansion, and culture of MiHA-specific CD8+ T cells gives rise 
to potent tumour-reactive, stem cell-like T cells.
We like to further optimise the suppression of T cell differentiation by inhibiting Akt-
signalling, thereby retaining stem cell-like properties in ex vivo-generated MiHA-specific 
CD8+ T cells (Figure 2). With this we could develop a highly potent adoptive T cell therapy 
with purified and expanded donor CD8+ T cells, that recognize haematopoietic-restricted 
MiHAs. To eventually extrapolate this into a clinical application, we will optimise the 
ex vivo-generation of MiHA-specific CD8+ Tscm cells using a clinical grade Akt-inhibitor 
where multiple factors involved in T cell differentiation will be taken into account, like 
cytokines involved in T cell differentiation (e.g. IL7, IL15, IL12, IL21). These Akt-inhibited 
cells will be extensively analysed on gene expression signature, phenotype, and glycolytic 
metabolism, the latter being an important process involved in T cell differentiation and 
functionality.30,31 Furthermore, the functional characteristics and anti-tumour potency of 
our Akt-inhibited T cells will be explored in in vitro and in vivo re-encounter assays, and 
in various tumour mouse models. Proof of principle whether Akt-inhibited MiHA-specific 
CD8+ T cells are a safe and feasible therapy, should be tested in a Phase I clinical trial. Here, 
eligible patients could receive adoptive T cell therapy of Akt-inhibited MiHA-specific CD8+ 
T cells, combined with DC vaccination, post allo-SCT (Figure 1), targeting haematopoietic 
-restricted MiHAs, like HA1.A2, UTA2-1.A2, ARHGDIB.B7, and LRH1.B7. Applying such a 
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therapy can lead to a long-term, specific and curative anti-tumour effect, which improves 
patient survival without loss of quality of life due to severe GVHD. 
Figure 2. Ex vivo-generation of Akt-inhibited MiHA-specific T cells. Tn, naive T cell; Tscm, stem cell memory 
T cell; Tcm, central memory T cell; Tem, effector memory T cell; Teff, effector T cell; MiHA, minor histocompatibility 
antigen.
Conclusion
In conclusion, allo-SCT is a strong, potent, and curative treatment option for patients 
suffering from haematological malignancies. However, relapses remain a serious problem 
and therapies are hampered by the detrimental GVHD, which limits the therapeutic 
potency. This situation creates the urge for additive therapies which specifically target 
malignant cells, without increasing the risk for GVHD. More research regarding the initiation 
and progression of GVHD, with all cells and factors included, is essential. This would give 
more insight in how to prevent GVHD, and which therapeutic strategies could be safely 
applied. The development of new therapeutic approaches follows different approaches. 
Non-antigen specific NK cell therapy, or the Akt-inhibited MiHA-specific CD8+ T cells 
with CIM-silenced DC vaccination, will possibly prevent relapse and improve survival of 
patients suffering from haematological or solid cancers, which will be unravelled in the 
coming years. 
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Introductie
Hematologische maligniteiten betreffen verschillende vormen van bloed- en 
beenmergkanker welke kunnen ontstaan uit zowel lymfoïde of myeloïde cellen. Dit 
zijn bijvoorbeeld acute en chronische myeloïde leukemie (AML en CML), maligne 
lymfomen, en myeloïde plasmacelziekten. Gezamenlijk omvat dit ongeveer 8% van alle 
nieuw gediagnosticeerde kankers in Europa, circa 250.000 patiënten per jaar. Patiënten 
met een hematologische maligniteit kunnen worden behandeld met chemotherapie, 
bestraling en/of medicijnen die specifieke moleculaire afwijkingen van de tumor 
aangrijpen. Daarnaast kunnen patiënten een allogene stamceltransplantatie (allo-SCT) 
ondergaan, een krachtige vorm van cellulaire immuuntherapie. Na een voorbehandeling 
(conditionering) met chemotherapie en bestraling wordt de patiënt getransplanteerd 
met stamcellen van een donor. Deze donor kan een familielid zijn, maar kan ook een niet-
verwante donor zijn via de stamcelregistratie.
Het uiteindelijke doel van allo-SCT is een krachtige en langdurige immuunrespons 
te ontwikkelen tegen de tumor, welke terugkeer van de ziekte voorkomt. Stamcel-
transplantatie werd aanvankelijk ontwikkeld om patiënten te redden van beenmergfalen 
na hoge dosis chemotherapie. Echter, het onverwachte succes van allo-SCT berust 
voornamelijk op de reactie van het getransplanteerde donor immuunsysteem tegen de 
achtergebleven maligne patiëntencellen. Donor Natural Killer (NK ) en T-cellen kunnen 
deze tumorcellen opsporen, herkennen en vernietigen, bekend als de graft-versus-tumor 
(GVT)-reactie. Deze effectorcellen herkennen hun doel via verschillende moleculaire 
mechanismen. NK-cellen worden geactiveerd op basis van de balans tussen remmende 
en activerende signalen. Wanneer er een mismatch is in de remmende-liganden, zullen er 
minder remmende signalen worden gepresenteerd door de patiëntcellen aan de donor NK-
cellen. Daarnaast kan verlies of verlaging van HLA klasse-I moleculen op het oppervlak van 
de maligne cellen ook leiden tot minder remmende signalen. Bovendien kunnen maligne 
cellen ‘stress-geïnduceerde’ activerende eiwitten opreguleren. Deze balans waarbij er 
meer activerende dan remmende signalen zijn, leidt dan tot activatie van de NK-cellen en 
het doden van de kwaadaardige patiëntcellen. Anderzijds kunnen T-cellen een targetcel 
herkennen welke een specifiek antigen tot expressie brengt overeenkomend met hun 
T-celreceptor. Hoewel allo-SCT meestal wordt uitgevoerd in een HLA-gematchte setting 
kunnen kleine verschillen in het DNA, ‘single nucleotide polymorfismen’ (SNPs) genaamd, 
welke variëren tussen patiënt en donor, resulteren in een mismatch. Dit worden minor 
histocompatibiliteits antigenen (MiHAs) genoemd. Als deze MiHAs alleen tot expressie 
komen op hematopoëtische cellen, kan er een specifieke GVT-reactie plaatsvinden. Echter, 
MiHAs met een breed expressiepatroon zullen zorgen voor activatie en deling van donor 
T-cellen welke gericht zijn tegen gezonde weefsels. Dit resulteert dan in de desastreuze 
graft-versus-host ziekte (GVHD), ook wel omgekeerde-afstotingsziekte genoemd. Deze 
ernstige complicatie is geassocieerd met hoge transplantatie-gerelateerde mortaliteit, 
en beperkt de therapeutische effectiviteit van allo-SCT. Hoewel allo-SCT genezend kan 
10
205
Nederlandse samenvatting 
zijn, blijft terugkomst van de ziekte een groot probleem. Betere klinische resultaten 
kunnen ontstaan  door nieuwe immunologische interventiestrategieën die zich richten 
op het voorkomen van GVHD, en/of de controle van de progressie van de ziekte. Nieuwe 
therapieën mogen het risico op GVHD niet verhogen, en moeten zich richten op donor 
effectorcellen die specifiek bijdragen aan het GVT-effect, zoals tumor-reactieve T- en NK-
cellen.
Aanpak van IL17-producerende T-cellen ter voorkoming van GVHD
Donor T-cellen kunnen patiëntcellen herkennen op basis van de expressie van 
verschillende MiHAs. Of een MiHA breed, of juist alleen op hematopoëtische cellen tot 
herkenning komt bepaalt de balans tussen een specifieke GVT-reactie of de schadelijke 
GVHD. Bij het optreden van GVHD zullen donor T-cellen gezonde weefsels herkennen 
welke de MiHA tot expressie brengen. Hierdoor ontstaat ernstige schade aan de GVHD-
gevoelige organen zoals de huid, lever, maag-darmkanaal, en de longen. De huidige 
behandelmogelijkheden voor GVHD is het gebruik van algemene immuunremmende 
geneesmiddelen zoals cyclosporine A en mycofenolaat mofetil. Het nadeel van deze 
middelen is echter dat deze het gehele immuunsysteem onderdrukken, wat voor een 
verhoogd risico op infecties en terugkeer van de maligne cellen kan zorgen. Tevens is het 
zo dat GVHD niet altijd kan worden gestopt door deze middelen, en de GVHD-schade aan 
de betrokken organen kan fataal zijn voor de patiënt. Om GVHD te voorkomen of specifiek 
te behandelen is het essentieel om de immuunmechanismen achter deze complicatie te 
begrijpen.
In hoofdstuk 2 bespreken we de rol van een relatief nieuwe T-cel subset, namelijk 
de IL17-producerende T-cellen, in de initiatie en pathofysiologie van GVHD. CD4+ Th17 
en CD8+ Tc17 cellen, genoemd naar hun productie van de pro-inflammatoire cytokine 
IL17, zijn geassocieerd met een aantal auto-immuunziekten zoals reumatoïde artritis. De 
laatste jaren zijn er verschillende studies uitgevoerd waarin werd aangetoond dat deze 
cellen ook betrokken zijn bij GVHD. In verschillende muismodellen is de rol van IL17, naast 
interferon (IFN)y, in (xenograft) GVHD aangetoond. Bovendien zijn de bloedwaarden 
van IL17-producerende T-cellen bepaald na allo-SCT via verschillende methoden (bijv. 
IL17-productie, CCR6 en / of CD161 expressie), die geassocieerd blijken te zijn met het 
optreden van GVHD. Toch blijven de gegevens beperkt en soms tegenstrijdig. Verder 
onderzoek naar de rol van deze cellen in het ontstaan en progressie van GVHD hebben 
we uitgevoerd in twee studies, gericht op de verschillende aspecten van deze cellen.
In hoofdstuk 3 hebben we de correlatie onderzocht tussen SNPs in de Th/Tc17-
geassocieerde genen IL23 receptor (IL23R) en CCR6 en het optreden van GVHD. We waren 
niet in staat om de eerder gepubliceerde correlatie tussen GVHD en de SNP rs11209026 
in IL23R te bevestigen. Het is mogelijk dat we deze genetische associatie niet konden 
bevestigen vanwege de gedeeltelijke ex vivo T-cel depletie in onze transplantaties, 
in tegenstelling tot de data gepubliceerd door Elmaagacli et al. waarbij geen T-cel 
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depletie plaatsvond. T-celdepletie is van invloed op het herstel van T-cellen na allo-SCT, 
en daarnaast worden patiënten met T-cel depletie na de transplantatie behandeld met 
andere immuunremmende medicatie dan patiënten zonder T-cel depletie. Hierdoor kan 
IL23, betrokken bij differentiatie en expansie van Th/Tc17 cellen, in de T-cel gedepleteerde 
setting anders betrokken zijn bij GVHD dan in de niet gedepleteerde setting. Echter, bij 
het bestuderen van een tweede gen prominent in de IL23/Th17 route, vonden we dat 
een tagSNP rond (rs2301436) en een SNP in CCR6 (rs3093023), gecorreleerd was met het 
optreden van chronische GVHD. Aangezien het is aangetoond dat 2 andere SNPs in en rond 
CCR6 de expressie van de chemokine receptor kunnen beïnvloeden, is het waarschijnlijk 
dat de door ons onderzochte en aan GVHD-gelinkte SNPs, het migratiepotentieel van Th/
Tc17 cellen kunnen beïnvloeden. 
Of Th/Tc17 cellen migreren naar GVHD-gevoelige weefsels, en daar een rol 
spelen in deze ontstekingsziekte is via verschillende benaderingen te onderzoeken, 
zoals bijvoorbeeld door het bepalen van het aantal circulerende Th/Tc17 cellen in 
bloedsamples van GVHD-patiënten. In hoofdstuk 4 vonden we, met behulp van de Th/
Tc17-marker CD161, een correlatie tussen de verlaagde celaantallen van circulerende 
CD161+CD4+ en CD161hiCD8+ T-cellen en het optreden van GVHD. Bovendien toonden 
we de migratiepotentie van deze CD161+ T-cellen via de CCR6/CCL20-as naar ontstoken 
weefsels aan, en vonden we expressie van CCL20 in GVHD-aangetaste weefsels. Via de co-
expressie van CCR6 op CD161+ cellen is daarna ook de aanwezigheid van deze cellen in 
GVHD-aangetaste weefsels aangetoond. De lagere celaantallen van circulerende CD161+ 
T-cellen in het bloed en hun aanwezigheid in GVHD-aangetaste weefsels wijzen erop dat 
deze cellen een rol kunnen spelen in de initiatie en / of progressie van GVHD. Vooral de 
waarneming dat patiënten met verlaagde waarden van CD161+ T-cellen in bloedsamples 
3 maanden na allo-SCT later chronische GVHD ontwikkelden, geeft hun betrokkenheid 
bij het ontstaan van  begin van de ziekte weer. Migratie van CCR6+CD161+ T-cellen naar 
de GVHD-gevoelige weefsels zou kunnen resulteren in verhoogde IL17-productie, het 
initiëren van de GVHD respons, en het aantrekken van andere immuuncellen die gezonde 
organen kunnen beschadigen.
Zoals verder besproken in hoofdstuk 2, zijn er meerdere factoren die de groei, 
differentiatie, en activatie van IL17-producerende T-cellen beïnvloeden. Deze kunnen 
daarom allen een potentiële rol spelen in GVHD. Bijvoorbeeld, verschillende dendritische 
cel (DC) populaties, zoals plasmacytoïde DCs en de myeloïde DC NK lectine groep receptor 
(DNGR)1+ DCs, hebben de mogelijkheid om Th/Tc17 te activeren door het vrijkomen van 
cytokines. De belangrijke cytokines IL1β, IL6, IL23 en TGFβ, waarvan bekend is dat deze de 
differentiatie en expansie van IL17 producerende T-cellen sturen, zijn sterk verhoogd in 
patiënten na allo-SCT. Bovendien komen er door de conditionering dode cellen vrij en is 
er sprake van verhoogde microbiële blootstelling. Dit zijn signalen die deze DC populaties 
sterk kunnen activeren. Vervolgens kunnen de DC de Th/Tc17-reactie stimuleren, wat het 
GVHD-proces kan initiëren of verergeren. Een beter begrip van de factoren en DC subsets 
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betrokken in de IL17-route, zal resulteren in de ontwikkeling en het testen van nieuwe 
therapeutische benaderingen voor de preventie van GVHD.
NK-celtherapie voor de behandeling van hematologische maligniteiten
De GVT-reactiviteit van donor NK-cellen zorgt voor een betere controle van terugkeer bij 
AML patiënten na allo-SCT. Dit maakt allogene NK-cellen als additionele immuuntherapie 
een interessante strategie, hetzij als extra behandeling naast chemotherapie voor 
hoogrisico AML patiënten, of als post-transplantatie infusies voor het versterken van 
GVT-immuniteit. De meeste tot nu toe uitgevoerde studies melden de werkzaamheid 
van perifeer bloed NK-cellen, welke zijn verrijkt door CD3-depletie met of zonder CD56-
selectie van donor aferese producten. Deze studies toonden aan dat deze verrijkte NK-cel 
infusies goed te verdragen zijn, zonder GVHD of ernstige bijwerkingen te induceren. Toch 
is het klinische effect van NK-cel therapie inconsistent en moeten verschillende aspecten 
worden geoptimaliseerd om de klinische werkzaamheid te verbeteren. Om meerdere 
donor NK-cel infusies mogelijk te maken, gebruikt ons laboratorium een kweekprotocol 
waarmee we grote aantallen geactiveerde NK-cellen kunnen genereren uit CD34+ 
hematopoëtische  stam- en voorlopercellen cellen, volgens de richtlijnen voor medische 
toepassingen.
In hoofdstuk 5 hebben we aangetoond dat ex vivo-gegenereerde NK-cellen efficiënt 
kunnen migreren naar verschillende lymfoïde organen, waaronder het beenmerg in 
immuundeficiënte NOD/SCID/IL2Rγnull (NSG) muizen. NK-cellen kunnen migreren via 
de CXCR4/CXCL12-as waarbij CXCL12 wordt geproduceerd door stromale cellen in het 
beenmerg. Ook kunnen de NK-cellen migreren via CXCR3, welke reageert op de ontstekings-
aangedreven chemokinen CXCL9-11. SPECT-CT en ex vivo-biodistributieanalyses lieten zien 
dat ~ 6,5% van de toegediende 111In-gelabelde NK-cellen naar het beenmerg migreert, wat 
essentieel is bij therapie van hematologische maligniteiten. De in vivo anti-leukemische 
potentie van NK-cellen hebben we aangetoond in ons intrafemuraal tumor muismodel, 
waarbij K562-leukemiecellen direct geïnjecteerd werden in het dijbeen van NSG muizen. 
Hierbij is een beenmerg-specifieke migratie van de toegediende NK-cellen nodig voor 
een anti-tumor respons. We vonden dat behandeling met NK-cellen, in combinatie met 
ondersteunende IL15 toediening, een krachtige remming gaf op de progressie van K562 
tumorgroei. Belangrijker, de overleving van deze muizen was verlengd, met een volledige 
en aanhoudende respons in 25% van de muizen na één enkele infusie van NK-cellen. Dit 
laat zien dat onze NK-cellen een veelbelovende immuuntherapeutisch celproduct is om 
de behandeling van AML te verbeteren.
Hoewel de NK-cellen veelbelovende effecten tonen in hoofdstuk 5, is verbetering 
van de NK-celtherapie essentieel om hoogrisico leukemie te behandelen. Dit is vooral 
belangrijk vanwege de lage maturatie status, bepaald met de expressie van CD16 en 
KIRs op de ex vivo-gegenereerde NK-cellen, welke essentieel zijn voor de herkenning en 
doden van maligne cellen. Bovendien blijkt uit klinische studies in de niet-transplantatie 
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setting dat allogene NK-cellen een relatief korte levensduur hebben in de patiënt na 
infusie. Gezien de tijdelijke verhoging in endogene IL15 na lymfoïde-depleterende 
chemotherapie, en de terugkeer van de T-cellen van de patiënt zullen de NK-cellen worden 
afgestoten. Het is dus belangrijk dat de in vivo expansie en allo-reactiviteit naar AML van 
de NK-cellen zo snel en effectief mogelijk is. Daarom onderzochten we de potentie van 
NK-cellen welke zijn gegenereerd in de aanwezigheid van IL12 in hoofdstuk 6. We laten 
zien dat vervanging van IL2 door IL12 resulteert in een superieure vernietigende activiteit 
en rijpingspotentieel van ex vivo-gegenereerde NK-cellen. Belangrijk is dat deze NK15/12 
cellen hogere vernietigingspotentie vertoonden tegen zowel gekweekte en primaire AML 
cellen in vitro en in ons intrafemuraal tumor muismodel. Bovendien zorgt IL12 voor het 
verhogen van het aantal CD16+ en killer immuunglobuline receptor (KIR)+ NK-cellen welke 
belangrijk zijn bij herkenning en doden van target cellen. Deze verhoging leidt tot de snelle 
ontwikkeling van hyper-responsieve CD16+ KIR+ NK-cellen na infusie. Deze snellere rijping 
van NK15/12 cellen in vivo zal bijdragen aan de krachtigere NK-cel reactiviteit tegen AML 
cellen. Bovendien zorgt IL12 voor een aanzienlijk verbeterde IFNy productiecapaciteit van 
de NK-cellen, die mogelijk de anti-leukemische activiteit in vitro en in vivo verbeterd door 
een beter celadhesie via ICAM-1. We voorzien dat hogere functionaliteit en sneller CD16 
en KIR werving zal leiden tot een krachtigere NK-cel alloreactiviteit tegen kwaadaardige 
cellen bij patiënten, en dat de combinatie van IL15 en IL12 een aantrekkelijke strategie is 
om de klinische NK-celproducten met superieure anti-tumor potentie te genereren. Dit 
zal verder onderzocht moeten worden.
 
Tumor-reactieve T-cellen en DC vaccinatie als anti-kankertherapie 
MiHA-specifieke CD8+ T-cellen gericht tegen een hematopoëtisch-gerestricteerde MiHA, 
kunnen een specifieke reactie tegen de kwaadaardige cellen van de patiënt geven zonder 
het induceren van GVHD. Daarom is het stimuleren van deze reactie een interessante 
strategie als additionele therapie. Een van de huidige behandelingen ter voorkoming 
of behandeling van terugkeer van de ziekte na allo-SCT is de ongeselecteerde donor 
lymfocyten infusie (DLI). In deze cellen is slechts een relatief klein aantal naïeve voorloper 
T-cellen aanwezig die hematopoëtisch-gerestriceerde MiHAs herkennen en aanvallen. De 
rest van de cellen herkennen andere antigenen die ook op niet hematopoïetische cellen 
voorkomen, welke ze mogelijk kunnen aanvallen, en zo het risico op GVHD vergroten. 
Daarom zou het ontwikkeling van een infusie met tumor-reactieve T-cellen, welke alleen 
een hematopoëtisch-gerestricteerde MiHA herkennen aantrekkelijker zijn. Op deze 
manier zou de GVT-reactie verbeterd worden in afwezigheid van GVHD. In hoofdstuk 7 
onderzochten we de ex vivo generatie van MiHA-specifieke CD8+ T-cellen, en de potentie 
van DC vaccinaties om deze cellen te activeren in vivo. We toonden aan dat kweken van 
(uit monocyten gekweekte) DCs met T-cellen van een MiHA-negatieve donor resulteerde 
in de expansie van MiHA-specifieke CD8+ naïeve voorloper T-cellen binnen 7 dagen. Deze 
cellen bleken zeer functioneel, zoals geanalyseerd aan de hand van het co-stimulerende 
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molecuul CD28, en de IFNy- en degranulatie-capaciteit na peptide-restimulatie. We 
toonden eerder aan, dat de expansie van antigeen-specifieke effector/geheugen T-cellen 
superieur was bij het gebruik van PD-L-negatieve DCs. De afwezigheid van remmende 
moleculen PD-L1 en PD-L2 resulteerde in een meer stimulerend fenotype van de DC. 
Deze PD-L negatieve DCs bleken ook efficiënter in de expansie van MiHA-specifieke CD8+ 
naïeve voorloper T-cellen. Vervolgens onderzochten we de potentie van PD-L negatieve 
DC vaccinatie in de expansie MiHA-specifieke CD8+ T-cellen in vivo. In immuundeficiënte 
NSG muizen hebben we een model opgezet bestaande uit een infusie van T-cellen 
gevolgd door wekelijkse DC vaccinatie. We toonden aan dat DC vaccinatie essentieel 
is in de deling en overleving van antigeen-specifieke T-cellen. Belangrijker, het gebruik 
van PD-L negatieve DCs zorgde voor de superieure expansie van MiHA-specifieke CD8+ 
T-cellen, wat zorgde voor meer MiHA-specifieke CD8+ T-cellen in zowel bloed als milt na 
drie DC vaccinaties. 
Bij het genereren van MiHA-specifieke CD8+ T-cellen is de antigen-specificiteit een 
belangrijk aspect. Daarnaast is de differentiatie-status van de gegenereerde T-cellen erg 
belangrijk. Na antigen-stimulatie van naïeve T (Tn) voorloper cellen, zal proliferatie en 
differentiatie van de cellen worden gestart. Dit leidt tot de vroege geheugen populaties, 
‘stem cell memory’ T (Tscm) cellen en de ‘central memory’ T (Tcm) cellen, en de latere 
populaties, de ‘effector memory’ T (Tem) cellen en ‘effector’ T (Teff) cellen. Vergeleken met 
de reactie van Tn cellen op een eerste activatie op antigen-presentatie, is het algemene 
kenmerk van geheugen T-cellen hun vermogen om een  snellere en sterkere respons te 
vertonen op herkenning van het antigeen. Echter, hoewel de latere ‘uitgedifferentieerde’ 
Teff cellen een krachtige anti-tumor vernietigingsactiviteit kunnen vertonen, zullen de 
meeste van hen dood gaan na een korte periode. De vroege geheugen Tscm en Tcm cellen 
bezitten niet alleen een hoger expansie vermogen dan de latere populaties, echter zij 
ook kunnen differentiëren tot de latere effector T-cel populaties. Het belangrijkste is 
dat ze een hoge zelfvernieuwingscapaciteit behouden, welke minder aanwezig is in de 
meer gedifferentieerde T-cel populaties. Dit maakt de vroege memory T-cellen het meest 
interessant voor therapeutische benaderingen. 
In hoofdstuk 8 hebben we vastgesteld dat na allo-SCT slechts enkele vroege 
geheugencellen aanwezig waren. Deze potentieel suboptimale geheugenpopulatie was 
nog dominanter binnen de antigeen-specifieke CD8+ T-cellen. Binnen de MiHA-specifieke 
CD8+ T-cellen na allo-SCT waren Tscm cellen niet detecteerbaar. Derhalve speculeren wij dat 
dit kan leiden tot slechts een kortdurend anti-tumor reactie die kan worden verbeterd door 
extra post-transplantatie MiHA-gebaseerde CD8+ T-cel-therapie. Daarom onderzochten 
wij de generatie van MiHA-specifieke CD8+ T-cellen bestaande uit vroege geheugencellen, 
via de remming van de Akt-signaleringsroute. Inhibitie van deze signaleringsroute tijdens 
de ex vivo generatie van MiHA-specifieke CD8+ T-cellen resulteerde in een geremde T-cel 
differentiatie welke we hebben bepaald door de expressie van naïef-geassocieerde 
transcriptiefactoren (bv. TCF7) en fenotypische markers (bijv. CCR7). De Akt-geremde 
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T-cellen waren zeer functioneel na restimulatie, met een superieure expansie en mogelijke 
zelfvernieuwingspotentie. Dit bleek zowel in vitro als in onze DC vaccinatie muismodel. 
Belangrijk is dat infusie van Akt-geremde MiHA-specifieke CD8+ T-cellen, in combinatie 
met DC vaccinatie, resulteerde in een verhoogd anti-tumor effect vergeleken met 
controle MiHA-specifieke CD8+ T-cellen. Muizen, intrafemuraal geïnjecteerd met multiple 
myeloom, welke werden behandeld met Akt-geremde CD8+ T-cellen vertoonden een 
vertraging van de tumorgroei en verbeterde overleving. Dit laat zien dat het remmen van 
de Akt-signaleringsroute tijdens de ex vivo priming en expansie van MiHA-specifieke CD8+ 
T-cellen leidt tot krachtige tumor-reactieve, stamcel-geassocieerde T-cellen.
Conclusie
Allo-SCT is een sterke, genezende, en krachtige behandelingsoptie voor patiënten met 
een hematologische maligniteit. Echter, terugkeer van de ziekte is een ernstig probleem 
en de therapie wordt gehinderd door de schadelijke GVHD, welke de therapeutische 
werkzaamheid beperkt. Deze situatie vraagt om additionele therapieën die specifiek 
zijn gericht op de kwaadaardige cellen, zonder verhoging van het risico op GVHD. Meer 
onderzoek met betrekking tot de initiatie en progressie van GVHD, met alle cellen en 
factoren betrokken in dit proces, is essentieel. Dit zou meer inzicht geven in hoe GVHD 
kan worden voorkomen en hoe therapeutische strategieën veilig kunnen worden 
toegepast. De ontwikkeling van nieuwe therapeutische benaderingen om terugkeer van 
de maligniteit te voorkomen gaat via meerdere wegen. De verschillende benaderingen, 
hetzij niet-antigeen-specifieke NK-celtherapie, of Akt-geremde MiHA-specifieke CD8+ 
T-cellen met PD-L negatieve DC vaccinatie, zal mogelijke terugkomst van de ziekte 
voorkomen en de overleving van patiënten die lijden aan hematologische of solide 
kankers verbeteren.
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we nog even konden spuien over alles wat niet gaat zoals we zouden willen, en hoe de 
(onderzoeks)wereld beter zou zijn als we overal lijstjes voor konden maken. Hoewel ik je 
altijd meer als mijn paranimf had gezien op deze dag, ben ik trots dat je straks tegenover 
me zit als mijn co-promotor. Ik kijk uit naar de komende jaren waar we nog veel onderzoek 
samen aan mogen pakken! 
Joop en Nicole, jullie input tijdens besprekingen en presentaties was altijd zeer 
welkom. Nicole, jouw blik vanuit de kliniek zorgt altijd voor veel vragen maar helpt ons 
onderzoekers de juiste koers aan te houden. Van bench naar bedside is alleen mogelijk 
door de goede samenwerking tussen lab en kliniek. Dank daarvoor. Joop, jouw moleculaire 
werk staat soms ver van mijn onderzoek af maar jouw brede interesse in hematologie en 
immunologie zorgt voor veel (onverwachte en) inspirerende adviezen. Bedankt voor je 
input in de verschillende projecten.
Robbert, hartelijk dank voor jouw input in de eerste jaren van mijn promotieonderzoek. 
Vooral je kennis over de muizenproeven waren erg belangrijk tijdens de start van mijn 
promotieonderzoek. Veel goeds gewenst in je nieuwe carrière als onderzoeksjournalist, 
waardoor we elkaar vast nog zullen tegenkomen op verschillende congressen.
Lieve Sanne en Marlijn, ik ben blij dan jullie op deze dag naast mij willen staan! 
Vanuit Biomedische Wetenschappen hebben we elk ons carrière-eigen pad gekozen, al 
ligt het soms ineens dichter bij elkaar dan we denken. Sanne, kijk nog maar eens goed 
naar hoofdstuk 2, referentie 69. Ik geniet van onze vrouwendagen en kijk uit naar ons 
weekendje weg! Ik hoop nog veel van deze momenten met jullie te mogen delen de 
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komende jaren. 
Onder de noemer ‘onderzoek doe je niet alleen’ horen zeker de analisten. Annelies, 
Hanny, Frans, Marij en Rob hartelijk dank voor al jullie inzet in de verschillende 
experimenten, het beantwoorden van mijn lastige vragen, en oplossen van alle 
labproblemen. Dat jullie allemaal voor mijn verschillende projecten werk hebben verricht 
vind ik een eer! Hanny, ik hoop de komende jaren nog met veel plezier samen te mogen 
werken aan de nieuwe uitdaging.
Basav, Fenna, Janneke, Jeannette, Jeroen, John, Karishma, Marian, Marleen, Mieke, 
Niken, Peter, Soley, Thomas, Tim en Wieger, bedankt voor jullie inspiratie en input in de 
projecten, de gezellige teambuildingsdagen, congressen, borrels in de Aesculaaf en alle 
andere mooie momenten samen. Jeannette, thanks for our collaboration on the NK cells. 
Keep up the good work with the new project. Janneke, Mieke, Soley en Tim, succes nog 
met jullie promotieonderzoek de komende jaren. Dat komt helemaal goed! Inderdaad 
Soley, your next!
Kelly, Sandra, Wieger en Willemijn, mijn voorgangers en voorbeelden in het 
promotieleven. Dank voor al jullie adviezen en gezellige momenten op congressen, het 
lab en de etentjes in deze periode. Sandra, succes met de (echte!) laatste loodjes en ik kijk 
uit naar jouw promotie!
Natuurlijk kan ik niet vergeten onze labbuurtjes te bedanken voor hun gezelligheid 
en nuttige moleculaire adviezen. Anne, Davide, Florentien, Gorica, Jimmy, Jolanda, 
Laurens, Leilei, Maaike, Mariam, Niccolo, Leonie, Pedro, Rinske, Ruth, Saskia, Saskia en 
Sylvie, ik hoop nog vaak van jullie kennis gebruik te mogen maken als ik me weer eens op 
onbekend gebied begeef! Saskia, dankjewel voor al je nuttige adviezen bij het kloneren 
en de virusproductie, en je fijne samenwerking op het lab maar ook in het organiseren van 
de geslaagde familiedag!
Tijdens mijn promotie heb ik meerdere studenten mogen begeleiden. Ik heb daar 
altijd veel plezier in beleefd en hoop mijn enthousiasme en kennis deels te hebben 
overgedragen. Astrid, Cynthia, Noortje en Santhosh, dank voor alles wat ik van jullie heb 
geleerd en succes in jullie verdere (onderzoeks)carrières.
Dat ons lab een combinatie is van onderzoek en diagnostiek is een unieke situatie. 
De kennis en beschikbaarheid van materiaal helpt ons in vele aspecten van het 
onderzoek! Daarom kan ik hier zeker alle mensen van de beenmergtransplantatie-
unit, de immuunfenotypering, morfologie, moleculaire diagnostiek en de trombose & 
hemostase niet vergeten. Dank jullie wel voor het beantwoorden van al mijn vragen en 
het beschikbaar stellen van de materialen. Ook dank aan alle andere stafleden, en Paul en 
Nelleke voor hun ondersteuning! 
De translationele visie van de afdeling is alleen mogelijk dankzij de samenwerking met 
de afdeling Hematologie. Naast Nicole wil ik Michel, Gerwin en Walter daar hartelijk voor 
bedanken. Walter, dank voor je input in de GVHD projecten. Ik hoop de komende jaren 
nog veel met jullie te kunnen samenwerken om ook de huidige projecten naar patiënten 
Chapter 10
10
218
te brengen.
Daarnaast wil ik ook alle verdere samenwerkingen binnen en buiten het Radboudumc 
bedanken. Ten eerste alle biotechnici en dierverzorgers van het dierenlab, dank jullie wel 
voor alle inzet en hulp bij de proeven. Ton, bedankt voor je statistische analyses! Astrid van 
Halteren van het LUMC, dank voor de immuunhistochemie kleuringen in de GVHD tissues. 
Prof. dr. Fred Falkenburg en Michel Kester van het LUMC, bedankt voor de tetrameren die 
wij binnen de vele projecten gebruiken. Luca, thank you for our collaboration on the stem 
cell-like T cells. I hope we can learn and collaborate more in the coming years. 
Dit proefschrift had er niet gelegen als ik naast mijn werk niet zoveel fijne familie en 
vrienden zou hebben om af en toe even mijn hoofd leeg te maken! Mijn lieve vriendjes 
gevonden via werkgroep 55 van Biomedische wetenschappen: Chris & Lieke, Duby & 
Viola, Kim & Emile, Lard & Jossje, Maarke & Harm, Mark & Clementine, Marlijn & Martijn, 
Peter & Floor, Piet & Charlotte, en Sanne & Thomas dank voor de gezellige momenten de 
afgelopen 10 jaar! Wat is het fijn om met je close vrienden je werk-gerelateerde pieken 
en dalen te kunnen delen. Duby, Kim, Peter, Piet, en Sanne dank voor de vele gezellige 
lunches! Ik geniet van onze ‘Varsseveld’-weekenden en kijk uit naar de vele die nog mogen 
volgen! Ik hoop nog vele onderzoeks- en niet-onderzoeksmomenten met jullie te mogen 
delen. Geert & Lonneke, wat heb ik genoten van onze Best-of-the-West trip. Ik kijk nu al 
uit naar ons Afrika avontuur. Dankjewel voor de leuke momenten samen en ik kijk uit naar 
de vele in de toekomst!
Lieve meisjes (en mannen), Bertine, Esmée, Fieke, Marjolein & Jan-Willem en Roos & 
Pepijn. Wat geniet ik van onze wekelijkse etentjes. Lekker bijkletsen en niet over onderzoek 
praten. Ik hoop dat we dit nog lang kunnen volhouden ook al verhuizen we soms verder 
weg. Ik vind het bijzonder om al zo lang (bijna 25 jaar!) vriendinnen met jullie te mogen 
zijn! Mogen daar nog meer dan 25 jaar bij komen!
Lieve René & Rianca, Maike, Milou, en Aniek, dank jullie wel dat jullie (nu officieel!) mijn 
gezellige schoonfamilie zijn. Freek, Gert-Jan & Marloes, Paul, en Sophie & Tristan dank jullie 
wel voor de gezelligheid op de familiemomenten. Ik kijk uit naar nog vele weekendjes 
Vlieland, skiën en natuurlijk die potjes Saboteur. Lieve Marloes en Jesper, wat fijn dat we 
zo gezellig broer en zussen kunnen zijn! Marloes, ik geniet van alle leuke momenten met 
jou & Dort & de meiden en kijk uit naar de komst van hun kleine broertje. Hopelijk wacht 
de kleine nog even, en kan je er 20 maart bij zijn. Jesper, wat ben ik trots dat jij hebt 
gevonden wat je leuk vindt in het leven en nu heerlijk ‘met de boot’ op pad gaat om de 
wereld een beetje beter te maken. Lieve Omi, hier is dan het o-zo-gewenste boekje waar 
u al zo lang naar gevraagd hebt. Ik ben trots om uw kleindochter te zijn!
Pap, ik weet niet waar ik moet beginnen met jou te bedanken. Dankjewel voor de 
kansen die je me hebt gegeven zodat ik heb kunnen komen waar ik nu sta, en mij te 
leren wat belangrijk is in het leven! Ik geniet ervan dat je samen met Simonet weer zoveel 
nieuwe uitdagingen in het leven hebt gevonden, ook al is jouw agenda soms nog voller 
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dan de mijne. Dankjewel dat jullie voor ons allen een fijn open huis hebben neergezet in 
Zwiep, dat is best een uitdaging met een gezin van ondertussen al 17 leden. 
Lieve Ward, ik kan me geen leven meer zonder jou voorstellen. Al negen jaar delen 
wij lief en leed, en ook al heb je vaak geen idee wat ik allemaal uitvoer op het lab, is jouw 
steun in mijn onderzoek me alles waard! Na het afsluiten van dit hoofdstuk kijk ik uit naar 
de vele nieuwe avonturen die nog op ons liggen te wachten! Ik hou van jou! 
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